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Thalassemia, the commonest monogenetic disorder in humans, has historically 
constituted a serious public heath problem in many parts of the world. In this study, 
several molecular diagnostic assays for identification of α- and β-thalassemia 
common mutations in Southeast Asia have been developed and validated. 
“Reconstituted” genomic DNA samples heterozygous for each of the seven α-
thalassemia deletions (-α3.7, -α4.2, --SEA, --THAI, -(α)20.5, --MED and –FIL) 
screened for in the seven-deletion multiplex PCR were generated from the existing 
patient DNA samples, serving as positive controls to give a more reliable PCR 
diagnosis results. Additionally, multiplex minisequencing assays were developed to 
detect the most common Southeast Asia α-and β-thalassemia point mutations together 
with the most common β-thalassemia deletion – 619bp deletion. Totally the multiplex 
minisequencing assays can detect 7 common HbA2 mutations (codon0∆1bp, Constant 
Spring, Paksé, Quong Sze, Suan Dok, codon30∆3bp, codon59) and 16 common HBB 
mutations (codon41/42, IVSIInt654, IVSI nt5, codon17, -28, -29, codon71/72, 
codon26, IVSInt1, codon19, initiation codon for translation, codon43, codon27/28, 
codon8/9, codon35 and ∆619bp deletion). A single-tube multiplex PCR assay was 
also developed to screen for the presence of α-globin gene triplications (αααanti-3.7 
and αααanti-4.2) in apparent β-thalassemia carriers with unexpectedly severe 
presentation, since extra copies of the α-globin gene may aggravate the severity of β-
thalassemia. These new molecular diagnostic assays provide a more rapid, efficient, 
and cost-effective alternative to current thalassemia molecular testing methods in the 
region.  
 viii
In addition, the genotype of 110 Hb H disease samples diagnosed by 
isoelectric focusing (IEF) from Thailand were characterized by the seven-deletion 
multiplex PCR and α-globin gene sequencing to evaluate the accuracy of IEF in Hb H 
disease classification. Several misclassifications of Hb H disease by IEF were found, 
which highlights the importance of molecular diagnosis in accurate determination of 
genetic mutations. A reliable protocol to sequence the high GC-rich α-globin genes 
was also developed. 
Furthermore, five premature termination codons (PTCs) caused by naturally 
occurring nonsense or frameshift mutations [codon1 ∆ 1bp GTG→−TG (PTC at 
codon 3/4 TGA), codon 17 AAG→TAG (PTC at 17 TAG), codon 8/9 +G (PTC at 
21/22 TGA), codon 27/28 +C (PTC at 42/43 TGA), and codon 41/42 −TTCT (PTC at 
60/61 TGA)] were characterized to study the relationship between the position of 
PTCs and the cell surveillance mechanism  − nonsense-mediated mRNA decay 
(NMD). The results support the hypothesis that PTCs at or 5’ to codon 17 are resistant 
to NMD, while PTCs at or 3’ to codon 21/22 are subject to NMD, which is an 
exception to the rule in the current dogma in NMD. In addition, by regulating 
translation specifically in the cytoplasm or globally, this study also supports a 
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Background and Literature Reviews 
 2
1.1  Background 
 Hemoglobin is the protein carried by red blood cells (RBC). Hemoglobin 
carries oxygen from the lungs to every part of the body and carries carbon dioxide 
back from the tissues to the lungs. Anemia occurs when the body has low number of 
red blood cells or low level of functional hemoglobin.  
Hemoglobinopathies are the commonest human monogenetic diseases; about 
7% of the world’s population are carriers of different inherited disorders of 
hemoglobin synthesis [1]. They can be classified into three major classes. Structural 
hemoglobin variants occur when the mutations alter the amino acid sequence of a 
globin chain, changing the physical properties and producing the clinical 
abnormalities. Thalassemias arise with the reduced rate of production of one or more 
of the globin chains. Another group of conditions is characterized by synthesis of high 
level of fetal hemoglobin in adult life, known as hereditary persistence of fetal 
hemoglobin (HPFH) [2].   
Thalassemia was first described by Thomas Cooley and Pear Lee in 1925 [3, 
4] for four young children with anemia and splenomegaly, enlargement of the liver, 
discoloration of the skin and of the sclera, and no bile in the urine. After that many 
Cooley’s anemia cases were reported predominantly in Mediterranean races. This 
disorder was later named thalassemia, from the Greek ‘θαλασσα’, meaning ‘the sea’, 
by Whipple and Bradford in 1932 [3, 4] to associate the disease with the 
Mediterranean area. After 1940, the genetic nature of thalassemia became clear. It 
was found that thalassemia not only occurs in the Mediterranean region but also in the 
Middle East, the Indian subcontinent and Southeast Asia. The similar distribution of 
thalassemia and the areas in which malaria was endemic indicates the positive 
selective agent for maintaining the high frequency of thalassemia might be malaria. It 
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is thought that the small genetic adjustment caused red blood cells to prevent parasite 
to survive and multiply. Thus thalassemia carriers were able to survive malaria as 
compared to healthy individuals and the number of carriers increased significantly 
over the years. 
By the early 1970s, it was apparent that there were many forms of 
thalassemias, all associated with defective production of one or more of the globin 
chains of hemoglobin [5].  
  
1.1.1 Human hemoglobin structure and switching 
Hemoglobins have different forms during the early and later stages of 
development. In adult, normal hemoglobin consists of a major component of 
hemoglobin A (HbA) and a minor component of hemoglobin A2 (HbA2). In fetus, the 
main hemoglobin is hemoglobin F (HbF). All the normal hemoglobins have the 
similar tetrameric structure that consists of two separate pairs of identical globin 
chains. Hb A is composed of two α- and two β-globin chains (α2β2), comprising 
about 97% of all hemoglobin. HbA2 is composed of two α- and two δ-globin chains 
(α2δ2), comprisng about 2.5% of hemoglobin. HbF, or fetal hemoglobin, is composed 
of two α- and two γ-globin chains (α2γ2), comprising trace amount (about 0.5%) of 
the normal adult hemoglobin. There are three embryonic hemoglobins in the embryo 
before the eighth week of intrauterine life, Hb Gower 1 (ζ2ε2), Hb Gower 2 (α2ε2), 
and Hb Portland (ζ2γ2) [6].  
The embryonic to fetal globin switch occur at about 5 weeks of gestation, the 
site of hematopoiesis changes from the yolk sac islands to the fetal liver. From 
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twentieth week of gestation, hematopoiesis subsequently occurs in the spleen and the 
bone marrow, causing the fetal to adult globin switch near the perinatal period [6]. 
 
 
1.1.2 α-Globin genes structure  
In humans, α-globin gene cluster is located on chromosome 16p13.3, 
occupying a region of about 70 kilobases [4]. The genes are arranged in the order 5’-
ζ-ψζ-ψα2-ψα1-α2-α1-θ1-3’ (Figure 1-1). The cluster contains 3 functional α-like 
genes, ζ, α2 and α1. ζ-Globin gene is embryonic α-like gene, expressing only in 
embryo. α2 and α1 genes are adult genes and they are highly homologous, differing 
only in the sequence within intervening sequence 2 (IVS 2) and in their 3’ non-coding 
region. Each α-globin genes contains three exons, separating by two introns, or 
intervening sequences. They encode identical proteins, but the expression between α2 
and α1 is about 3:1 throughout all stages of development and in adult life [5]. In 
addition to the functional α-like genes, the cluster also contains three pseudogenes 
(ψζ, ψα2, ψα1) and another gene, θ1. The pseudogenes are thought to be relics of 
past evolutionary changes within the globin gene cluster. So far no protein product 






Figure 1-1 The α-globin gene cluster on chromosome 16. X, Y, and Z boxes are homologous 
segments separated by nonhomologous elements I, II, and III. 
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Mapping and analysis of DNase1-hypersensitive sites around the α-globin 
genes suggest that an element 40 kb upstream of the ζ globin gene (HS-40) is the 
major regulatory element of the α-globin gene cluster. Each of the α genes contains 
typical promoter boxes, TATA and CCAAT homology boxes, 30 and 70 bp upstream 
of the mRNA CAP site [4].  
The DNA sequence of the α-globin gene cluster shows that α-globin locus lies 
very close to the telomere of the short arm of chromosome 16. The region around α-
globin gene cluster is very GC-rich and contains many Alu family repeats. The linked 
α-globin genes are located within two highly homologous, about 4-kb long segments. 
These regions are divided into homologous subsegments (X, Y, Z) by nonhomologous 
elements (I, II, III) [4] (Figure 1-1).  
 
1.1.3 β-Globin genes structure  
The β-globin gene cluster is located on the short arm of chromosome 11, band 
11p15.4 containing β-like globin genes arranged in the following order: 5’-ε-Gγ-Aγ-
ψβ-δ-β-3’ (Figure 1-2). The genes are also expressed in the same order during 
development [6]. The major regulatory region, called locus-control region (LCR), is 
located on the upstream of the embryonic ε gene. It contains four erythroid-cell-
specific DNase1-hypersensitive sites, spanning about 15 kb. It is essential in 












Figure 1-2 The β-globin gene cluster on chromosome 11. Vertical arrows indicate the DNase1-
hypersensitive sites in the β-globin gene locus-control region (LCR). 
 
 The β-globin complex contains microsatellite repeats of (CA)n (usually 17 
dinucleotides) and an (ATTTT)n repeat between the δ and β gene. The cluster also 
contains a lot of single nucleotide polymorphisms. Many of them affect cleavage sites 
for restriction endonucleases, giving rise to restriction fragment length 
polymorphisms (RFLPs) [4]. 
The β-globin gene spans 1600 bp and codes for 146 amino acids. It is divided 
into three exons by two intervening sequences (IVSs) (or introns). The β-globin gene 
promoter includes three positive cis-acting elements: TATA box, CCAAT box and 
duplicated CACCC motifs, located 28 to 105 bp upstream of the mRNA CAP site. 
The enhancer is found in intron 2 and 3’ of the β-globin gene, 600–900 bp 
downstream of the poly(A) site [7]. 
 
1.1.4 Genetic classification of thalassemia 
All forms of thalassemia are characterized by the absence or reduced output of 
one or more of the globin chains of hemoglobin, leading to the imbalanced globin-
chain synthesis. This is the hallmark of all thalassemia syndroms. Depending on 
which globin or globins are underproduced, thalassemia can be divided broadly into 




α, β, γ, δβ, δ and εγδβ varieties [5]. The commonest and clinically most important 
forms are α- and β-thalassemia. 
 
1.2 α-Thalassemia 
α-Thalassemia is caused by absent or reduced production of α-globin chains 
due to a deletion or point mutation of one or more of the four α-globin genes located 
on chromosome 16, resulting in an excess of β-globin chains. Analysis of the human 
α-globin gene cluster has revealed a remarkable degree of polymorphism due to point 
mutations, deletions, and insertions of DNA. There are two main varieties of α-
thalassemia, α+- and α0-thalassemia, depending on the relative output of both α genes 
per haploid genome. In the α+-thalassemias, one of the linked α-globin genes is 
inactivated by deletion (−α/αα) or point mutation (ααT/αα). In the α0-thalassemias, 
both α-globin genes on one chromosome are inactivated, most commonly by 
deletions (−−/αα) [5].  
The common mutations are deletions, involving one or both of the α-globin 
genes, or entire ζ-α-globin gene cluster [8]. The most common α+-thalassemia 
deletions are −α3.7 and −α4.2 determinants. They are found in every population in 
which α-thalassemia is common. Misalignment and reciprocal crossover between the 
homologous Z boxes at meiosis produce one chromosome with a rightward deletion − 
3.7 kb deletion (−α3.7) and another chromosome with triplicated α-globin gene 
(αααanti3.7). The −α3.7 deletion can be further subdivided into −α3.7I, −α3.7II, and 
−α3.7III, depending on the exact position of the crossover within the Z boxes. A similar 
process occurring between the two homologous X boxes give rise to the leftward 
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deletion −4.2 kb deletion (−α4.2) and αααanti4.2. There are three rare single gene 
deletions that have been described. They are −α3.5, −α2.7 and (α)α5.3 [9].  
Deletions that completely or partially remove both α-globin genes result in no 
α-globin being produced from the affected chromosome, leading to α0-thalassemia. 
The mechanisms behind include illegitimate recombination, reciprocal translocation, 
and truncation of chromosome 16. Unlike α+-thalassemia, α0-thalassemia deletions 
are restricted to their geographic distribution. The most common α0-thalassemias in 
Southeast Asia and Mediterranean region are Southeast Asia deletion (−−SEA) and 
Med deletion (−−MED), respectively [5]. Filipino deletion (−−FIL) and Thai deletion 
(−−THAI) are predominantly found in the descendants of the Philippines and Thailand 
[10-16]. 
 Although single point mutations or oligonucleotide insertions and deletions 
are less frequent than deletions in α-thalassemia, they appear to have a more severe 
effect on α-globin gene expression and hematologic phenotype than single gene 
deletions. This may be because the majority of the nondeletionl mutations involve α2 
gene whose expression is two to three times greater than α1. In addition, the 
remaining α globin gene does not increase to compensate the loss of expression from 
the other α-globin gene inactivated by point mutations. The nondeletional mutations 
in α-thalassemia involve mutations affecting mRNA splicing, mutations affecting 
initiation of mRNA tranlation, mutations affecting the poly(A) addition signal, in-
frame deletions, frameshifts, nonsense mutations and chain termination mutations [9]. 
 In α-thalassemias, the defective α-globin chain synthesis cause β-globin chain 
in excess in RBC. The degree of imbalanced globin chain synthesis is a critical factor 
determining the severity of the phenotype in α-thalassemia [5]. According to the 
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number of functional α-globin genes left, clinically α-thalassemias can generally be 
classified into α-thalassemia trait, Hemoglobin H disease and Hemoglobin Bart’s 
hydrops fetalis syndrome [17]. 
 α-Thalassemia traits involve people who have one or two α-globin gene 
inactivated by either deletion or point mutation. They could be heterozygous α+-
thalassemia (−α/αα or ααT/αα), heterozygous α0-thalassemia (−−/αα) or 
homozygous α+-thalassemia (−α/−α or ααT/−α). Their phenotypes are asymptomatic, 
spanning the clinical and hematologic phenotypes between the normal individual and 
those with Hb H disease [18].  
 Hb H disease patients have only one functional α-globin gene. The 
insufficient synthesis of α-globin chain causes the excess of β-globin chains to form 
β4 homotetramer (Hb H). Hb H can precipitate and attach to erythroid cell membrane, 
causing membrane dysfunction and early erythroid cell death [19]. Hb H inclusions 
are always detectable in the peripheral RBC of the patients. The clinical phenotype of 
Hb H disease is variable, from asymptomatic to severe anemia requiring periodic 
blood transfusions. The hematologic values also show significant variations [19].  
Hb H disease is most commonly caused by the interaction of a double gene 
deletion which remove both α-globin gene on one chromosome 16 and a single gene 
deletion which remove one α-globin gene on the other chromosome 16, known as 
deletional Hb H disease (−−/−α). Like α0-thalassemia, Hb H diseases are 
predominatly found in Southeast Asia and Mediterranean. The most common 
genotype of Hb H disease is −−SEA/−α in Southeast Asia, whereas −−MED/−α and 
−(α)20.5/−α in Mediterranean [18]. Less frequent Hb H disease results from the 
interaction of a double gene deletion which remove both α-globin gene on one 
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chromosome 16 and point mutation or small insertion/deletion which inactivate one of 
the two α-globin gene on the other chromosome, known as nondeletional Hb H 
disease (−−/αTα). Usually, the phenotype of the patient with nondeletional Hb H 
disease is more severe than that of deletional Hb H disease patient. Hb H disease can 
also occur in the homozygotes or heterozygotes for some nondeletional α+-
thalassemia which contains mutations in α2-globin gene on each of the two 
chromosome 16 (αTα/αTα) [19].  
The most severe form of α-thalassemia is Hb Bart’s hydrops fetalis syndrome 
that results from homozygous α0-thalassemia. There is no functional α-globin gene in 
the affected fetuses. The γ-globin chains form γ4 homotetramers (Hb Bart’s) without 
oxygen delivery function in utero. Certain α0-thalassemia delete both the embryonic 
ζ-globin gene and α-globin genes (eg. −−FIL), whereas some α0-thalassemia only 
remove two α-globin genes (eg. −−SEA). With the presence of at least one intact 
embryonic ζ-globin gene, the affected fetuses can survive into the second or third 
trimesters of gestation and ultimately die in utero or shortly after birth. Without 
embryonic ζ-globin gene, the fetuses can’t survive beyond early embryonic life [8]. 
α-Thalassemia is common throughout the tropical and subtropical regions 
where malaria is endemic.  α+-Thalassemia is commonly distributed across tropical 
Africa, the Middle East, certain regions of India, and throughout Southeast Asia. It 
appears that the −α3.7 type deletion is predominant in Africa whereas both −α3.7 and 
−α4.2 type deletions are common in Southeast Asia and the Pacific Islands. The 
distribution of α0-thalassemia is only limited to the Mediterranean region and parts of 
Southeast Asia [4]. Hb H disease is observed in the populations with both α+- and α0-
thalassemia, including many parts of Southeast Asia, the Middle East and the 
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Mediterranean. Numerous Hb Bart’s hydrops fetalis have been reported in Southeast 
Asia, but sporadically reported in Middle East and Mediterranean [20].  
 
1.3 β-Thalassemia 
 β-Thalassemias are caused by mutations that result in the reduced or absent 
production of β-globin chain. They are subdivided into β0-thalassemias, in which 
there is no β-globin chain production from the affected allele, and β+ or β++-
thalassemias, in which there is a severe or mild reduction of β-globin chain 
production from the affected allele, respectively. So far, almost 200 β-thalassemia 
mutations have been characterized. Unlike α-thalassemias, the vast majority of β-
thalassemias are caused by point mutations. β0-thalassemias are caused by mutations 
affecting the initiation codon, a splice junction site or mutations producing a nonsense 
codon or frameshift, whereas β+-thalassemias are caused by mutations affecting the 
transcription or mRNA processing [7, 21]. Among the rare deletions, only a 619 bp 
deletion involving the 3’ end of the β-globin gene is common in the Sind and Punjab 
populations of India and Pakistan and accounts for 20% of the β-thalassemia alleles in 
these populations [22, 23]. 
 In β-thalassemias, the absence or variable reduction of β-globin chain leads to 
imbalanced globin chain synthesis and an excess of α-globin chain. The excess α-
chains precipitate in red blood cell precursors and their progeny, leading to ineffective 
erythropoiesis with large-scale destruction of red cell precursors in the bone marrow. 
Abundant evidence has shown that the severity of β-thalassemia is related to the 
degree of globin-chain imbalance [24].  
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  The clinical phenotypes of β-thalassemias are extremely diverse, from 
symptomless to profound anemia with regular blood transfusions. They can be 
classified into three groups, thalassemia major, thalassemia intermedia and 
thalassemia trait. Thalassemia major, also called Cooley’s anemia, describes severe 
transfusion-dependent anemia, which presents during the first year of birth as the 
level of Hb F declines. With inadequate transfusion, the affected children show the 
symptoms described by Cooley, early growth retardation, pallor, icterus, and 
characteristic skeletal changes by progressive expansion of the bone marrow. They 
usually result from the inheritance of two β-thalassemia genes in compound 
heterozygous or homozygous states. Classical β-thalassemia traits are characterized 
by mild anemia with hypochromic microcytic red blood cells, low MCV and MCH, 
increased level of Hb A2 (3.5 to 5.5%) and slightly increased level of Hb F (less than 
2%). Some β-thalassemia traits have normal Hb A2 level or even no hematological 
changes so that they are called as “silent” β-thalassemias. Usually, β-thalassemia 
traits are heterozygous state of β0- or β+-thalassemias. Thalassemia intermedia cover a 
wide range of clinical phenotypes from a condition slightly less severe than 
thalassemia major to a symptomless disorder that is only ascertained by routine 
examination of blood. Their genotypes are also very heterogeneous, resulting from the 
interactions of one or two β-thalassemia alleles and other genetic variables [5, 7].   
  Dominantly inherited form of β-thalassemia describes individuals who inherit 
one β-thalassemia allele and normal α-globin genes but show a severe phenotype. 
They are characterized by a morphological evidence of dyserythropoiesis associated 
with the presence of large intraerythroblastic inclusions except for the usual features 
of heterozygous β-thalassemia [2, 7]. The mutations causing the dominantly inherited 
β-thalassemia include missense mutations, minor deletions, frameshifts resulting in 
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elongated β variants and nonsense mutations. They result in synthesis of highly 
unstable β chain variants. It is also noted that most of the nonsense mutations 
associated with dominant β-thalassemia are located in exon 3, whereas majority of the 
nonsense mutations associated with recessive β-thalassemia are located in exons 1 
and 2 [21, 25, 26]. 
 The diverse phenotype of β-thalassemia is not only due to the many different 
mutations in the β-globin gene, but also affected by other genetic elements relevant or 
irrelevant to globin synthesis. Since the severity of β-thalassemia is dependent on the 
degree of imbalance of globin chain, the co-inheritance of α-thalassemia can 
ameliorate the severity of β-thalassemia, whereas presence of extra α-globin gene 
(triplicated or quadruplicated α-globin gene arrangement, ααα or αααα) can worsen 
the severity of β-thalassemia. A high level of Hb F output after birth is another 
important factor in modifying the clinical course of β-thalassemia. In addition, other 
factors, such as iron metablism, bone disease, folic acid deficiency, and recurrent 
infection, can undoubtfully modify the clinical course of β-thalassemia [2, 27]. 
 It is estimated that at least 80 to 90 million people − 1.5% of the world’s 
population are carriers of β-thalassemia [20]. They are mainly distributed in the 
regions previously endemic for malaria, including Mediterranean, Middle East, parts 
of Africa, India, Southeast Asia, and southern China [2]. Although a large numbers of 
β-thalassemia mutations have been described, only a few common mutations and a 
varying number of rare ones account for most of the cases in each high-frequency area 




1.4 Laboratory diagnosis of thalassemia 
 
Apart from clinical manifestations, laboratory tests also play an important role 
in the diagnosis of thalassemia, particularly for antenatal diagnosis. With the 
improvement of techniques, laboratory diagnosis is more useful and reliable for 
confirming the clinical diagnosis, explaining the hematological abnormality, prenatal 
diagnosis, genetic counseling and population screening for carriers. The tests can be 
subdivided into non-molecular and molecular diagnosis. The former is based on 
hematological changes, such as complete blood count (CBC), Hb H test, HPLC for 
HbA2 and F quantification, electrophoresis and isoelectric focusing of Hbs to identify 
various presentations. The latter on the other hand is based on DNA analysis to 
identify the underlying mutations. 
 
1.4.1 Non-molecular diagnosis 
 
 
Complete blood count (CBC) 
CBC mainly includes red blood cell (RBC) number, Hb, mean corpuscular 
volume (MCV), mean cell hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red cell distribution width (RDW), hematocrit (HCT), white 
blood cell (WBC) count, and platelet count. 
Generally, thalassemias are characterized by hypochromatic and microcytic 
anemia.  In thalassemias, the RBC number is increased and the Hb concentration is 
decreased in varying degree with low MCV and MCH. Asymptomatic individuals 
with MCH below 27pg or MCV below 80fl should be investigated for thalassemia 




 Electrophoresis is a common and traditional technique for the identification of 
variant hemoglobins. It can be carried out on filter paper, cellulose acetate membrane, 
or agarose to separate variant hemoglobins at alkaline pH or acid pH. For example, 
electrophoresis at acid pH will distinguish Hb C from Hb E, and Hb O and Hb S from 
Hb D and Hb G. But this method is slow, labor-intensive, and inaccurate in the 
quantification of low concentration Hb variants (HbA2) or in the detection of fast Hb 
variants (Hb H, Hb Bart’s) [28-30]. 
 
Isoelectric focusing (IEF) 
 In IEF, various hemoglobins are separated in a pH gradient gel according to 
their isoelectric point (pI). The sharper bands on IEF allow the separation of some 
hemoglobins that cannot be distinguished by electrophoresis. This method is not 
suitable for precise quantification of low concentration Hbs (HbA2) [28, 29]. IEF also 
can be used in the classification of Hb H disease because of the good separation of Hb 
H and Hb Constant Spring tetramers in IEF gel.  
 
High performance liquid chromatography (HPLC) 
 HPLC can be used for identification and quantification of normal and variant 
hemoglobins, such as Hb A, Hb A2, Hb F, Hb S, and Hb C. It has been commonly 
used to diagnose thalassemia and hemoglobinopathies [28, 29]. 
 
Hb H inclusions 
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 In Hb H disease, and some α0-thalassemia carriers, excess β-globin chains 
caused by the reduction of α-globin chain form homotetramer β4 (Hb H). Hb H 
precipitates in red blood cells and can be visualized under microscope [28]. 
 
1.4.2 Molecular diagnosis 
Many DNA analysis techniques have been used in the detection of deletions 
and point mutations in α- and β-globin genes. Since most α-thalassemias are caused 
by deletions, while β-thalassemias are mostly caused by point mutations, the methods 
for detection of deletions are mainly for α-thalassemia, and the methods for detection 
of point mutations are mainly for β-thalassemia. 
 
Southern blot analysis 
 This is the traditional method to diagnose common α-thalassemia deletions 
and α-globin gene triplication or quadruplication. Combination of a BamHI or BglII 
digestion of DNA hybridized to an α-globin gene probe or a ζ-globin gene probe can 
be used to detect single, double, triple, quadruple α-globin gene alleles and –(α)20.5, 
−−SEA and −−MED alleles. The −−THAI and  −−FIL deletions are diagnosed by SstI 
digestion hybridized to a DNA probe located downstream of the ζ-globin gene (LO 
probe) [4, 15]. However, this method is time-consuming, labor-intensive, and may 
require the use of radioactive components. 
 
Gap PCR for deletions 
 Gap PCR is a simple technique to amplify the deletion junction fragment from 
the deletion containing allele with primers complimentary to the regions flanking the 
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deletion. Presence of the expected amplification product indicates the existence of the 
deletion, because the primers are too far apart to amplify successfully from the normal 
allele.  
Many Gap PCRs have been developed to detect the most common α0- and α+-
thalassemia deletions, including −−SEA, −−THAI, −−FIL, −−MED, −(α)20.5, −α3.7 and −α4.2 
[16, 31-35]. Recently, a multiplex PCR screen was developed to identify the seven 
most common α-thalassemia deletions in one reaction [36]. The single-tube 
multiplex-PCR for detection of common α-thalassemia deletions is simple, sensitive, 
reliable and cheap [36]. Evaluation of the multiplex-PCR in a clinical laboratory 
suggests that it is suitable as a standard clinical screening protocol for detecting 
common α-globin deletions [37]. 
A few gap PCR strategy for detection of β-thalassemia deletions have also 
been developed [4, 38]. 
 
Dot-blot and reverse dot-blot hybridization 
 Both methods are based on the hybrydization of allele-specific oligonucleotide 
(ASO) probes to amplified genomic DNA. Initially dot-blot hybridization was 
developed as the amplified genomic DNA binds to a nylon membrane in the form of 
dots. To permit a large number of mutations to be screened in a single hybridization 
step, ASO probes are fixed to the membrane, so called reverse dot-blot hybridization. 
There are two oligonucleotide probes for each mutation, one complementary to the 
mutant sequence, and the other to the normal sequence. They have been widely used 
in the diagnosis of β-thalassemia mutations [39-43]. For α-thalassemia, one reverse 
dot-blot method was also developed for the detection of 4 major types of 
nondeletional α-thalassemia mutations [44]. However, these methods are tedious, 
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time-consuming and the optimization for all the probes to hybridize at same 
temperature is not easy. 
 
Restriction fragment length polymorphism (RFLP) analysis 
 RFLP combines PCR amplification and restriction endonuclease analysis. 
More than 40 β-thalassemia mutations create or destroy a restriction endonuclease 
site, but this approach is limited by the small fraction of thalassemia mutations that 
affect the restriction enzyme site [4]. This method has been applied to the 
identification of Mediterranean β-thalassemia mutations [45]. 
 
Denaturing gradient gel electrophoresis (DGGE) 
 PCR amplification from samples heterozygous for a mutation generates 
heteroduplex and homoduplex DNA fragments during denaturation and reanealing of 
single-stranded DNA molecules. Presence of any single mismatch affects the melting 
behavior of the heteroduplex fragments so that they can be separated during 
electrophoresis through denaturing gradient gels and generate different migration 
patterns from that of homozygous samples [46]. 
 DGGE is suitable for screening unknown mutations, but the mutations have to 
be characterized by other methods, such as direct sequencing. It has been used in the 
identification of β-thalassemia mutations [46-49] and α-thalassemia point mutations 
[50]. 
 
Amplification refractory mutation system (ARMS) 
ARMS allows rapid identification of any known mutations in the genomic 
DNA. In ARMS, the allele-specific primers are designed to stop at the site of the 
 19
mutation with the 3’ terminal nucleotide complementary to the base in either mutant 
or normal sequence.  To enhance the specificity of the allele-specific primer, a 
deliberate mismatch is introduced into the sequence close to the 3’end of the primer. 
In addition, two control primers must be included in the PCR to amplify an unrelated 
fragment simultaneously to ensure the reaction is working correctly [51].  
Many ARMS assays have been developed for detection of point mutations in 
β-thalassemia [52-54] Two to three β-thalassemia mutations can be screened 
simultaneously in a single PCR reaction by combine-ARMS [55]. A multiplex ARMS 
assay has been developed to detect seven nondeletional α-thalassemia mutations [56]. 
 
Direct DNA sequencing 
 Direct DNA sequencing is the gold standard method for detection of known 
and unknown mutations. This technique has been applied on both α- [57, 58] and β-
globin gene [59] for mutation detection. It is also used as the confirmation method for 
characterization of mutations detected by DGGE, and ARMS [46, 47, 50, 59]. 
 
1.5 β-Thalassemia major and nonsense mediated mRNA decay 
Generally, β-thalassemia is transmitted as autosomal-recessive disorders. 
Inheritance of two mutant β-globin genes is required to produce clinically detectable 
phenotype. However, dominantly inherited β-thalassemia has been identified in 
individuals who inherited a single copy of an abnormal β-globin gene with normal α-
globin genotype. It was first found in an Irish family in 1973 and after which many 
families with dominantly inherited β-thalassemia have been described [26, 60-62]. 
The clinical severity of this syndrome is diverse, ranging from just detectable clinical 
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phenotype to transfusion dependency. However, the majority of the affected 
individuals present in adulthood with mild anemia, splenomegaly, jaundice, as well as 
elevated level of HbA2 and HbF, unbalanced α-/β-chain ratio, and presence of 
inclusion bodies in the erythroid precursors and peripheral red blood cells after 
removal of the spleen [26]. 
The molecular basis of the dominantly inherited β-thalassemia is 
heterogeneous. More than 30 mutations have been identified in families with different 
ethnic origin. They include missense mutations, minor deletions or insertions of intact 
codons, premature termination mutations, and frameshifts or aberrant splicing causing 
elongated or truncated β-chain variants [26]. However, most of the premature 
termination mutations that cause dominantly inherited β-thalassemia are located in 
exon 3 or beyond, whereas the termination mutations in exon 1 or 2 are recessively 
inherited [2]. The premature termination mutations that cause dominantly inherited β-
thalassemia are associated with substantial amounts of abnormal cytoplasmic mRNA, 
leading to the synthesis of highly unstable truncated β-globin products that fail to 
form functional tetramers with α-globin chain. The continuous degradation of these 
nonfunctional β-globin chains adds an extra burden to the proteolytic mechanism of 
the red blood cell precursors, leading to ineffective erythroiesis and a more severe 
phenotype (dominant negative mechanism) [2, 25, 26]. In contrast, premature 
termination mutations in exon 1 or 2 are associated with little amount of abnormal β-
globin mRNA in the cytoplasm. This is the effect of a surveillance mechanism, 
nonsense mediated mRNA decay, to prevent the premature termination containing 




1.5.1 Nonsense mediated mRNA decay (NMD) 
It is estimated that one-third of inherited genetic diseases and many forms of 
cancers are due to premature termination codons (PTCs) that have been generated 
from frameshift or nonsense mutations [65]. However, the majority of these PTCs do 
not produce truncated proteins. This is because the nonsense transcripts are 
recognized and degraded by the cell via a pathway named nonsense mediated mRNA 
decay (NMD). 
NMD is a post-transcriptional mechanism to control the quality of mRNA 
function by selectively degrading mRNAs that prematurely terminate translation 
because of a frameshift or a nonsense mutation [66, 67]. This surveillance mechanism 
prevents the production of truncated proteins that may cause deleterious dominant 
negative or gain-of-function effect [65, 68]. In addition to the PTC-containing 
transcripts, NMD also targets on other abnormal transcripts which result from routine 
errors, such as alternative spliced mRNAs [67].  
In mammalian cells, NMD is dependent on pre-mRNA splicing and the 
pioneer round of translation. During pre-mRNA splicing, an exon-exon junction 
complex (EJC) is deposited around 20-24 nucleotides upstream of each exon-exon 
junction in spliced mRNA. The EJC functions to direct mRNA nuclear export and 
recruit up-frameshift (UPF) proteins (UPF1, UPF2 and UPF3 or UPF3X) that are 
required for NMD [68-70]. Previous studies propose a general rule for the position of 
a PTC and NMD, which is if the PTC is located more than 50-55 nucleotides 
upstream of the 3’ most exon-exon junction, the mRNA is subjected to NMD [63, 64, 
71, 72].  
The pioneer round of translation, that is the first time that the mRNA passes 
through ribosome, is important in the distinction of PTC from normal termination 
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codon. During the first round of translation, ribosome removes the EJC or other 
mRNA ribonucleoprotein particle (mRNP) complexes from along the entire coding 
region till the termination codon. NMD is activated when EJC remains on the mRNA 
following termination codon [73]. There are two explanations for how the NMD may 
be triggered. One model suggests that ribosome deposits a Upf-containing protein 
complex on the mRNA after stopping at the premature termination codon; this protein 
complex scans the downstream for EJCs and NMD is triggered if an EJC is present 
[74]. The other model suggests that the 3’ terminal mRNP domains mark a proper 
context for translation termination to differentiate the normal termination codon from 
the PTC. NMD is triggered if ribosome encounters an improper mRNP environment 
when stopping at a PTC [75, 76].  
Data indicate that the newly synthesized mRNA that is bound by the 
heterodimeric cap-binding proteins CBP80 and CBP20 is subjected to NMD [77, 78]. 
In mammalian cells, the recognition of a mRNA as nonsense-containing by the NMD 
machinery leads to two degradation pathways which involves decapping followed by 
5’ to 3’ decay and deadenylation followed by 3’ to 5’ decay [79].  
It is still not clear whether NMD leads to a reduction of the cytoplasmic or 
nucleus-associated forms of PTC-containing mRNAs. Most mammalian mRNAs that 
have been studied are subjected to nucleus-associated NMD, such as transcripts for 
human triosephosphate isomerase [80, 81], human β-globin gene in nonerythroid cells 
[64, 82], hamster dihydrofolate reductase [83], and mouse T-cell receptor β (TCR-β) 
[84, 85]. However, a few mammalian nonsense messages showed a cytoplasmic mode 
of decay, such as selenium-dependent glutathione peroxidase I (GPx-1) [86] and 
human hexosaminidase A (HEXA) [87]. Theoretically, the nucleus-associated NMD 
could occur in the perinuclear cytoplasm during nuclear export of the mRNA but 
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before being released from the nuclei into the cytoplasm, involving mRNA translation 
in either the nucleus or the cytoplasm [88, 89]. More evidence has surfaced to suggest 
the presence of the PTC-scanning mechanism in the nucleus is based on the findings 
such as nonsense mutations modulating mRNA splicing, presence of basic translation 
factors in nucleus and nuclear translation [90, 91]. In contrast, there are also 
arguments against nuclear translation [92, 93].  
 
1.5.2 NMD and β-thalassemia 
In humans, NMD was initially discovered in the studies of β0-thalassemia 
caused by PTCs [94, 95]. Gradually, the role of NMD as a modifier of the phenotype 
generated from nonsense mutations became more evident [65]. Among the β-
thalassemia mutations, the majority generate premature termination codons in the first 
or second of the three exons in β-globin gene. Individuals who are heterozygous for 
these mutations are generally asympotomatic and exhibit either absent or low levels of 
mutant β-globin mRNA [4, 82]. However, the nonsense mutations in the last exon 
(exon 3) of the β-globin gene are associated with dominantly inherited β-thalassemia 
and exhibit high levels of mutant β-globin mRNA [61, 96, 97]. Translation of the 
mutant transcripts produces truncated β-chains, which causes the dominantly inherited 
β-thalassemia via a dominant-negative molecular mechanism. 
Human β-globin transcripts with nonsense mutations in the last exon are 
resistant to NMD, a finding consistent with current knowledge of the mechanism of 
NMD. In addition, most human β-globin transcripts containing PTCs more than 50 
nucleotides upstream of the last exon-exon junction are subjected to NMD. Finer 
mapping shows that a boundary exists in exon 2 [63, 64, 82]. However, it has been 
shown in erythroid cells that nonsense mutations in the 5’ half of exon 1 are resistant 
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to NMD, an exception for the current model of NMD [98]. The PTCs of human β-
globin that have been studied on the expression level of aberrant transcripts are shown 
in Figure 1-8. Except for the mutations downstream of the 3’ boundary, a few 
mutations in the 5’ half of exon 1 also fail to elicit NMD. These observations suggest 
that the relative position of the PTC to the last exon-exon junction is not sufficient to 
induce NMD in these cells. In addition, the localization of NMD for β-globin gene is 








Figure 1-3 Schematic representation of the PTCs in human β-globin gene that have been studied 
on the expression level of aberrant transcripts. PTCs that are located in the 5’ half of exon 1 and 
downstream of 3’ end boundary (50-55 nts upstream of intron 2) are resistant to nonsense-mediated 
mRNA decay (NMD) and associated to high level of PTC-containing mRNAs. They are shown on top 
of the β-globin gene. PTCs that are located in the 3’ half of exon 1 and 5’half of exon 2 (upstream of 3’ 
end boundary) are subjected to NMD and result in low level of PTC-containing transcripts. They are 
shown below the β-globin gene. *Contradictory results were shown from two studies for PTC17, one 
with high level and one with low level of the mutant mRNA. 
 
1.6 Objectives 
Although molecular diagnostic methods are available for α- and β-
thalassemia, most of them are tedious, time-consuming or expensive. One major 
objective of this study is to develop simple and universal molecular assays to detect 
the most common forms of α- and β-thalassemia alleles in Southeast Asia. Mutations 
that are common in the Mediterranean regions and African are not included in the 
assays. However, if these new molecular methods can be used in the diagnostic assays 
Exon 1 Exon 2 Exon 3 
5’-UTR IVSI IVSII 3’-UTR
0 30 303 104 105 146 
21/22 26 37 39 72/73 82
5 15 17* 88 91 95 98 101, 103 106 107 114 121 127 141
3’ end boundary of NMD
(50-55nts upstream of intron 2) 
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for the Southeast Asian mutations, they should be easily applied on the development 
of the assays for the common mutations in other populations.  
The second objective involved molecular characterization of α-thalassemia 
mutations in Hb H disease patients to evaluate the accuracy of isoelectric focusing 
(IEF) in classifying hemoglobin H disease. A robust and accurate α-globin gene 
sequencing protocol was also included in this study.  
In addition, a few β-thalassemia mutations close to the 5’ end of the β-globin 
gene were studied on the mRNA level to characterize the relationship of mutation 
localization and nonsense-mediated mRNA decay (NMD). The results presented 









2.1  Importance of improved tools for molecular diagnosis of α- and β-
thalassemia in Southeast Asia 
 Improvement of new technologies and rapid advances in bioinformatics enable 
accurate diagnostics and effective therapies to be rapidly developed. Making used of 
information generated from population study and applying state-of-the-art 
technologies, we have developed novel molecular diagnostics for common α- and β-
thalassemia mutations in Southeast Asia.  These new molecular tools are intended to 
provide a more rapid, efficient, and cost-effective alternative to current thalassemia 
molecular testing methods. 
 
2.1.1 Importance of positive controls for the PCR-based diagnosis 
PCR is one of the most powerful technologies in molecular diagnosis and 
research. Its efficiency depends on several aspects, such as the specificity of primers, 
concentration of primers, kinds of polymerase, quality and quantity of templates 
(DNA), PCR conditions, and even different thermal cycler. After every condition has 
been optimized, failure of PCR is still possible. That could be due to using new batch 
of synthesized primers, different DNA samples or other unknown reasons. Therefore, 
a positive control system is essential to allow a real targeting event to be distinguished 
from various types of false positives and false negatives that may arise during the 
diagnostic PCR. 
We and others recently described strategies for multiplex polymerase chain 
reaction (PCR) analyses of deletional determinants of α-thalassemia [32-34], 
culminating in the development of a single-tube assay for simultaneous screening of 
seven common deletions [36].  Since then, several molecular diagnostic laboratories 
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wishing to set up the test have requested DNA samples carrying these deletions for 
use as validation and positive controls.  These requests have resulted in a critical 
shortage of our limited stocks of genomic samples, especially those with the rarer 
deletions, resulting in our inability to fulfill all requests.  The ideal solution to limited 
genomic DNA is to establish immortal lymphoblastoid cell lines from patients’ 
peripheral blood leukocytes by Epstein-Barr virus transformation [103, 104].  To do 
so, however, requires recontact and reconsent of patients to provide a fresh aliquot of 
blood for transformation, which may be inconvenient or impractical for third-party 
referral laboratories to implement.  
We have devised an alternative strategy for creating a renewable resource of 
positive control samples of known α-thalassemia genotype, derived from existing 
patient DNA samples. 
 
2.1.2 Importance of multiplex-minisequencing in screening for common α- and 
β-thalassemia mutations 
More recently, fluorescence-based multiplex-minisequencing  followed by gel 
electrophoretic size separation has been used to simultaneously detect multiple 
mutations and other nucleotide variants [105-107]. In minisequencing, a primer is 
hybridized to DNA next to a variant nucleotide site and extended with DNA 
polymerase by a single appropriate dideoxyribonucleotide triphosphate (ddNTP) that 
matches the nucleotide at the target site.  Minisequencing on solid-phase arrayed 
primers to detect 10 point mutations in the β-globin gene has also been demonstrated 
[108].  Arrayed minisequencing strategies are extremely attractive for multi-mutation 
screening applications, but require robotics and other instrumentation which are 
beyond the reach of most diagnostic laboratories. 
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We have developed a rapid screening procedure based on liquid-phase 
multiplex-minisequencing and capillary electrophoresis to detect the most common 
Southeast Asian and Indian α- and β-thalassemia mutations. 
 
2.1.2.1 Common β-thalassemia mutations in Southeast Asia and India 
Although over 200 β-thalassemia alleles have now been characterized,  in each 
affected ethnic group, a few common mutations together with a variable number of 
rare mutations account for most of the cases [4, 21]. 
In Southeast Asia and India, β-thalassemia is a serious public health problem 
throughout the region.  In these regions, less than 20 variations account for the 
overwhelming majority of β-thalassemia alleles.  These include −29 A→G, −28 
A→G, initiation codon for translation T→G, codon8/9 +G, codon17 A→T, codon19 
A→G, codon26/HbE G→A, codon27/28 +C, IVSI,1 G→T, IVSI,5 G→C, codon35 –
C, codon41/42 −TTCT, codon43 G→T, codon71/72 +A, IVSII,654 C→T, and the 
∆619bp deletion [4, 11, 22, 43, 109-111].  Three variants alone account for over two-
thirds of the β-thalassemias in the combined region; IVSI,5 G→C (33%), codon41/42 
−TTCT (27%) and IVSI,1 G→T (9%) [4]. 
 
2.1.2.2 Common α-thalassemia non-deletional mutations in Southeast Asia 
Most α-thalassemia mutations involve deletions of one (−α) or both (−−) α-
globin genes, while point mutations within the α-globin genes (αTα or ααT) are much 
less frequent.  Nonetheless, the number of point mutations that have been described 
has been steadily increasing, with more than 40 identified to date [5, 9].   
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The importance of non-deletional α-thalassemia mutations is underscored by 
the observation that patients with non-deletional Hemoglobin (Hb) H disease 
(αTα/−−) are generally more severely affected and more likely to require transfusions 
compared with deletional Hb H disease patients (−α/−−) [19].  There has also been a 
few reports of Hb H disease caused by homozygosity or compound heterozygosity of 
non-deletional mutations involving the α2-globin gene (αTα/αTα) [5, 19].  
Additionally, non-deletional Hb H disease involving the α2 codon30 or codon59 
mutation can cause the fatal Hb H hydrops fetalis syndrome, especially if associated 
with large zeta-alpha globin gene deletions [112].  In certain regions of Southeast 
Asia, non-deletional Hb H disease can account for as much as 50% of all Hb H 
disease patients [19]. 
A multiplex-minisequencing assay was developed to detect 7 Southeast Asian 
non-deletional mutations: Hb Constant Spring (α2 codon142 TAA→CAA), Hb Paksé 
(α2 codon142 TAA→TAT), and Hb Quong Sze (α2 codon125 CTG→CCG), α2 
codon0 ∆1bp (−T), α2 codon30 ∆3bp (−GAG), Hb Suan Dok (α2 codon109 
CTG→CGG), and α2 codon59 (GGC→GAC). 
 
2.1.3 Importance of screening for anti-3.7 and anti-4.2 α-globin gene 
triplication 
β-Thalassemia is caused by mutations in the β-globin gene that result in absent 
or reduced β-globin chain synthesis.  As a consequence, the excess α-globin chains 
begin to precipitate in the red cell precursors, resulting in ineffective erythropoiesis, 
hemolysis of RBCs, anemia and other sequelae.  Both genetic and environmental 
factors are known to cause the extreme diversity in clinical severity of the β-
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thalassemias. There is abundant evidence demonstrating the relationship between 
severity of β-thalassemia and the degree of globin-chain imbalance [24].  Typically, 
the inheritance of a single β-thalassemia allele is associated with mild anemia and 
hypochromic microcytic red cells.  However subjects who have β-thalassemia may 
also inherit α-thalassemia as these mutations coexist at a high frequency in many 
populations.  Studies have shown that whilst the co-inheritance of α-thalassemia 
generally ameliorates the severity of β-thalassemia by reducing chain imbalance, 
coinheritance of triplicated α-globin genes (ααα) exacerbates phenotypic severity of 
β-thalassemia by causing more globin chain imbalance [2].  Compared with simple β-
heterozygotes, co-inheritance of triplicated or quadruplicated α-globin genes in β-
heterozygotes often leads to more significant anemia, splenomegaly, more 
pronounced red cell abnormalities, the presence of circulating normoblasts, higher 
hemoglobin F concentrations, and even the presence of inclusion bodies in 
erythroblasts [113, 114]. Because the α- and β-globin gene clusters are physically 
unlinked and segregate independently, β-thalassemia carriers who also carry 
triplicated or quadruplicated α-globin genes have a 25% risk of having a similarly 
affected offspring, although their partners may be entirely normal. 
Triplicated α-globin genes appear to be ubiquitous and have been found in 
most populations [2].  They result from misalignment and unequal crossover between 
the homologous X-, Y- and Z-box segments of the α-globin gene cluster during 
meiosis (Figure 2-1).  Generally, two types of triplicated alleles can be generated from 
an unequal crossover, αααanti3.7 and αααanti4.2.  If the crossover occurs between the 
homologous Z2 and Z1 boxes, also referred to as a “rightward crossover”, this results 
in a −α3.7 single gene deletion allele and the reciprocal αααanti3.7 triplicated allele.  
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However, if the crossover occurs between the X2 and X1 boxes (a “leftward 
crossover”), a −α4.2 single gene deletion allele and the reciprocal αααanti4.2 triplicated 










Figure 2-1 Schematic illustration of misalignment and unequal crossover at the α-globin gene 
cluster to generate single gene deletion and reciprocal gene triplication. Crossovers between 
misaligned Z boxes give rise to −α3.7 and αααanti3.7 chromosomes (rightward crossover).  Crossovers 
between misaligned X boxes give rise to −α4.2 and αααanti4.2 chromosomes (leftward crossover). 
 
A Sri Lankan study of individuals with severe to moderate β-thalassemia 
revealed a 2% frequency of α-globin gene triplications [115], whereas a preliminary 
study in Hong Kong suggests that the frequency of α-globin gene triplication carriers 
among individuals with β-thalassaemia and iron deficiency is ~3.3% [E.S.K. Ma, 
A.Y.Y. Chan, L.C. Chan, unpublished observation].  The true prevalence of α-globin 
gene triplications is not well defined in other populations.  Because the α- and β-
globin gene clusters are unlinked, it is likely that the percentages derived from the β-
thalassemia cohorts are a reasonable indicator of the general population frequency of 
α-globin gene triplication carriers.  
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Current PCR methods can only detect the anti-3.7 but not the anti-4.2 
triplication [31, 32], and Southern blotting is required to detect both the anti-3.7 and 
anti-4.2 triplication and quadruplication alleles [116].  Although highly sensitive and 
specific, Southern blotting is labor-intensive and time-consuming, and is thus not an 
ideal screening tool.  A simple, rapid and reliable single-tube multiplex-PCR assay 
was developed to screen for the presence of the anti-3.7 and anti-4.2 α-globin gene 
triplications. 
 
2.2 Molecular verification of Hb H disease classification by isoelectric 
focusing (IEF) 
Hemoglobin (Hb) H disease is a severe form of α-thalassemia.  It usually 
results from inactivation of three out of four α-globin genes, leaving only one 
functional gene.  As a result, the synthesized α-globin chains are insufficient for 
balanced tetramerization with β-globin chains necessary to form Hb A (α2β2).  The 
excess β-globin chains form relatively unstable Hb H molecules (β4 tetramers) in the 
erythrocytes [5].  The Hb H molecules precipitate and can attach to the cell membrane 
to cause membrane dysfunction and hemolysis [19]. Genetically, there are two types 
of Hb H disease, deletional and non-deletional.  The phenotype of Hb H disease is 
extremely variable, from symptomless to severe anemia requiring blood transfusions.  
Generally, patients with non-deletional Hb H disease present with a more severe 
phenotype than those with deletional Hb H disease [5, 19]. 
Hb H disease is particularly prevalent in Southeast Asia because of the high 
frequency of α-thalassemia carriers in these areas [5, 19].  In north Thailand, about 
1.5% (1:65) of babies are expected to be born with Hb H disease [12].  In addition, 
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non-deletional Hb H disease with αConstant Spring (Hb H CS) is very common in 
Thailand, where ~40-50% of Hb H disease patients have non-deletional Hb H with 
αConstant Spring [117].  
Since the 1980s, isoelectric focusing (IEF) has been widely used in the 
identification of hemoglobin variants.  It has also been used in the diagnosis of Hb H 
disease and Hb Bart’s hydrops fetalis because of the good separation of Hb Bart’s, Hb 
H, and Hb CS tetramers in IEF gels.  But the accuracy of IEF in Hb H disease 
classification is unknown.  To evaluate the accuracy of IEF in predicting α-globin 
genotype, we analyzed the genotypes of 110 Thai patients diagnosed as either 
deletional Hb H disease or non-deletional Hb H CS disease by IEF.  A multiplex gap-
PCR assay was used to detect deletions, and a robust sequencing protocol was 
developed to screen for mutations within the GC-rich α-globin genes and their 
promoter and upstream sequences. 
 
2.3 Characterization of the relationship between premature termination 
codon (PTC) and nonsense mediated mRNA decay (NMD) 
Nonsense-mediated mRNA decay (NMD) is an mRNA quality control 
mechanism that selectively degrades mRNAs that carry premature translation 
termination codons (PTCs) [66]. By removing the abnormal transcripts, NMD 
prevents the synthesis of truncated proteins that could have dominant-negative effects 
on cell function [72]. This surveillance mechanism has been found in yeast, worms, 
flies and humans with conserved core proteins and process [118]. 
The ability of NMD to modulate phenotypic severity has been shown in β-
thalassemia. Most aberrant mRNAs containing PTCs located on exon 1 and 2 are 
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subjected to NMD and associated with recessively inherited β-thalassemia [82]. In 
contrast, the PTCs in the last exon of β-globin gene, exon 3, do not trigger NMD and 
are associated with dominantly inherited β-thalassemia [61, 97]. The truncated β-
globin chains generated in the dominantly inherited β-thalassemia are extremely 
unstable and they are hardly detectable but predicted from the DNA sequence [26]. 
These observations are consistent with the current rule for defining PTCs that elicit 
NMD. It is proposed that PTCs located more than 50-55 nucleotides upstream of the 
3’ most exon-exon junction generally elicit NMD [64, 119].  
However, exceptions are also reported for this “3’ boundary rule”. For 
example, mouse T-cell receptor (TCR)-β transcripts with PTCs within 50 nucleotide 
upstream of the 3’ most exon-exon junction can still trigger NMD. In addition, the 
PTCs in TCR-β cause boundary-independent polar NMD, which means that the closer 
the PTCs to the 3’ most exon-exon junction, the less efficient for them to trigger 
NMD [84, 120]. Studies in human triosephosphate isomerase (TPI) gene and breast 
cancer 1 (BRCA1) gene show that the 5’ end nonsense mutations do not lead to NMD 
or lead to less efficient mRNA degradation, which suggests the translation re-
initiation protect the PTC-containing mRNAs from NMD [121, 122]. An exception is 
also shown in the β-globin gene where nonsense mutations in the 5’ half of exon 1 are 
resistant to NMD in erythroid cells [98]. These results suggest that the position of the 
PTCs relative to the downstream exon-exon junction is not sufficient to determine 
NMD. 
A few nonsense mutations in exon 1 and 2 of the β-globin gene have been 
studied at the mRNA level [25, 63, 64, 82, 98, 123]. All showed reduced mRNA 
accumulation except for codon5 (CCT→TAG), codon15 (TGG→TGA) and codon17 
(AAG→TAG) [98] that are the 5’ most PTCs. These results indicate the presence of a 
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5’ boundary in the β-globin gene that distinguishes PTCs that do and do not undergo 
NMD. This boundary may exist in between codon17 and codon21/22 since the level 
of mutant mRNA with PTC at codon17 is high whereas the level of mutant mRNA 
with PTC at codon21/22 is low [64, 98]. However, an earlier study detected a low 
level of mutant mRNA from the PTC at codon17 [82], which is contradictory to this 
hypothesis. 
In this study, five naturally occurring nonsense mutations close to the 5’ end 
of the human β-globin gene were analyzed to determine the relationship between the 
position of PTCs at the 5’ end of the β-globin gene and resistance to NMD. Since 
NMD is dependent on translation [68], both cytoplasmic translation regulation and 
global translation regulation (cytoplasmic plus nuclear translation) were applied to 
distinguish between the NMD and non-NMD pathways and to identify the cellular 
localization of NMD. Our results support the existence of a 5’ boundary and a 




Materials and Methods  
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3.1  Development of improved tools for molecular diagnosis of α- and β-
thalassemia in Southeast Asia 
 The materials and methods of each molecular diagnostic assay are described 
below in detail individually. 
 
3.1.1 Construction of “reconstituted” positive controls for the 7-deletion 
multiplex-PCR 
 
3.1.1.1 Preparation of seven deletion junction fragments 
Five genomic DNA samples of known α-thalassemia genotypes (αα/−−FIL, 
−α3.7/−−THAI, −α3.7/−−SEA, −α20.5/−−MED, and αα/−α4.2) were used as the templates to 
amplify the seven deletion junction fragments individually by PCR. Each 50 µl 
reaction contained 0.2 mM of each dNTPs (Roche Biochemicals, cat No. 1969064), 1 
× PCR buffer containing 1.5 mM MgCl2, 1 × Q solution and 2 units of HotStarTaq 
DNA polymerase (Qiagen, Hilden, Germany. cat No. 203203), 100ng of genomic 
DNA and the relevant primer pair for each deletion at various concentration as 
described previously in the 7-deletion multiplex-PCR [36]. Thermal cycling was 
performed in a Biometra T3 thermal cycler (Biometra, GmbH Germany) with 
conditions same as the 7-deletion multiplex-PCR: initial enzyme activation at 95°C 
for 15 minutes; followed by 30 cycles of denaturation at 98°C for 45 seconds, 
annealing at 60°C for 1 minutes 30 seconds, extension at 72°C for 2 minutes 15 
seconds; a final extension at 72°C for 5 minutes.  
All 50 µl of each amplified product was analyzed by electrophoresis though a 
1% agarose gel (with ethidium bromide) in 1 × Tris-Borate-EDTA (TBE) buffer at 10 
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volts/cm for an hour. GeneRulerTM 1kb DNA ladder (MBI Fermantas, cat No. 
SM0311) was used as size maker in the agarose gel analysis. The agarose gel was 
visualized on ultraviolet transilluminator and the expected amplicon for each of the 
deletion junction fragments was cut out from the gel into polypropylene micro-
centrifuge tubes for purification.  
The amplicon of each deletion junction fragment was purified out from the gel 
band by using GFXTM PCR DNA and gel band purification kit (Amersham 
Biosciences, cat No.27-9602-01). According to the manufacturer’s protocol, the 
agarose gel was dissolved in the capture buffer at 60°C, and then the sample was 
passed through the GFX column to capture the DNA onto the glass fiber matrix, 
followed by matrix-bound DNA washing with an ethanolic wash buffer. The purified 
DNA was eluted from the GFX column into 30 µl TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0).  
The concentration of each purified PCR product was estimated by dot blot, 
comparing the brightness of the fluorescence emitted from sample to that of DNA 
standards (10 ng/µl, 25 ng/µl, 50 ng/µl, 75 ng/µl, and 100 ng/µl). The mixture of 1 µl 
of each DNA sample or DNA standard and 5 µl of ethidium bromide (2 µg/ml) were 
dotted on a parafilm and the fluorescence was visualized on an ultraviolet 
transilluminator. 
 
3.1.1.2 Construction of T-vector 
T-vector was constructed from pBluescript II KS (+) plasmid DNA (Figure 3-
1). 5 µg of pBluescript II KS (+) plasmid DNA (Stratagene, cat No. 212207) were 
digested with 10 units of restriction enzyme EcoRV (MBI Fermentas, cat No. 
ER0301) in supplied 1 × buffer R+ to generate the linearized DNA with blunt ends. 
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The digestion reaction mixture was incubated at 37°C for 2 hours.  5 µl aliquot of the 
digestion products was checked by electrophoresis through 1% agarose gel to make 










Figure 3-1 Strategy of cloning seven deletion junction fragments. Schematic representation of T-
vector cloning of deletion junction fragments that were PCR-amplified from actual patient genomic 
DNA. 
 
Phenol-chloroform purification of the linearized plasmid DNA was carried out 
using the following protocol. The digestion products were topped up to 100 µl with 
deionized water and then mixed with equal volume of Phenol:Chloroform:Iso-
amylalcohol (in the ratio of 25:24:1 v/v). They were mixed thoroughly to form a 
transiently homogeneous suspension by vortex and centrifuged at 13000 rpm for 5 
minutes to separate the proteins from the DNA solution using a tabletop micro-
centrifuge (Heraeus Biofuge pico, GmbH Germany). The aqueous upper phase 
containing DNA was carefully transferred to a new polypropylene micro-centrifuge 
tube containing 100 µl of Chloroform: Iso-amylalchohol (in the ration of 24:1 v/v) to 
remove phenol and proteins from the previous wash. After vortex and centrifugation 
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at 13000 rpm for 5 minutes, the aqueous upper phase was transferred to a new 
polypropylene centrifuge tube containing two volumes (200 µl) of ice-cold absolute 
ethanol. After keeping the mixture at –20°C for 20 minutes, the DNA was precipitate 
down by centrifugation at 13000 rpm for 20 minutes. The pellet was washed with 500 
µl 70% ethanol and centrifuged at 13000 rpm for 10 minutes. The DNA pellet was 
air-dried and then dissolved into 30 µl of TE buffer.  
T-vector was constructed by adding dTTP to the 3’end of the linearized 
pBlusecript II KS (+). The 50 µl reaction contained 1 × PCR buffer, 1.5 mM MgCl2, 2 
mM dTTP, 5 units of Platinum® Taq DNA polymerse (Invitrogen life technologies, 
cat No. 10966-018) and 30 µl of the linearized plasmid DNA. The Platinum® Taq 
DNA polymerse was activated at 95°C for 5 minutes first before adding DNA and 
then the whole mixture was incubated at 72°C for 1 hour.  The T-vector products were 
subjected to phenol-chloroform purification again following the protocol described 
preciously and the DNA pellet was re-suspended into 50 µl TE. The DNA 
concentration of the T-vector was determined using a spectrophotometer by reading 
optical density at absorbance 260 nm. 
 
3.1.1.3 T-A cloning 
T-A cloning strategy was used to permit the direct ligation of PCR amplified 
DNA to a T-vector (Figure 2-1). This approach takes advantage of the single 3' 
deoxyadenylate (dATP) extension that the Taq DNA polymerase adds to the terminal 
ends of the amplified DNA. Each 5ul ligation reaction contained 15ng T-vector and 
an amount of PCR product resulting in a final vector to insert molar ratio of 1:3, and 
1unit T4 DNA ligase in 1× supplied ligation buffer (MBI Fermentas, cat No.EL0334).  
Ligation reactions were incubated at 16°C for 16 hours. 
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Each ligation product was transformed into Subcloning EfficiencyTM DH5α™ 
competent cells (GibcoBRL Life Technologies, cat. No. 18265-017) using the 
following protocol. 1µl of each ligation product (1-10 ng DNA) was gently mixed 
with 50 µl competent cells in a polypropylene micro-centrifuge tube by flicking the 
tube and incubating on ice for 30 minutes. After heat-shock at 37°C for 20 seconds 
without agitation, the tubes were rapidly transferred into ice and chilled for 2 minutes.  
0.95 ml of room temperature SOC medium (2% Tryptone, 0.5% Yeast extract, 0.05% 
NaCl, 20 mM Glucose, 2.5 mM KCl, and 10 mM MgCl2, pH 7.0) was added to each 
tube and the tubes were transferred to a shaking incubator set at 37°C, 225 rpm. 
Incubation was allowed for 1 hour to allow the bacteria to recover and to express the 
makers encoded by the plasmid. During the incubation, 100 µl of 100 mM IPTG 
(isopropyl-beta-D-thiogalactopyranoside) beta-galactosidase inducer (BioRad, cat No. 
170-3201) and 20 µl of 50 mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) (BioRad, cat No. 170-3455) were mixed and plated over the 
surface of each LB agar plate with ampicillin (100 µg/ml). The plates were allowed to 
absorb IPTG and X-Gal for 30 minutes at 37°C prior to use. The presence of IPTG 
and the color-changing substrate X-Gal of beta galactosidase encoded by LacZ gene 
in pBluescript allows blue-white screening to identify the colonies containing 
plasmids with inserted sequence. After expression, 100 µl of each culture was plated 
on a LB ampicillin agar plate containing IPTG and X-Gal using a glass spreader. 
After precipitation of the bacteria left in each tube by centrifugation, 800 µl 
supernatant was taken out and discarded from each tube. The rest of the 100 µl culture 
media and bacteria pellet left in each tube were mixed and plated on another LB 
ampicillin agar plate with IPTG and X-Gal. Plating at two dilutions for each culture 
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ensures that isolated colonies are obtained. The plates were incubated at 37°C for 16 
hours.   
 Recombinant colonies containing each junction fragment were identified by 
blue-white screening and PCR amplification. 5 single white colonies were scratched 
out from each plate using sterile small micropipetter tips and transferred into 
individual tubes containing 10 µl of LB medium (1% Tryptone, 0.5% Yeast extract, 
and 1% NaCl, pH 7.5).  1 µl of the LB medium containing bacteria was used as the 
template of PCR amplification. The tubes left with 9 µl of the LB medium containing 
bacteria were stored at 4°C. To identify the recombinant colonies containing each 
deletion junction fragment, two PCR reactions were performed. One was performed 
using specific primers for each deletion junction fragment following the PCR protocol 
described previously. The other PCR reaction contained vector-specific primers: T7 
(5’→3’ GTA ATA CGA CTC ACT ATA GGG C) and T3 (5’→3’ AAT TAA CCC 
TCA CTA AAG GG), which flank the multiple cloning site in the pBluescript II KS 
(+), in 0.2 µM concentration (Figure 2-1). The PCR protocol was same as described 
previously. This amplification was used to confirm that one copy of each deletion 
junction fragment was inserted in the plasmid DNA. Following PCR, 10 µl of each 
amplified product was analyzed together with GeneRulerTM 1kb DNA ladder (MBI 
Fermantas, cat No.SM0311) by electrophoresis through a 1% agarose gel in 1 × TBE 
buffer at 10 volts per centimeter for one hour. After visualization of the ethidium 
bromide stained agarose gel under UV transilluminator, the samples with the correct 
amplicon size were used for bacteria inoculation and plasmid DNA minipreparation. 
 One tube of LB medium with bacteria (9 µl) that contained the correct 
insertion for each deletion junction was used to inoculate 5 ml LB medium with 
ampicillin (100 µg/ml) in a 15 ml Falcon tube. The tubes were shaken at 225 rpm 
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overnight at 37°C. The recombinant plasmid DNAs containing each deletion junction 
fragment were isolated from each cultured bacteria by Wizard® Plus Minipreps DNA 
Purification System (Promega, cat No. A7510) following the manufacturer’s protocol. 
The concentration of each recombinant plasmid DNA was determined using a 
spectrophotometer by reading optical density at absorbance 260 nm. 
 
3.1.1.4 Preparation and validation of 7 heterozygous reconstituted positive 
controls 
 To generate a reconstituted genomic DNA sample heterozygous for an α-
thalassemia deletion, recombinant plasmid DNA containing the relevant deletion 
junction fragment was mixed with genomic DNA extracted from a lymphoblastoid 
cell line (GM07428, Corell Institute, Camdem, N.J.), that was previously determined 
to be homozygous normal (non-deleted) at the α-globin locus. 7-deletion multiplex-
PCR amplifications were performed as described [36], and one-fifth of each product 
was resolved in 1% agarose (1× Tris-Borate-EDTA) at 15 volts/cm for 1 hour.  
Starting with equimolar mixes of haploid genome equivalents and supercoiled 
plasmid constructs, the molar ratios were empirically adjusted such that the multiplex-
PCR results for each of the reconstituted heterozygous positive control samples 
closely resembled those obtained from actual heterozygous patient samples.  We 
further re-adjusted the ratios of plasmid constructs to normal genomic DNA such that 
the signal intensities of the amplified deletion junction fragments relative to the 
normal control α2 fragment were weaker coming from reconstituted positive control 
samples than from actual heterozygous patient samples (Table 3-1).  The higher 
stringency conditions for detection of deletion junction fragments from reconstituted 
positive controls compared with actual samples should ensure authenticity of negative 
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diagnostic test results when the reconstituted positive controls are positive, thus 
avoiding false negative results that could occur due to sub-optimal PCR amplification 
conditions.   
Table 3-1 Generation of heterozygous α-thalassemia genomic samples: optimization of mixtures 
of normal genomic DNA with plasmid constructs carrying deletion junction fragments. 
 
Deletion Junction fragment, bp 
Construct 
size, bp 
Molecular  weight 
of construct 
Construct added per 
100ng gDNA,a, b pg 
Molar ratio 
(deletion : α2c) 
−α3.7 2029 4990 3.29 x 106 0.566 ~ 3.5 : 1 
−α4.2 1628 4589 3.03 x 106 0.459    ~ 3 : 1 
−−SEA 1349 4310 2.84 x 106 0.714    ~ 5 : 1 
−−THAI 1153 4114 2.72 x 106 1.176 ~ 8.5 : 1 
− (α)20.5 1007 3968 2.62 x 106 0.227 ~ 1.5 : 1 
−−MED 807 3768 2.48 x 106 0.271    ~ 2 : 1 
−−FIL 546 3507 2.31 x 106 0.750 ~ 6.5 : 1 
a One hundred nanograms of human genomic DNA contain ~ 3 × 104 haploid genome-equivalents. 
Normal human genomic DNA contains 1 copy of the α2 globin gene per haploid genome. 
b gDNA, genomic DNA. 
c Ratio of α2 globin gene copies to deletion junction copies in reconstituted genomic samples necessary 
to achieve results similar to actual heterozygous DNA samples. 
 
3.1.2 β-Thalassemia multiplex-minisequencing assay 
 
3.1.2.1 DNA samples 
Archived genomic DNA samples of various β-thalassemia genotypes were 
used in assay optimization.  The genotypes of these patient samples were previously 
determined by direct β-globin gene sequencing and/or ARMS PCR.  Assay specificity 
was evaluated by analysis of DNA samples heterozygous and homozygous for each 
mutation.  Where actual samples homozygous for a particular mutation were not 
available, the assay was tested directly on recombinant plasmids containing the 
relevant cloned mutant allele. 
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There were no patient samples with a codon35 –C mutation available.  A 
mutant allele carrying this mutation was therefore artificially created using PCR 






















Figure 3-2 Strategy of PCR mutagenesis to generate mutation Cd35 -C in human β-globin gene.  
Cd35m-F and Cd35m-R primers are the mutagenesis primers that contained the Cd35 –C mutation 
sequence and annealed to the region involving Cd35. The red dot indicates the wildtype sequence at 
Cd35. while the blue cross indicates the Cd35 –C mutation sequence. The mismatch at Cd35 between 
mutagenesis primers and wildtype DNA would not affect the primer annealing. Two overlapped PCR 
fragments A and B were generated from first round of PCR and both of them contained Cd35 –C 
mutation. In the second round of PCR, they were used as template to generate a 1.4 kb fragment 
contained Cd35 –C mutation.  
 
As shown in Figure 3-2, two rounds of PCR were involved in the PCR 
mutagenesis. In the first round of PCR, two overlapping β-globin gene fragments A 
(423bp) and B (1054 bp) containing Cd35 –C mutation were generated using primers: 
β-F and Cd35m-R, Cd35m-F and β-R1, respectively (Table 3-2). Cd35m-F and 
Cd35m-R primers are mutagenesis primers and annealed to the sequence involving 
Cd35. They contained Cd35 –C mutation which caused mismatch at Cd35, but the 
2nd round of PCR 
PCR fragment A 















mismatch would not affect primers annealing during PCR. Both the PCRs for 
amplification of fragment A and B were performed in 50 µl reaction volume 
containing 100 ng of genomic DNA with wildtype β-globin gene, 0.2 µM of the PCR 
primers, 0.2 mM of each dNTPs (Roche Biochemicals, cat No. 1969064), 1 × PCR 
buffer containing 1.5 mM MgCl2 and 1 unit of HotStarTaq DNA polymerase (Qiagen, 
Hilden, Germany, cat No. 203203). Thermal cycling was performed in a Biometra T3 
thermal cycler (Biometra, GmbH Germany), with an initial 15 minutes enzyme 
activation at 95°C, followed by 30 cycles of 98°C denaturation for 1 minute, 55°C 
annealing for 1 minute, 72°C extension for 30 seconds (fragment A) or 1 minute 30 
seconds (fragment B), and a final extension at 72°C for 5 minutes. 
Table 3-2 Primer sequences for the β-globin gene Cd35 –C mutagenesis PCR. 
Name Sequence 5’→3’ Nucleotides ID in HUMHBB Amplicon (size) 
β-F ACG GCT GTC ATG ACT TAG AC 62010→ 62029 
Cd35m-R GTC CAA GGT AGA CCA CCA G 62432→ 62413 
Fragment A 
(423 bp) 
    
Cd35m-F CTG GTG GTC TAC CTT GGA C 62413→ 62432 




After thermal cycling, all the 50µl of each PCR product was analyzed by 
electrophoresis through a 1% agarose gel (with ethidium bromide) in 1 × Tris-Borate-
EDTA (TBE) buffer at 10 volts/cm for an hour. GeneRulerTM 1kb DNA ladder (MBI 
Fermantas, cat No. SM0311) was used as size maker in the agarose gel analysis. The 
agarose gel was visualized on ultraviolet transilluminator and the gel band containing 
the expected amplicon for each fragment was cut out into polypropylene micro-
centrifuge tubes for purification.  
Fragment A and B were purified out from gel band using GFXTM PCR DNA 
and gel band purification kit (Amersham Biosciences, cat No.27-9602-01). Following 
the manufacturer’s protocol, the agarose gel band was dissolved in the capture buffer 
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at 60°C, and then the sample was passed through the GFX column to captured the 
DNA onto the glass fiber matrix, followed by matrix-bound DNA washing with an 
ethanolic wash buffer. The purified DNA was eluted from the GFX column into 30 µl 
TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
The concentration of each purified PCR product was estimated by dot blot, as 
described previously. 10 ng of fragment A and 25 ng of fragment B were used as the 
template in the second round of PCR to amplify the 1.4 kb β-globin gene fragment 
containing Cd35 –C mutation. The reaction was performed in a total volume of 50 µl 
containing the same formulation as the first round of PCR except that the primers 
were replaced with β-F and β-R1 (Table 3-1). Thermal cycling conditions remained 
same as the condition for amplifying fragment B.  
The PCR products were analyzed through gel electrophoresis and the expected 
fragment was gel purified as described above. The mutation-containing fragment was 
cloned into the T-vector constructed from pBluescript II KS (+) plasmid DNA 
following the procedure described previously.  
Assay specificity for this mutation was determined by direct testing on the 
recombinant plasmid (to mimic homozygosity), as well as by testing on non-β-
thalassemia genomic DNA mixed with an equimolar amount of recombinant plasmid 
(to mimic heterozygosity).  DNA samples compound heterozygous for various 
mutations were also tested.  Final validation of the optimized assay was accomplished 
by blinded analysis of 81 β-thalassemia samples of known genotype and 8 normal 




Table 3-3 List of 89 DNA samples of known β-globin genotype used in a blinded validation 
analysis of the PCR-multiplex minisequencing assay. 
Genotypes Number
IVSII,654 / β 17 
IVSI,5 / β 10 
Cd17 / β  8 
-28 / β 7 
Cd41/42 / β 5 
-29 / β 3 
Cd26 / β 3 
Cd41/42 / Cd41/42 3 
Cd41/42 / -28 2 
Cd41/42 / IVSII,654 2 
Cd43 / β 2 
Cd8/9 / β 2 
Cd19 / β 2 
Cd71/72 / β 2 
Cd0 / β 2 
Cd41/42 / Cd17 2 
IVSI,1 / β 1 
Cd17 / IVSII,654 1 
-28 / IVSII,654 1 
Cd41/42 / Cd26 1 
IVSI,5 / Cd26 1 
Cd27/28 / β 1 
Cd27/28 / IVSII,654 1 
∆619bp / β 2 
β / β (Normal control) 8 
Total 89 
 
3.1.2.2 β-Globin gene gap-PCR and ∆619bp mutation detection 
 A gap-PCR strategy was adopted to amplify an intact β-globin gene fragment 
and/or a ∆619bp deletion junction fragment, if present, involving the use of a forward 
primer β-F and two reverse primers β-R1 (Table 3-2) and β-R2 (5’-
CAGATTCCGGGTCACTGTG-3’; GenBank HUMHBB sequence nucleotides 
64299→64281) (Figure 3-2).  Genomic DNA template (100ng) was amplified in a 
Biometra T3 thermal cycler (Biometra, GmbH Germany) in a total volume of 50µl 
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containing 0.2µM of each of the 3 primers, 200µM of each dNTP, and 1 unit of 
HotStarTaq polymerase in 1 x supplied PCR buffer (Qiagen, Hilden, Germany, cat 
No. 203203).  An initial denaturation at 95°C for 15 minutes was followed by 35 step-
cycles of incubation at 98°C for 45 seconds, 55°C for 45 seconds, and 72°C for 1 














Figure 3-3 Schematic illustration of β-globin gene (HBB) gap-PCR and the PCR results.  A. 
Thermal cycling conditions were established to amplify only a 1457 bp fragment of the HBB gene from 
primers β-F and β-R1.  In the presence of a ∆619 bp deletion allele, however, the annealing sequence 
for primer β-R1 is absent, and a 1671 bp gap-PCR fragment is amplified instead from primers β-F and 
β-R2.  B. Agarose gel electrophoresis of HBB gene PCR of a homozygous non-deleted sample and a 
sample heterozygous for the ∆619 bp deletion. 
 
 A 10 µl aliquot of each amplified product was resolved on a 1% agarose gel in 
1 x Tris-Borate-EDTA at 15 volts/cm for 40 minutes.  Presence of a 1671 bp deletion 
junction fragment, in addition to a 1457 bp fragment, indicates heterozygosity for the 
∆619 bp allele (Figure 3-3). 
3.1.2.3 Multiplex-minisequencing 
 
 Excess PCR primers and unincorporated dNTPs in each PCR product were 
fragmented and functionally inactivated, respectively, in a one-step reaction by the 
1671 bp 
1457 bp 








1457 bp (non-deleted allele) 
A 
1671 bp (∆619 bp allele)
β-F β-R2 
5’ ∆619 bp 
breakpoint 
3’ ∆619 bp 
breakpoint 
β-F β-R1 
Exon 2 Exon 1 Exon 3 
Exon 2 Exon 1 
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addition of exonuclease I (ExoI) (USB Corporation, cat No. 70073Z) and shrimp 
alkaline phosphotase (SAP) (USB Corporation, cat No. 70092Z).  One microliter of 
SAP (1 U/µl) and 0.5 µl of Exo I (10 U/µl) was added to 2.5 µl of PCR product to 
yield a final volume of 4 µl, and the mixture was incubated at 37°C for 15 minutes, 
followed by enzyme deactivation at 80°C for 15 minutes. 
To each tube of purified PCR product was added 1µl of panel A or B 
mutation-detection primer mix (see below), 2.5µl of HPLC-grade water, and 2.5µl of 
SNaPshotTM Multiplex Ready Reaction Mix (Applied Biosystems, cat no. 4323151) 
containing AmpliTaq® DNA polymerase and fluorescently labeled ddNTPs.  Each 
10µl multiplex-minisequencing mix was subjected to 25 single-base extension cycles 
consisting of denaturation at 96°C for 10 seconds; primer annealing at 50°C for 5 
seconds; and extension at 60°C for 30 seconds. 
Following cycle-minisequencing, unincorporated fluorescent ddNTPs were 
enzymatically inactivated by incubation with 1 unit of SAP at 37°C for 1 hour, 
followed by enzyme deactivation at 75°C for 15 minutes. 
 
3.1.2.4 β-globin gene mutation-detection primers 
Fifteen β-globin gene mutation-detection primers were divided into two 
panels, A and B, necessitated by the close proximity and clustering of many of these 
mutations.  Both panel A and panel B consist of 8 primers (Figure 3-4).  Within each 
panel, each mutation-detection primer differs in total length from the others.  This was 
achieved through the addition of variable length non-specific polynucleotide tails to 
the 5’ ends of the primers.  The ability to differentiate between the mutation-detection 
primers based on length thus enables the minisequencing reaction to be multiplexed.  
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The use of non-specific tails simplifies standardization of annealing temperatures for 
all primers in both panels regardless of total primer length. All minisequencing 
primers were purified by polyacrylamide gel electrophoresis or HPLC.  Table 3-4 











Figure 3-4 Schematic illustration of β-globin gene (HBB) multiplex-minisequencing assay. 
Relative positions of minisequencing primers and mutation sites within the HBB gene.  Primers were 
designed to anneal next to each mutation, each primer differing in length from the others by the 
inclusion of 5’ non-specific tails of varying lengths.  
 
3.1.2.4 Capillary electrophoresis and genotype analysis 
Multiplex-minisequencing products were resolved by automated capillary 
electrophoresis on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
USA).  Nine microliters of Hi-Di™ formamide (Applied Biosystems, cat No. 
4311320) and 0.5 µl of GeneScanTM-120 LIZTM size standard (Applied Biosystems, 
cat No. 4324211) were added to 0.5 µl of multiplex-minisequencing product. After 
denaturation at 95°C for 5 minutes, the fluorescently-tagged extended primers in the 














































containing Performance-Optimized-Polymer (POP)-4TM (Applied Biosystems) for 25 
minutes, and analyzed using GeneScan™ application software version 3.7 (Applied 
Biosystems).  Automated allele calling and tabulation of results was accomplished 
with the aid of Genotyper™ 3.7 application software (Applied Biosystems). 
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Table 3-4 Mutation-specific primers used in the β-globin multiplex-minisequencing assays. 
Panel A Mutations β0/β+ Primer Sequence (5’Æ3’)1 Primer Length 
Conc. 
(uM) 2 
WT allele3 / 
GS length4 
MT allele3 / 
GS length4 
IVS I,5 GÆC (or IVS I,5 GÆT/A)* β+ InI5-R5 CCTGTCTTGTAACCTTGATA 20 0.25  dC / 25.0     dG / 24.6 
Codon 41/42 –TTCT, [TTC⋅TTT (Phe⋅Phe)Æ −−− −TT] 
(or Codon 41 –C, [TTC (Phe)Æ TT−])* β0 Cd41/42-F
5 (a)14  CCTTGGACCCAGAGGTT 31 1.00  dC / 30.5   dG / 30.1 
–29 TATA box AÆG β+ -29-F (a)19  AGCCAGGGCTGGGCAT 35 0.60  dA / 34.9  dG / 33.7 
Codon 26 GAG (Glu)ÆAAG (Lys) / HbE β+ Cd26-R (gact)5  CAACCTGCCCAGGGCCT 37 0.20  dC / 39.6  dT / 41.1 
–28 TATA box AÆG (or –28 AÆC)* β+ -28-R5 (gact)6  GATGGCTCTGCCCTGACTT 43 0.15  dT / 48.2  dC / 47.2 
Codon 17 AAG (Lys)ÆTAG (stop) β0 Cd17-R act (gact)7  CAACTTCATCCACGTTCACCT 52 0.20  dT / 54.9  dA / 54.3 
Codon 71/72 +A, [TTT⋅AGT (Phe⋅Ser) ÆTTT⋅AAG⋅T] β0 Cd71/72-F ct (gact)8  AGAAAGTGCTCGGTGCCTTTA 55 0.10  dG / 57.0  dA / 58.1 
IVSII,654 CÆT β+ InII654-F (gact)9  CAGTGATAATTTCTGGGTTAAGG 59 0.60  dC / 62.8  dT / 63.7 
Panel B Mutations        
β0  dA / 24.9 IVSI,1 GÆT 
IVSI,1 GÆA β0 InI1-R
 TCTTGTAACCTTGATACCAA 20 0.30  dC / 24.1 
 dT / 25.8 
Initiation codon ATGÆ AGG β0 Cd0-F (a)10  GCAACCTCAAACAGACACCA 30 0.30  dT / 30.1  dG / 27.9 
Codon 43 GAG (Glu)ÆTAG (stop) β0 Cd43-R (a)23  ACAGATCCCCAAAGGACT 41 0.50  dC / 38.7  dA / 39.3 
619 bp deletion β0 ∆619-F atc (gact)3 AATATTTCTGCATATAAATTGTAAC 40 2.00 dT / 43.6 dA / 42.8 
Codon 19 AAC (Asn)ÆAGC (Ser) β+ Cd19-F t (gact)6  CCCTGTGGGGCAAGGTGA 43 0.60  dA / 48.0  dG / 47.3 
Codon 27/28 +C, [GCC⋅CTG (Ala⋅Ser) ÆGCC⋅CCT⋅G] β0 Cd27/28-F t (gact)8  AAGTTGGTGGTGAGGCCC 51 0.10  dT / 55.2  dC / 54.2 
Codon 8/9 +G, AAG⋅TCT (Lys⋅Ser) ÆAAG⋅GTC⋅T β0 Cd8/9-R ct (gact)9  ACAGGGCAGTAACGGCAGAC 58 0.50  dT / 61.1  dC / 59.9 
Codon 35 –C, TAC (Tyr) ÆTA− β0 Cd35-F ct (gact)10 gac  TAGGCTGCTGGTGGTCTACC 65 0.10  dC / 67.4  dT / 68.6 
1Sequences in lowercase represent the non-specific tails, and subscripted numbers indicate the multiples of the “gact” tetranucleotide. 
2Concentration of each primer in the final primer mixture. 
3 Nucleotide peaks that will be detected from wild-type (WT) and mutant (MT) alleles after GeneScan™ analysis. 
4 Mean apparent nucleotide length of extended primer as sized by GeneScan™. 
5These primers can detect more than one mutation or nucleotide variant (indicated by asterisks), but GS lengths of these MT alleles have not been determined. 
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3.1.3 α-Thalassemia multiplex-minisequencing assay 
 
3.1.3.1 DNA samples 
Archived genomic DNA samples of various α-thalassemia genotypes were 
used in assay optimization.  The point mutations in these samples were previously 
determined by direct α2-globin gene resequencing and/or MARMS PCR, while the 
deletions were determined by Southern blot or multiplex-PCR analysis.  Assay 
specificity was evaluated by analysis of DNA samples heterozygous for each point 
mutation, as well as samples compound heterozygous for a deletion and the point 
mutation.  
No patient samples carrying a Hb Suan Dok or codon59 mutation were 
available.  Mutant alleles of Hb Suan Dok or codon59 were therefore artificially 
created using PCR mutagenesis, and cloned into bacterial plasmids following the 
procedure described previously. In the first round of PCR, two overlapping mutation-
containing PCR fragments for each mutation were generated using the primers listed 
in Table 3-5. All the PCR reactions were performed in 50 µl volume containing 100 
ng of genomic DNA with normal α-globin gene sequence (αα/αα), 0.2 µM of the 
corresponding primers, 0.2 mM of each dNTPs, 1 × PCR buffer containing 1.5 mM 
MgCl2, 1 × Q-solution and 1 unit of HotStarTaq DNA polymerase (Qiagen, Hilden, 
Germany, cat No. 203203). Thermal cycling was performed in a Biometra T3 thermal 
cycler (Biometra, GmbH Germany), with an initial 15 minutes enzyme activation at 
95°C, followed by 30 cycles of 98°C denaturation for 1 minute, 60°C annealing for 1 
minute, 72°C extension for 1 minute per kb, and a final extension at 72°C for 5 
minutes. 
 56
Table 3- 5 Primer sequences for the α2-globin gene Cd59 (GGC→GAC) and Hb Suan Dok 
(codon 109 CTG→CGG) mutagenesis PCR. 
Name Sequence 5’→3’ Nucleotides ID in HUMHBA4 Amplicon (size) 
α2-F CCC CTC GCC AAG TCC ACC C 5676→5694 
Cd59m-R CTT CTT GTC GTG GCC CTT AAC C 7005→6984 
Fragment Cd59-A 
(1330 bp) 
    
Cd59m-F GTT AAG GGC CAC GAC AAG AAG G 6985→7006 
α2-R AGA CCA GGA AGG GCC GGT G 7475→7457 
Fragment Cd59-B 
(491 bp) 
    
α2-F As above As above 
SDm-R GGC GGC CCG GGT CAC CAG C 7297→7279 
Fragment SD-A 
(1622 bp) 
    
SDm-F TGC TGG TGA CCC GGG CCG C 7278→7296 




 After gel purification and dot quantification, the first round PCR products 
were used as template in the second round of PCR. 27 ng of fragment Cd59-A and 10 
ng of fragment Cd59-B were used in Cd59 second round of PCR; 82 ng of fragment 
SD-A and 10 ng of fragment SD-B were used in Hb Suan Dok second round of PCR. 
The PCR formulations were the same as the first round of PCR except that the 
primers were replaced with α2-F and α2-R (Table 3-5). Thermal cycling conditions 
also remained the same as the first round of PCR. After gel purification, the 1.8 kb 
mutation-containing fragments were cloned into the T-vector generated from 
pBluescript II KS (+) plasmid DNA. 
Plasmid DNAs containing the α-globin gene mutations were mixed with an 
equimolar amount of normal DNA (αα/αα) to mimic heterozygosity (αTα/αα), or of 
DNA homozygous for the −−SEA double gene deletion (−−SEA/−−SEA) to mimic a non-
deletional Hb H disease genotype (αTα/−−SEA).  The mutant allele of codon30 was 
also cloned from the DNA of a αCd30α/αα carrier, and mixed with −−SEA/−−SEA 
genomic DNA to generate the corresponding Hb H disease genotype.  Final validation 
of the optimized assay was accomplished by blinded analysis of 45 archived α-
thalassemia and normal samples of known genotypes (Table 3-6). 
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Table 3-6 List of 45 DNA samples of known α-thalassemia genotype used in a blinded validation 
analysis of the multiplex-PCR and multiplex-minisequencing assay. 
Genotypes Number 
αα / --SEA 6 
αCSα / --SEA 4 
αPsα / --SEA 4 
αQSα / αα 4 
αCSα / αα 3 
αQSα / --SEA 2 
αCd30α / αα 2 
αα / --FIL 2 
αPsα / αα 1 
αSDα / --SEA 1 
αSDα / αα 1 
αCd0∆1α / --SEA 1 
αCd0∆1α / αα 1 
αCd30α / --SEA 1 
αCd59α / αα 1 
αCd59α / --SEA 1 





 The template for the multiplex-minisequencing was obtained from either of 
two sources.  Firstly, in the context of a comprehensive α-thalassemia mutation 
screen, a 7-deletion multiplex-PCR was first performed on the DNA sample, using 
previously described conditions [36], with the exception that primer α2-R was 
changed to α2-R(g/c) (5’-AGACCAGGAAGGGCSGGTG-3’ HUMHBA4 
7475→7457, where S = dG or dC), which was used at 0.2 µM final concentration.  In 
situations where only a double α-globin gene deletion was detected in a Hb H disease 
patient, or where only a single α-globin gene deletion was detected in a suspected 
homozygous α-thalassemia-2 patient, an aliquot of the remaining multiplex-PCR 
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product was used directly in the α2-globin gene multiplex-minisequencing analysis.  
This is possible because the 7-deletion multiplex-PCR assay will amplify the α2-
globin gene fragment whenever at least one α-globin gene-cluster is intact, i.e. not 
deleted [36]. 
Alternatively, to screen only for point mutations, the α2-globin gene was 
specifically amplified using primer pair α-AF (5’-CCCCAAGCATAAACCATGGC-
3’, HUMHBA4 6630→6649) and α2-R(g/c) to generate an amplicon of 846 bp.  Each 
50 µl PCR reaction contained 200 µM of each dNTP, 1 × Q-solution, 1 unit 
HotStarTaq DNA polymerase in supplied 1 × PCR buffer (Qiagen, Hilden, Germany. 
cat No. 203203), 100ng of genomic DNA and 0.2 µM of each primer.  Samples were 
amplified in a Biometra T3 thermal cycler (Biometra, GmbH, Germany) using the 
following cycling parameters: initial denaturation at 95°C for 15 minutes, followed by 
35 cycles of 98°C denaturation for 1minute, 55°C annealing for 1 minute, and 72°C 
extension for 1 minute, then finally extended at 72°C for 5 minute. 
In either situation, “clean-up” of PCR product was achieved in a one-step 
reaction by the addition of exonuclease I (ExoI) (USB Corporation, cat No. 70073Z) 
and shrimp alkaline phosphatase (SAP) (USB Corporation, cat No. 70092Z), to digest 
away residual PCR primers and inactivate unincorporated dNTPs, respectively.  To 
2.5 µl of each PCR product, 1 µl of SAP (1U/µl) and 0.5 µl of ExoI (10U/µl) was 
added, and the mixture was incubated at 37°C for 15 minutes, followed by 
inactivation at 80°C for 15 minutes. 
To each tube of “purified” PCR product, 1 µl of primer mix (consisting of 7 
different mutation-specific primers) was added together with 2.5 µl of HPLC-grade 
water, and 2.5 µl of SNaPshotTM Multiplex ready reaction mix (Applied Biosystems, 
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cat No. 4323151) containing AmpliTaq® DNA polymerase and fluorescently labeled 
ddNTPs.  Each 10 µl multiplex-minisequencing reaction was subjected to 25 
extension cycles consisting of denaturation at 96°C for 10 seconds, primer annealing 
at 50°C for 5 seconds; and extension at 60°C for 30 seconds. 
The 7 point mutations of the α2-globin gene screened for in the multiplex-
minisequencing assay are Hb Constant Spring, Hb Paksé, Hb Quong Sze, codon0 
∆1bp, codon30 ∆3bp, Hb Suan Dok, and codon59.  Each mutation-specific primer 
differs in total length from the others by the addition of 5’ non-specific polynucleotide 
tails that differ in length among the primers.  All primers used in the multiplex-
minisequencing assay were purified by polyacrylamide gel electrophoresis or HPLC 
after synthesis.  Details of the primers and their concentrations in the primer mix are 
shown in Figure 3-5 and Table 3-7. 
Following cycle-minisequencing, unincorporated fluorescent ddNTPs were 
enzymatically inactivated by incubation with 1 unit of SAP at 37oC for 1 hour, 








Figure 3-5 Schematic illustration of relative positions of minisequencing primers and mutation 
sites within the α2-globin (HBA2) gene.  Primers were designed to anneal next to each mutation, each 


























Table 3-7 Mutation-specific minisequencing primers used in the α2-globin (HBA2) gene multiplex minisequencing assay.  Sequence and length of each 
minisequencing primer, and expected migration size and fluorescence color of each terminator-extended primer. 
 
Mutations Primer Sequence (5’→3’) Primer Length
Conc. 
(uM)1 
WT allele2 / 
GS length3 
MT allele2 / 
GS length3 
Codon0 ∆1bp ATG→A−G [or ATG→ACG*] Cd0-F4  CTC AGA GAG AAC CCA CCA 18 0.30  dT / 22.9   dG / 20.7 
Codon142 Constant Spring TAA(Ter)→CAA(Gln) 
[or Codon142 Icaria TAA(Ter)→AAA(Lys)  
or Codon142 Seal Rock TAA(Ter)→GAA(Glu)*] 
CS-F (a)2 GCT GAC CTC CAA ATA CCG T 21 0.15  dT / 26.8  dC / 25.0 
Codon30 ∆3bp −GAG(−Glu) Cd30-F (gact)3 TAT GGT GCG GAG GCC CTG 30 0.15  dG / 34.1  dA / 36.1 
Codon142 Paksé TAA(Ter)→TAT(Tyr) Ps-R t (gact)4 GGC TAC CGA GGC TCC AGC 35 0.25  dT / 39.0  dA / 38.5 
Codon109 Suan Dok CTG(Leu)→CGG(Arg) SD-F ct (gact)5 CAC TGC CTG CTG GTG ACC C 41 0.50  dT / 45.2  dG / 43.6 
Codon125 Quong Sze CTG(Leu)→CCG(Pro) QS-F ct (gact)7 ga CTG CGG TGC ACG CCT CCC 50 0.50  dT / 53.5  dC / 52.5 
Codon59 GGC(Gly)→GAC(Asp) Cd59-R act (gact)9 GGC GTC GGC CAC CTT CTT G 58 3.00  dC / 61.2  dT / 62.0 
1 Concentration of each primer in the final primer mixture. 
2 Nucleotide peaks that will be displayed for wild-type (WT) and mutant (MT) alleles after GeneScanTM analysis. 
3 Mean apparent nucleotide length of extended primer as analyzed by GeneScanTM. 
4 Cd0-F and CS-F primers can detect more than one mutation (indicated by *), but GS length of these MT alleles have not been determined. 
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3.1.3.3 Capillary electrophoresis and genotype analysis 
 Multiplex-minisequencing products were resolved by automated capillary 
electrophoresis on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
USA), and results analyzed, genotyped, and tabulated using GeneScan™ 3.7 and 
Genotyper™ 3.7 application software (Applied Biosystems), as described previously. 
 




3.1.4.1 DNA samples 
Genomic DNA samples carrying either an αααanti3.7 or αααanti4.2 triplication 
allele, as determined by Southern blot analysis, were used in assay optimization.  
Final validation of the optimized assay was accomplished by blinded analysis of 31 
archived samples that were either positive (n=21) or negative (n=10) for triplicated α-
globin genes.   
 
3.1.4.2 Primer design 
Oligonucleotide primers were designed to specifically amplify the unequal 
crossover region(s) within the anti-3.7 or anti-4.2 chromosomes.  Primers AT3.7-F 
and AT3.7-R were designed to anneal to the unique stretches between the Y1 and Z1 
homology boxes, and between the Z2 and X1 boxes, respectively to amplify an ∼1.9-
kb fragment only from the hybrid Z1Z2 box of the anti-3.7 allele (Figure 3-6).  
Similarly, primers AT4.2-F and AT4.2-R anneal to the unique regions between the Z2 
and X1 boxes, and between the X2 and Y2 boxes, respectively, to amplify an ∼1.7-kb 
fragment only from the hybrid X1X2 box of the anti-4.2 allele. Additionally, 
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amplification of a large fragment (∼2.5 kb) of the 3’ untranslated region (UTR) of the 
LIS1 gene was included as a control for amplification success, using primers LIS1-







Figure 3-6 Schematic illustration of the relative position of the triplication multiplex-PCR 
primers on the anti-3.7 and anti-4.2 triplication allele.  
 
Table 3-8 Anti-3.7/4.2 α-globin multiplex-PCR primer sequences and expected amplicon sizes. 
Name Sequence 5’→3’ GenBank ID: nucleotides Conc. 
Amplicon 
(size) 
LIS1-2.5F GTC GTC ACT GGC AGC GTA GAT C HSLIS10: 407→ 428 0.5 µM 
LIS1-2.5R GAT TCC AGG TTG TAG ACG GAC TG HSLIS10: 2909→2887 0.5 µM 
LIS1 3’UTR* 
(2503 bp) 
     
AT3.7-F CCA CCT CCA TTC TCC AAC CAC HSGG1: 36371→36391 0.3 µM 
AT3.7-R CAG CGG GCA GGA GGA ACG G HSGG1: 34498→34480 0.3 µM 
Anti-3.7 
(1932/1939 bp) 
     
AT4.2-F CCT TGC ACC GGC CCT TCC TG HSGG1: 34525→34544 0.4 µM 
AT4.2-R GAA CTG GCT GAA AGG GAT GCA G HSGG1: 31978→31957 0.4 µM 
Anti-4.2 
(1711 bp) 
* UTR, untranslated region. 
 
3.1.4.3 Anti-3.7/4.2 multiplex-PCR 
 Each 50 µl of anti-3.7/4.2 multiplex-PCR reaction contained 200 µM each of 
the deoxynucleotide triphosphates (dNTPs), 1.5 mM MgCl2, 1× Q-solution (Qiagen, 
Hilden, Germany), 2 units HotStarTaq DNA polymerase in supplied reaction buffer 
(Qiagen), 100 ng of genomic DNA, and the six primers at different concentrations 
(Table 5-1).  Thermal cycling was performed in a T3 instrument (Biometra, 
αααanti3.7 allele ψα1 α2 α1
X2 Z2  Y2 Y1X1 Z1 Y1 X1Z1 Z2 
α2α1
AT3.7-F AT3.7-R 
αααanti 4.2 allele 
AT4.2-F AT4.2-R 
ψα1 α2 α2 α1
Z2 Z1 X1X2 Z2 X1/X2 Y2 Y2 Y1 
 63
Göttingen, Germany), under conditions identical to the 7-deletion multiplex-PCR 
assay [36].  Ten microliters of each anti-3.7/4.2 multiplex-PCR product was analyzed 
by electrophoresis through a 1% agarose gel in 1 × Tris-Borate-EDTA buffer at 15 
volts/cm for an hour. 
 
3.1.4.4 7-deletion multplex-PCR 
 This assay was performed and analyzed exactly as previously described, and 
was used to detect the seven common α-thalassemia deletions [36]. 
 
3.2 α-Globin genotyping by PCR and direct sequencing 
 
3.2.1 Patient samples 
Archived patient samples were used in this study. These patients were seen at the 
Division of Hematology, Department of Medicine, King Chulalongkorn Memorial 
Hospital, Chulalongkorn University, Bangkok, Thailand.  They were classified as 
having either deletional Hb H disease or non-deletional Hb H CS disease by IEF 
of hemoglobins. 
 
3.2.2 Molecular analysis of the α-globin gene cluster 
Genomic DNA was extracted from peripheral blood leukocytes using standard 
methods.  A single-tube multiplex gap-PCR assay was employed to identify the 
double-gene and single-gene deletions [36]. Samples with only one double-gene 
deletion present were screened for point mutations in the HBA1 (α1-globin) and 
HBA2 (α2-globin) genes by direct DNA sequencing.  Each gene was amplified by 
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PCR separately, using the α-F forward primer which is common to both genes, and 
either the α1-R or α2-R reverse primer specific to the HBA1 and HBA2 genes, 
respectively (Figure 3-7, Table 3-9).  Each 50µl PCR reaction contained 0.2 µM of 
each forward and reverse primer, 200 µM of each deoxynucleotide triphosphate, 1× Q 
solution (Qiagen), and 1 unit of HotStarTaq DNA polymerase in 1× supplied PCR 
buffer (Qiagen).  Thermal cycling was performed in a T3 instrument (Biometra), with 
an initial denaturation at 95 °C for 15 min, followed by 35 cycles of denaturation at 
98 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 1 min 30 
sec, with a final extension at 72 °C for 5 min.  The PCR reactions will generate HBA1 








Figure 3-7 Strategy for gene-specific DNA amplification and sequencing of HBA1 and HBA2 gene 
regions.  A common forward primer α-F is used in combination with either α1-R or α2-R reverse 
primer to amplify the HBA1 and HBA2 genes, respectively.  Using these primers, the coding and 
untranslated regions as well as promoter and some upstream sequences of each gene are amplified.  
Primers α-AF, α-BF and α-R are used for sequencing of both HBA1 and HBA2 gene fragments. 
 
After PCR, 3 µl of amplified product was incubated with 1 µl of shrimp 
alkaline phosphatase (United States Biochemical, 1 U/µl) and 0.4 µl of exonuclease I 
(United States Biochemical, 10 U/µl) at 37 °C for 15 min to remove excess PCR 




α1: 1380 bp / α2: 1303 bp 
α1-R  
or α2-R 
Exon 1 Exon 2 Exon 3 
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primers and unincorporated deoxynucleotide triphosphates.  The reaction was stopped by 
incubation at 80 °C for 15 min. 
Table 3-9 Primers used in the HBA1 and HBA2 gene PCR amplification and sequencing. 
Name 5’→3’ Sequence GenBank HUMHBA4 nucleotides Length 
α-F CGC GCA TTC CTC TCC GCC C 6173 → 6191 (α2) or 9984 → 10002 (α1) 19 
α1-R ATG CTG GCA CGT TTC TGA GGG 11363 → 11343 21 
α2-R AGA CCA GGA AGG GCC GGT G 7475 → 7457 19 
α-AF CCC CAA GCA TAA ACC CTG GC 6630 → 6649 (α2) or 10441 → 10460 (α1) 20 
α-BF GGC TCT GCC CAG GTT AAG GG 6973 → 6992 (α2) or 10784 → 10803 (α1) 20 
α-R CAC CAT ACT CGC CAG CGT GC 6781 → 6762 (α2) or 10592 → 10573 (α1) 20 
 
Purified PCR products were sequenced using three primers: α-AF, α-BF and 
α-R (Figure 3-7).  All three primers will anneal to both the HBA1 and HBA2 PCR 
products and were designed to work optimally under a single cycle-sequencing 
condition to enable all sequencing reactions to be performed in the same thermal 
cycler block.  Each 10 µl cycle sequencing reaction mixture contained 4.4 µl of 
purified PCR products, 1.6 µl of sequencing primer at 1 µM stock concentration, 2 µl 
of 5× Q solution (Qiagen), and 2 µl of BigDye Terminator Ready Reaction Mix v3.0 
(Applied Biosystems).  After an initial denaturation at 95 °C for 2 min, 25 sequencing 
cycles were carried out, consisting of denaturation at 98 °C for 30 sec, annealing at 50 
°C for 30 sec, and extension at 60 °C for 4 min.  Cycle sequencing products were 
precipitated with ethanol, re-suspended in 12 µl Hi-Di™ formamide (Applied 
Biosystems), and analyzed by automated capillary electrophoresis on an ABI PRISM® 
3100 Genetic Analyzer (Applied Biosystems).  The rapid sequencing protocol was 
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employed, involving a 40 min electrophoresis through POP-4™ polymer across a 36 
cm long capillary (Applied Biosystems). 
 
3.3 Characterization the relationship between PTC and NMD 
 
3.3.1 Plasmid constructs 
The constructs used in this study (pIREB-EGFP) contain a 3.4 kb human β-
globin gene fragment (wild-type and with different mutations) and an enhanced green 
fluorescent protein (EGFP) gene. The β-globin gene fragment was generated by PCR 
and a 35bp functional iron-resonsive element (IRE) fragment was inserted into the 5’-
UTR of the β-globin gene fragment to regulate the translation of the β-globin gene 
mRNA. The interaction between iron-responsive elements (IREs) and iron-regulatory 
proteins (IRPs) enables the specific translational regulation of mRNAs bearing IREs 
in their 5’-UTRs [124, 125]. Since ribosomal translation is required for NMD [26, 63, 
71, 72], IRE can be used for specific experimental activation and inactivation of 
translation and hence, NMD of the transcript. In iron deficient cells, the binding of 
IRP to IRE specifically inhibits the formation of a protein complex at 5’end of the 
mRNA, thus blocking an early step of translation [126]. Elevation of intracellular iron 
levels inactivates IRP binding and thus permits the translation of the mRNA. EGFP 
was used as an internal control to normalize the transfection efficiency.  
 
3.3.1.1 Generation of a 3.4 kb β-globin gene fragment with IRE insertion  
The 3.4 kb human β-globin gene fragment comprises of the 1.6 kb β-globin 
gene along with 0.8 kb of the 5’UTR and promoter, and 1 kb of the 3’ flanking region 
including 3’UTR and downstream enhancer. The fragment was generated by PCR 
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from the human genomic DNA with the wildtype β-globin gene sequence. During the 
PCR, a 35 bp functional IRE was inserted in the 5’-UTR 37 nucleotides downstream 












Figure 3-8 The PCR strategy used in the generation of a 3.4 kb β-globin gene fragment with IRE 
fragment insertion in the 5’-UTR. The IRE-F and IRE-R primers are designed to anneal to the 
downstream and upstream sequence next to the insertion point (37 nucleotides downstream of  the cap 
site), respectively and both of them contain a tail of 35 bp IRE fragment. PCR 1 and 2 generate 
overlapping fragment A and B containing IRE fragments. The final β-globin gene fragment with IRE 
insertion is generated by PCR 3 using fragments A and B as template. 
 
 
As shown in Figure 3-8, IRE-F and IRE-R primers were designed to anneal to 
the sequence downstream or upstream immediately from the insertion point, 
respectively. Both of them were tailed with a 35 bp IRE fragment (Sequence 5’-GGG 
TTT CCT GCT TCA ACA GTG CTT GGA CGG AAC CC-3’). In PCR 1, 61322F 
and IRE-R primers amplified the left fragment of the insertion point linked with the 
IRE fragment – fragment A which is 897 bp in length, including the β-globin gene 
promoter and part of the 5’-UTR (Table 3-10). In PCR 2, IRE-F and 64710R primers 
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fragment B which is 2.5 kb in length, including part of the 5’-UTR, the whole β-
globin gene, the 3’-UTR and a downstream enhancer (Table 3-10). Both PCR were 
performed in 50 µl reaction using AdvantageTM-HF 2 PCR kit (BD Biosciences, cat 
No.K1914-1). Each 50 µl reaction contained 1 × HF 2 PCR buffer, 1 × HF 2 dNTP 
mix, 0.2 µM of each PCR primers, 1 × Advantage-HF 2 polymerase mix, and 200 ng 
human genomic DNA with normal β-globin gene. Thermal cycling was performed in 
a Biometra T3 thermal cycler (Biometra, GmbH, Germany), with initial enzyme 
activation at 94°C for 1 minute, followed by 20 cycles of 94°C for 30 seconds, 65°C 
for 4 minutes. Finally, the reaction was incubated at 68°C for 3 minutes. The two PCR 
products were mixed and purified through the GFXTM PCR DNA and gel band 
purification kit (Amersham Biosciences, cat No.27-9602-01) to get rid of the PCR 
primers and dNTPs. According to the manufacturer’s protocol, the PCR products 
were mixed with 500 µl of capture buffer, and then the mixture were passed through 
the GFX column to capture the DNA onto the glass fiber matrix, followed by matrix-
bound DNA washing with an ethanolic wash buffer. The purified DNA was eluted 
from the GFX column into 50 µl TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
The overlapping fragment A and B were used as template in PCR 3 to amplify 
the 3.4 kb fragment (IREB) containing the whole β-globin gene with the IRE insertion 
(Figure 3-8). PCR 3 was performed in 50 µl reaction using AdvantageTM-HF 2 PCR 
kit (BD Biosciences, cat No.K1914-1). The 50 µl reaction contained 1 × HF 2 PCR 
buffer, 1 × HF 2 dNTP mix, 0.2 µM of each PCR primers (61322F and 64710R), 2 × 
Advantage-HF 2 polymerase mix, and 5 µl of the purified fragment A and B mixture. 
The thermal cycling conditions for PCR 3 were the same as PCR 1 and 2 except that 
the cycle number was 25. The PCR products were analyzed by gel electrophoresis and 
 69
the 3.4 kb IREB fragment was purified from the gel by using GFXTM PCR DNA and 
gel band purification kit (Amersham Biosciences, cat No.27-9602-01). The purified 
DNA was eluted from the GFX column into 30 µl TE buffer. 
Table 3-10 The primers used in the generation of a 3.4 kb β-globin gene fragment with IRE 
fragment insertion in the 5’-UTR. 
Name Sequences (5’→3’)∗ GenBank ID: nucleotides 
Amplicon 
Size 
IRE-F GGG TTT CCT GCT TCA ACA GTG CTT GGA CGG AAC CC TCA AAC AGA CAC CAT GGT GCA CCT G 
HUMHBB: 
62174→62198 





    




GGG TTC CGT CCA AGC ACT GTT GAA GCA GGA 






∗Underlined sequences are the sequences of tails. 
 
 
3.3.1.2Generation of pBS-IREB wild type construct 
The gel purified IREB fragment was ligated to pBluescript II KS (+) T-vector 
to generate pBS-IREB construct. As described previously, the T-vector was 
constructed by adding dTTP to the 3’end of the linearized pBluescript II KS (+) that 
was cut by restriction enzyme EcoRV. The 5 µl of ligation reaction contained 15 ng 
of 2.9 kb T-vector, 90 ng of 3.4 kb IREB fragment, and 2 units of T4 ligase in 1 × 
supplied ligation buffer (MBI Fermentas, cat No.EL0334). The ligation reaction was 
incubated at 16°C for 16 hours. 
The ligation product was transformed into Subcloning EfficiencyTMDH5αTM 
competent cells (GibcoBRL Life Technologies, cat No.18265-017) using the protocol 
described previously. 10 white recombinant colonies were transferred into individual 
tubes containing 10 µl LB medium. The β-globin gene PCR was used to check the 
presence of IREB in the vector. Each 50 µl β-globin gene PCR reaction contained 1 
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µl of the bacteria-containing LB medium as template, 0.2 µM of β-F and β-R1 
primers as described previously, 200 µM of each dNTP, and 1 unit of HotStarTaq 
polymerase in 1 × supplied PCR buffer (Qiagen, Hilden, Germany, cat No. 203203). 
The PCR reactions were performed in a Biometra T3 thermal cycler (Biometra, 
GmbH Germany) with an initial denaturation at 95°C for 15 minutes, followed by 35 
cycles of incubation at 98°C for 45seconds, 55°C for 45 seconds, and 72°C for 1 
minute 30 seconds, and a final extension at 72°C for 5 minutes. 
A 10 µl aliquot of each amplified product was resolved on a 1% agarose gel in 
1 × Tris-Borate-EDTA at 15 volts/cm for 50 minutes. Presence of a 1492 bp fragment 
indicates the successful insertion of IREB fragment into pBlusecript II KS (+) to 
generate the pBS-IREB construct. Each 9 µl LB medium of the samples with correct 
insertion was used to inoculate 5 ml LB medium with amplicillin (100 µg/ml) in a 15-
ml Falcon tube. The tubes were shaken at 225 rpm overnight at 37°C. The plasmid 
DNA of each pBS-IREB construct was isolated from each bacteria culture by 
Wizard® Plus Minipreps DNA Purification System (Promega, cat No. A7510) 
following the manufacturer’s protocol. The concentration of each plasmid DNA was 
determined using a spectrophotometer by reading optical density at absorbance 260 
nm. 
The sequence of IREB fragment in each pBS-IREB plasmid DNA was 
checked by sequencing using ABI PRISM® BigDyeTM Terminator v3.0 Ready 
Reaction Cycle Sequencing Kit (Applied Biosystems, cat No. 4390242). Each 20 µl 
sequencing reaction contained 4 µl of BigDye Terminator Ready Reaction Mix, 3.2 
pmol of one sequencing primer, and 300 ng of the plasmid DNA. 8 primers were used 
to sequence the whole IREB fragment (Table 3-11, Figure 3-9).  
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Table 3-11 Primers sequences for sequencing IREB fragment. 
Name Sequence 5’→3’ Nucleotides ID in HUMHBB Length 
βS-R1 GTG GAA GAG CTT TGT CTA CC 61782 → 61763 20 
βS-R2 GGG CAG TAA CGG CAG AC 62229 → 62213 17 
β-F ACG GCT GTC ATC ACT TAG AC 62010 → 62029 20 
βS-F1 CCT TGG ACC CAG AGG TT 62425 → 62441 17 
β-R1 AAG AGG TAT GAA CAT GAT TAG C 63466 → 63445 22 
βS-F2 TGA TAA TTT CTG GGT TAA GG 63265 → 63284 20 
β-R2 CAG ATT CCG GGT CAC TGT G 64299 → 64281 19 










The extension products were purified by ethanol/sodium acetate precipitation 
in 96-well reaction plates following the procedure described in the ABI PRISM® 
BigDyeTM Terminator v3.0 Ready Reaction Cycle Sequencing Kit protocol book. The 
pellets were re-suspended in 12 µl Hi-Di™ formamide (Applied Biosystems, cat No. 
4311320), denatured at 95°C for 2 minutes and analyzed by automated capillary 
electrophoresis on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
USA).  The rapid sequencing protocol was employed, involving a 40 minutes 
electrophoresis through Performance-Optimized-Polymer (POP)-4™ (Applied 
Biosystems) across a 36 cm long capillary (Applied Biosystems). 
The sequence of IREB fragment in each pBS-IREB clone was aligned against 










Exon 1 Exon 2 Exon 3
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with the correct β-globin gene sequence as HUMHBB was chosen to be pBS-IREB 
wild type construct. 
 
3.3.1.3 Generation of pBS-IREB mutant constructs 
Five mutations that cause premature termination codons (PTCs) in exon 1 and 
2 were involved in this study: codon 1 ∆ 1bp GTG→−TG (PTC at codon 3/4 TGA), 
codon 17 AAG→TAG (PTC at 17 TAG), codon 8/9 +G (PTC at 21/22 TGA), codon 
27/28 +C (PTC at 42/43 TGA), and codon 41/42 −TTCT (PTC at 60/61 TGA).  
 
3.3.1.3.1 Generation of pBS-B mutant construct 
The 1.4kb β-globin gene DNA fragments containing mutations at codon 17 
(A→T), codon 8/9 (+G), or codon 41/42 (−TTCT) were directly amplified from 
patients’ genomic DNA using β-globin gene PCR by primers β-F and β-R1 as 
described previously. The β-globin gene DNA fragment with mutation at codon 27/28 
(+C) was artificially created by PCR mutagenesis as described previously. The 
primers used in the mutagenesis PCR were listed in Table 3-12. All the mutation-
containing fragments were cloned into T-vector constructed from pBluescript II KS 
(+) plasmid DNA to generate pBS-B constructs with different mutations, following 
the procedure described previously. 
Table 3-12 Primer sequences and amplicon sizes for the β-globin gene codon 27/28 +C 
mutagenesis PCR. 
Name Sequence 5’→3’ 
Nucleotides ID in 
HUMHBB Amplicon (size) 
β-F Same as above Same as above 
Cd27/28m-R CTG CCC AGG GGC CTC ACC 62278→ 62162 
Fragment A 
(270 bp) 
    
Cd27/28m-F GTG AGG CCC CTG GGC AGG 62263→ 62279 






The mutation-containing β-globin gene sequence in each pBS-B construct was 
confirmed by sequencing, using β-F, βS-F1, and β-R1 primers, and following the 
protocols described above. 
 
3.3.1.3.2 Generation of pBS-IREB constructs with mutation at codon 17, codon 
8/9, codon 27/28, or codon 41/42 
 The pBS-IREB mutant constructs were generated from pBS-IREB wild type 
construct by digesting out the wild type β-globin gene fragment and replacing it with 
the mutation-containing fragment that was cut from pBS-B constructs. 
The mutation-containing 425bp β-globin gene fragments (with mutations at 
codon 17 A→T, codon 8/9 +G, codon 27/28 +C, or codon 41/42 −TTCT) including 
exon 1 and part of exon 2 were digested from pBS-B constructs. In each 60 µl 
digestion reaction, 3 µg of each 4418bp pBS-B mutation-containing constructs were 
digested by 30 units of restriction enzyme NcoI (MBI Fermentas, cat No. ER0571) 
and 30 units of Eco72I (PmaCI) (MBI Fermantas, cat No. ER0361) in supplied 1 × 
Buffer Y+/TANGOTM. The digestion reaction mixture were incubated at 37°C for 3 
hours. NcoI generates sticky ends whereas Eco72I (PmaCI) generates blunt ends. 
3993bp and 425bp fragments were generated from the digestion reaction and they 
were separated by electrophoresis through 1% agarose gel. The 425bp mutation-
containing β-globin gene fragment was purified out from gel band using GFXTM PCR 
DNA and gel band purification kit (Amersham Biosciences, cat No. 27-9602-01). 
Each purified DNA fragment was eluted from GFX column into 30 µl TE buffer (10 
mM Tris-HCL, 1 mM EDTA, pH 8.0).  
pBS-IREB wild type construct was also digested by the same restriction 
enzymes: NcoI and Eco72I to generate 5980bp and 425bp fragments using the same 
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digestion reaction protocol. The fragments were separated by electrophoresis through 
1% agarose gel. The 5980bp fragment was purified out from gel band and eluted into 
30 µl of TE buffer (10 mM Tris-HCL, 1 mM EDTA, pH 8.0) using the same method 
described above. 
The concentration of each purified fragment was estimated by dot blot, 
comparing the brightness of the fluorescence emitted from each sample to that of the 
fluorescence emitted from the DNA standards (10 ng/µl, 25 ng/µl, 50 ng/µl, 75 ng/µl 
and 100 ng/µl). The procedure was described previously. 
Each gel purified 425bp mutation-containing β-globin gene fragment (with 
mutation at codon 17 A→T, codon 8/9 +G, codon 27/28 +C, or codon 41/42 −TTCT) 
which was cut from pBS-B was ligated with a gel purified 5980bp fragment, which 
was cut from pBS-IREB wild type construct, to generate pBS-IREB mutant constructs 
by sticky-blunt end ligation. Each 10 µl ligation reaction contained 50 ng of 5980bp 
fragment, 10 ng of 425 bp fragment, and 2.5 units of T4 DNA ligase (5 U/µl, MBI 
Fermentas, cat No. EL0334) in 1 × supplied ligation buffer. The ligation mixture were 
incubated at 22°C for 3 hours, followed by heating the mixture at 65°C for 10 minutes 
to inactivate T4 DNA ligase.  
 
3.3.1.3.3 Generation of pBS-IREB constructs with mutation of codon 1 ∆ 1bp (-
G) 
Unlike the rest of the pBS-IREB mutant constructs, the pBS-IREB mutant 
construct with codon 1 (-G) cannot be generated by the method described above. This 
is because the codon 1 (-G) mutation destroys the recognization sequence of the 
restriction enzyme NcoI (Figure 3-10). In addition, no other restriction enzymes with 
single cutting site that are present in both pBS-B (codon 1 –G) and pBS-IREB wild 
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type constructs are available to cut the fragment containing codon 1 (-G) mutation 
from pBS-B and paste to pBS-IRES.  
Each ligation product was transformed into Subcloning efficiencyTM DH5αTM 
competent cells (GibcoBRL Life Technologies, cat No. 182655-017) using the 
protocol described previously. The recombinant colonies containing pBS-IREB 
mutant construct were identified by β-globin gene PCR using primers β-F and β-R1 
as described previously. Presence of the 1.4kb fragment indicates the successful 
ligation of the two fragments. 
 The correct colonies were used to inoculate 5 ml LB medium with ampicillin 
(100 µg/ml) in 15 ml Falcon tubes. After shaking at 225 rpm at 37°C for 14 hours, the 
recombinant plasmid DNAs were extracted from the bacteria culture by Wizard® Plus 
Minipreps DNA Purification System (Promega, cat No. A7510), in according to the 
manufacturer’s protocol. The concentration of the plasmid DNAs was determined by 
spectrophotometer. 
 
--- g a c a c c A T G G T G C A C C T G A C T --- 
--- c t g t g g T A C C A C G T G G A C T G A --- 
Figure 3-10 The nucleotides sequence recognized by restriction enzyme NcoI in β-globin gene.  
NcoI recognizes the sequence involving the nucleotides in red and creates sticky ends after digestion. 
Deletion of the first G in codon 1 (highlighted in blue) destroys the recognization sequence of NcoI.     
The pBS-IREB (-G) construct was created by digestion and re-ligation. 
Restriction enzyme NcoI can cut the plasmid DNA just before the G, while Alw44I 
can cut the plasmid DNA just after the G (Figure 3-10, 3-11).  
 
--- g a c a c c A T G G T G C A C C T G A C T --- 
--- c t g t g g T A C C A C G T G G A C T G A --- 
Figure 3-11 The nucleotides sequence recognized by restriction enzyme Alw44I in β-globin gene.  
Alw44I recognizes the sequence involving the nucleotides in red and creates sticky ends after digestion. 





The procedure of the generation of pBS-IREB (-G) was shown in Figure 7-5. 4 
µg of pBS-IREB wild type plasmid DNA was digested by 20 units of NcoI in 1 × 
Buffer Y+/TANGOTM in 30 µl reaction. The mixture was incubated at 37°C for 3 
hours to generate the 6405bp linearized DNA with sticky ends. After purification of 
the DNA fragment from gel band using GFXTM PCR DNA and gel band purification 
kit (Amersham Biosciences, cat No. 27-9602-01), the recessed 3’ terminal of the 
double-stranded DNA was filled-in by 5 units of Klenow fragment (Promega) in 1 × 
supplied reaction buffer and 0.05mM dNTPs (Roche) in a total volume of 20 µl 
reaction. The reaction mixture was incubated at 28°C for 10 minutes followed by 
enzyme inactivation at 75°C for 10 minutes. After filling-in, the 3’ end of the sense 
sequence of the double stranded DNA stopped just before the codon 1 of the β-globin 
gene. Then the blunt-end fragment was further digested by 20 units of MunI (MBI 
Fermentas) in 1 × buffer G+ in a total volume of 30 µl reaction. The reaction was 
incubated at 37°C for 3 hours. Two fragments were generated from this digestion: 
619bp (A) and 5790bp (B). The 5790bp fragment (B) was purified out from the gel 
band using GFXTM PCR DNA and gel band purification kit (Amersham Biosciences, 
cat No. 27-9602-01). 
 As shown in Figure 3-12, 4 µg of pBS-IREB wild type plasmid DNA was also 
digested by 20 units of Alw44I in 1× Buffer Y+/TANGOTM in 30 µl reaction. The 
reaction was incubated at 37°C for 3 hours. 3 fragments were generated from the 
digestion reaction: 3282bp, 1246bp, and 1877bp fragment. The 3282bp fragment 
containing the MunI digestion site was purified from the gel band as described above. 
The recessed 3’ terminal of the 3282bp double-stranded DNA was filled-in by 
Klenow fragment (Promega) as described above. The 5’ terminus of the sense strand 
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of the blunt-end fragment starts from the second nucleotide of the codon 1 of β-globin 
gene, just after the first G in codon 1. Then the fragment was digested by MunI as 
described above to generate two fragments: 614bp (C) and 2668bp (D). The 614bp 
fragment (C) was purified from the gel as described above. 
 The 5790bp fragment B and the 614bp fragment C were ligated together to 
form a 6404bp circular DNA which is short of the first G in codon 1 of the β-globin 
gene compared to pBS-IREB wild type, and named pBS-IREB (-G) (Figure 3-12). 
The 10 µl ligation reaction contained 50 ng of 5790bp fragment B, 20 ng of 619bp 
fragment C, 2.5 units of T4 ligase (5 U/µl, MBI Fermentas) in 1 × supplied ligation 
buffer. The reaction was incubated at 22°C for 2 hours. 
The ligation product of fragment B and C was transformed into Subcloning 
efficiencyTM DH5αTM competent cells (GibcoBRL Life Technologies, cat No. 
182655-017) using the protocol described previously. The recombinant colonies 
containing pBS-IREB (-G) were identified by β-globin gene PCR using primers β-F 
and β-R1 as described previously. Presence of the 1.4kb fragment indicates the 











































Figure 3-12 Construction of pBS-IREB (-G) from pBS-IREB wild type construct by digestion and 
re-ligation. An aliquot of the pBS-IREB wild type plasmid DNA was digested by NcoI to linearize the 
DNA. The sticky ends of the linearized DNA were filled-in using klenow fragment. Then the fragment 
was further digested by MunI to generate fragments A and B. Another aliquot of the pBS-IREB wild 
type plasmid DNA was digested by Alw44I to generate 3 fragments. The 3282bp fragment containing 
MunI digestion site was purified out and its recessed 3’end was also filled-in by klenow fragment. The 
blunt end fragment was further digested by MunI to generate fragments C and D. 5790bp fragment B 
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TGCACCTGACT---------gggctgtgtgca
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TGCACCTGACT---------gggctgtg 
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The correct colonies were used to inoculate 5 ml LB medium with ampicillin 
(100 µg/ml) in 15 ml Falcon tubes. After shaking at 225 rpm at 37°C for 14 hours, the 
recombinant plasmid DNAs were extracted from the bacteria culture by Wizard® Plus 
Minipreps DNA Purification System (Promega, cat No. A7510) following the 
manufacturer’s protocol. The concentration of the plasmid DNAs were determined by 
a spectrophotometer. 
The mutation sequence of pBS-IREB (-G) plasmid DNA was further 
confirmed by direct sequencing. Each 20 µl sequencing reaction contained 4 µl of 
BigDye Terminator Ready Reaction Mix (Applied Biosystems, cat No. 4390242), 3.2 
pmol of β-F or βS-R2 primer, and 300 ng of the plasmid DNA (Table 3-11, Figure 3-
9).  
The extension products were purified by ethanol/sodium acetate precipitation 
in microcentrifuge tubes following the procedure described in the ABI PRISM® 
BigDyeTM Terminator v3.0 Ready Reaction Cycle Sequencing Kit protocol book. The 
pellets were re-suspended in 12 µl Hi-Di™ formamide (Applied Biosystems, cat No. 
4311320), denatured at 95°C for 2 minutes and analyzed by automated capillary 
electrophoresis on an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
USA).  The rapid sequencing protocol was employed, which involved a 40 minutes 
electrophoresis through the Performance-Optimized-Polymer (POP)-4™ (Applied 
Biosystems) across a 36 cm long capillary (Applied Biosystems). All pBS-IREB (-G) 
constructs showed correct mutant sequence. 
 
3.3.1.4 Generation of pIREB-EGFP wild type and mutant constructs 
The fragment containing enhanced green fluorescent protein (EGFP) gene 
driven by cytomegalovirus (CMV) major immediate-early promoter/enhancer and the 
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selectable marker ⎯ ampicillin resistance gene (Amp r) was cut out from the 
construct pMDR-EGFP (kindly given by Dr. Caroline Lee) by restriction enzyme 
NarI and SacII.  
Firstly, 5 µg of 9778bp pMDR-EGFP were digested by 50 units of SacII 
(Cfr42I) (10 U/µl, MBI Fermemtas) in 1 × supplied buffer B+ in a total volume of 50 
µl reaction. The reaction was incubated at 37°C for 3 hours to generate 4 fragments: 
30bp, 2780bp, 3480bp, and 5990bp. The 5990bp fragment containing EGFP gene and 
Amp r gene was gel purified and eluted in 30 µl of TE buffer as described previously. 
Then, the 5990 bp fragment in 30 µl of TE was further digested by 20 units of NarI 
(4U/µl, New England Biolabs) in 1 × supplied NEBuffer 1 in a 50 µl reaction. After 
incubation at 37°C for 3 hours, the digestion products were separated by gel 
electrophoresis through 1% agarose gel. 2 fragments were generated from this 
digestion: 4448bp and 1542bp. The 4448bp fragment containing EGFP gene and Amp 
r gene was purified from gel as described previously (Figure 3-13). 
The IREB fragments containing the IRE element and 3.4 kb β-globin gene 
fragment (wild type or with mutations) were cut out from pBS-IREB constructs by 
restriction enzyme NarI and SacII. In each 50 µl digestion reaction, 3 µg of each pBS-
IREB plasmid DNA (wild type or with mutation) was linearized by 20 units of NarI 
(4U/µl, New Engaland Biolabs) in 1 × NEBuffer 1. After incubation at 37°C for 5 
hours, each linearized digestion product was gel purified and eluted into 30 µl TE 
buffer. Then each linearized pBS-IREB fragment was digested by 10 units of SacII 
(10U/µl, MBI Fermentas) in 1 × Buffer B+ in a 50 µl reaction. After incubation at 
37°C for 5 hours, the digestion products that contained 3 fragments: 3432bp, 2916bp, 
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and 57bp were separated by gel electrophoresis. The 3432bp IREB fragment was 































Figure 3-13 Construction of pIREB-EGFP from pMDR-EGFP and pBS-IREB constructs by 
digestion and re-ligation. pMDR-EGFP plasmid DNA was digested by NarI and SacII. The 4.4 kb 
fragment containing Amp r and EGFP was purified out and ligated with IREB (wild type or mutant) 
fragment that was digested from pBS-IREB (wild type or mutant) plasmid DNA to generate pIREB-
EGFP (wild type or mutant) construct. 
 
The 4448bp EGFP-Amp r fragment and each 3432bp IREB fragment (wild 
type or with mutation) were ligated together to form the pIREB-EGFP construct. Each 
10 µl ligation reaction contained 20 ng of 4448bp fragment, 20 ng of 3432bp 
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The reaction was incubated at 22°C for 4 hours followed by enzyme inactivation at 
65°C for 10 minutes.  
 The ligation products were transformed to Subcloning efficiencyTM DH5αTM 
competent cells (GibcoBRL Life Technologies, cat No. 182655-017) using the 
protocol described previously. Three recombinant colonies for each ligation product 
were used to inoculate 5 ml LB medium with ampicillin (100 µg/ml) in 15 ml Falcon 
tubes. After shaking at 225 rpm at 37°C for 14 hours, the recombinant plasmid DNAs 
were extracted from the bacteria culture by Wizard® Plus Minipreps DNA 
Purification System (Promega, cat No. A7510) following the manufacturer’s protocol. 
The concentration of the plasmid DNAs was determined by a spectrophotometer. All 
the plasmid DNAs were checked by restriction enzyme digestion. 1 µg of each 
plasmid DNA was digested by 20 units of EcoRI in 1 × buffer EcoRI+ in a 20 µl 
reaction and the reaction was incubated at 37°C for 3 hours. The digestion products 
were resolved by gel electrophoresis through a 1% agarose gel. Presence of 3150bp 
and 4730bp fragments indicates the correct recombination of pIREB-EGFP 
constructs. Large amount of plasmid DNA for each correct pIREB-EGFP constructs 
(wild type or with mutation) were prepared for transfection using QIAGEN 
EndoFreeTM Plasmid Maxi purification kit. The concentration of the plasmid DNA 
was determined by a spectrophotometer. 
 
3.3.2 Cell culture and transfection 
The HeLa cell line was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco) supplemented with 10% Fetal Calf Serum (FCS). The cell line was 
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cultivated in an atmosphere of 5% CO2 at 37°C and routinely passaged by 
trypsinization.   
The HeLa cells were transiently transfected by calcium phosphate 
precipitation. Firstly, HeLa cells were seeded in 90mm culture dishes at a density of 1 
× 106 cells in 10 ml DMEM per dish. The cells were incubated at 37°C for 24 hours or 
until the cell culture achieving 50-70% confluency. The old medium in each dish was 
replaced by fresh medium 30 minutes before transfection. The transfection mixture 
was mixed as follows: 30µg of each test construct (pIREB-EGFP wild type and with 
mutations) was diluted in 438µl of sterile deionized water first; 62 µl sterile 2M CaCl2 
was dropped into the DNA solution while vortexing; then the CaCl2-DNA mixture 
was dropped into 500 µl of 2 × HBS buffer (280 mM NaCl, 10 mM KCl, 1.5 mM 
Na2HPO4.2H2O, 12 mM dextrose, 50 mM HEPES, pH 7.05, filtered through 
membrane with pore size 0.22 µm) while vortexing; the 1 ml mixture was incubated 
at room temperature for 25 minutes. Fine white precipitate should be seen at the end 
of the incubation period. The 1 ml transfection mixture was added into each dish 
while gently swirling the medium. The cells were washed in 1 × phosphate buffered 
saline (PBS) after incubation at 37°C for 16 hours and fresh medium were added into 
each dish. Specific translation initiation of the IRE-containing β-globin gene mRNAs 
was achieved by supplementing the culture medium with 100 µM heme arginate 
(Normosang®, Orphan Europe) 8 hours after washing. Specific translation inhibition 
of the IRE-containing β-globin gene mRNA was achieved by iron depletion with 100 
µM deferoxamine mesylate (Sigma) added to the culture medium 4 hours after 
washing [127]. Translation inhibition was also achieved by supplementing the culture 
medium with 100 µg/ml cycloheximide (Sigma), 100 µg/ml puromycin (Sigma) or 
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100 µg/ml anisomycin (Sigma) 4 hours before harvesting [128]. The cells were 
harvested 24 hours after washing. Transfection efficiency was checked for the 
expression of EGFP protein in HeLa cells under fluorescent microscope with FITC 
filter. Three independent transfections were performed for each construct under 
different translation initiation or inhibition conditions. 
 
3.3.3 RNA extraction and real-time RT-PCR 
Cytoplasmic and nuclear RNA was isolated from the transfected HeLa cells 
according to the manufacturer’s protocol using PARISTM Protein and RNA isolation 
System (Ambion). The concentration of the RNA was measured 
spectrophotometrically by the absorbance at 260 nm. The RNAs were stored at –86°C 
until use. Before RT-PCR, 1.4 µg of each RNA sample was purified using DNA-
freeTM DNase Treatment and Removal Reagent (Ambion) to remove contaminating 
DNA during RNA extraction.  
The first strand of cDNA was synthesized using TaqMan Reverse 
Transcription Reagents (Applied Biosystems) with oligo dT as the primer. The 10 µl 
reverse transcription reaction contained 120 ng RNA treated by DNase I, 1 × RT 
buffer, 5.5 mM MgCl2, 500 µM each dNTP, 2.5 µM Oligo d(T)16, 0.4 U/µl RNase 
inhibitor and 1.25 U/µl MultiScribeTM reverse transcriptase. The reaction was 
incubated at 25°C for 10 minutes for primer-RNA template binding, followed by 
reverse transcription at 48°C for 1 hour, and finally with reverse transcriptase 
inactivation at 95°C for 5 minutes. 
A β-globin gene cDNA fragment and a EGFP gene cDNA fragment were 
amplified using SuperScriptTM One-step RT-PCR with Platinum® Taq (Invitrogen) 
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from the purified RNA. The primers are listed in Table 3-13. Each 50µl reaction 
contained 1 × reaction mix, 0.2 µM each of the forward and reverse primers, 1 µl of 
RT/Taq mix and 12 ng of the RNA template extracted from HeLa cells transfected 
with pIREB-EGFP wild type construct. The amplified cDNA fragments, HBB (361 
bp) and EGFP (416 bp) were cloned into the pBluescript T-vector by T-A cloning to 
generate the constructs pBS-HBB (361bp) and pBS-EGFP (416bp). Plasmid DNAs 
were extracted from the bacterial culture. Serial ten-fold dilutions (104 to 108 
molecules) of the plasmid DNAs were used as the reference molecules for a 
validation experiment to demonstrate that the real-time PCR efficiencies of the target 
gene (HBB) and the reference gene (EGFP) are approximately equal. The target 
(HBB) and reference (EGFP) real-time PCR were run in separate tubes. The threshold 
cycle (CT) values for each dilution of the target (HBB) and the reference (EGFP) were 
obtained and the difference for each dilution was calculated (∆CT). Then, a plot of log 
input (from 4 to 8) amount versus ∆CT was prepared. The slope of the plot of log 
input amount versus ∆CT is 0.012, much less than 0.1 (Figure 3-14). This value 
indicates that the efficiencies of the real-time PCRs for two amplicons are 
approximately equal (ABI 7700 User Bulletin #2) and the comparative CT method 
(∆CT method) can be used for quantitation.   
The primers used in the real-time PCR analysis of β-globin gene and EGFP 
gene were designed using Primer Express 2.0 (Table 3-13). The real-time PCR 
reactions were performed in an ABI PRISM® 7000 Sequence Detection System using 
the SYBR Green PCR master mix (Applied Biosystems). Thermocycling was done in 
a final volume of 25 µl containing 6 ng of cDNA sample, 1 × SYBR Green PCR 
master mix, and 900 nM each of the forward and reverse primers. After 10 minutes at 
95°C to activate the AmpliTaq Gold DNA polymerase, the cycle conditions were as 
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follows: 40 cycles consisting of denaturation at 95°C for 15 seconds, annealing and 
extension at 60°C for 1 minute.  
Relative Efficiency Plot
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Figure 3-14 HBB and EGFP PCR relative efficiency plot of log input amount versus ∆CT. The 
absolute value of the slope of log input amount vs. ∆CT is 0.012, which is less than 0.1. This 
demonstrates that the efficiencies of target (HBB) and reference (EGFP) real-time PCR are 
approximately equal. 
 
Table 3-13 Primer sequences and amplicon sizes for the PCR for cDNA cloning and real-time 
PCR for gene quantification.  
PCR Name Sequence 5’→3’ Amplicon (size) 
BG68F TGA GGA GAA GTC TGC CGT TAC 
BG428R TGG TGG GGT GAA TTC TTT GCC 361 bp 
   
E761F CGG TCA CGA ACT CCA GCA GG 
PCR for cDNA 
cloning  
E1176R CAT GCC CGA AGG CTA CGT CC 416 bp 
    
HBB341F GCA CGT GGA TCC TGA GAA CTT C 
HBB423R GGG TGA ATT CTT TGC CAA AGT G 83 bp 
   
EGFP280F CTC GAT GTT GTG GCG GAT CT 
Real-time PCR for 
gene quantification 
EGFP350R ACG TCT ATA TCA TGG CCG ACA AG 71 bp 
 
After PCR, a dissociation curve analysis was performed by increasing the 
temperature from 65°C to 95°C to differentiate the desired PCR product from primer 
dimmer. To ensure that the correct products were amplified from each reaction, all 
PCR products were separated by 1% agarose gel electrophoresis to check the 
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amplicon size. Both β-globin gene and EGFP gene were amplified three times from 
each sample.  
The comparative CT method (∆CT) was used for relative quantitaion of β-
globin gene mRNA. EGFP gene, which is present in the same construct as β-globin 
gene, was used as the endogenous reference to normalize the differences in 
transfection efficiency and the amount of template in the PCR reaction. Within one 
PCR run, the RNA sample extracted from the HeLa cells that had been transfected 
with pIREB-EGFP wild type construct was used as the calibrator to normalize the 
samples from mutation-containing constructs that were transfected at the same time as 
the wild type construct under the same translation regulation conditions. The 
calculations for the quantitation involve firstly, finding the difference (∆CT) between 
the CT values of the target (HBB) and the reference (EGFP).  
∆CT = CT (HBB) − CT (EGFP) 
This value was calculated for each sample to be quantitated. Then, the comparative 
∆∆CT was calculated by getting the difference between each sample’s ∆CT (∆CT,mt) 
and the calibrator’s ∆CT (∆CT,wt).  
∆∆CT = ∆CT,mt − ∆CT,wt 
The last step in quantitation is to transform these values to absolute values. According 
to Applied Biosystems guidelines, for amplicon size less than 150, the PCR efficiency 
is close to 100%. Therefore, the amount of target (HBB), normalized to the 
endogenous reference (EGFP) and relative to the calibrator (wild type), is given by: 
 Comparative expression level = 2−∆∆CT 
 ABI Relative Quantification software was used to automatically calculate the 
comparative expression level of the β-globin gene from the raw data (CT values) 
generated from the real-time PCR relative quantification plate documents. The results 
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were exported into Excel to calculate the mean and the standard deviation from the 
three independent transfection repeats for each construct under the same translation 
regulation conditions. 
 
3.3.4 Western blot 
Cytoplasmic protein was extracted from transfected HeLa cells after lysis in 
cold cell fraction buffer from PARISTM Protein and RNA isolation System (Ambion) 
following the manufacturer’s protocol. The concentration of protein in the cell lysis 
was quantified by Bradford protein assay using Bio-Rad protein assay kit following 
its microtiter plate protocol. The absorbance at 595 nm was measured using Wallac 
1420 VICTOR2 V plate reader (Perkin Elmer). 
30 µg of protein from each sample was resolved through 5-15% SDS-
polyacrylamide gradient mini gel (29:1) together with 8 µl of Precision Plus ProteinTM 
Standards Dual Color (Bio-Rad) at 100 Volts for 2 hours. Following electrophoresis, 
the gel was equilibrated in transfer buffer (48 mM Tris, 39 mM glycine, 20% 
methanol, pH 9.2, do not add acid or base to adjust pH) for 15 minutes.  The protein 
was transferred from the gel to the wet Immuno-BlotTM PVDF membrane (Bio-Rad) 
that had been soaked in transfer buffer for 30 minutes using Trans-Blot SD Semi-Dry 
Electrophoretic Transfer Cell (Bio-Rad) at 15 Volts for 1 hour.  
The membrane was blocked with blocking buffer (freshly prepared 5% 
skimmed milk in Tween-Tris buffered saline (TTBS) buffer: 0.1% Tween-20 in 20 
mM Tris, 30 mM NaCl, pH 7.5) on a rotating shaker at 4°C overnight. The primary β-
globin antibody was raised in rabbit against the first 13 amino acids of the N-terminal 
of the human β-globin (Biogene, Germany) [63]. After incubating in the primary 
 89
antibody diluted in TTBS (1: 200,000) buffer for 1 hour at room temperature, the 
membrane was washed three times for 5 minutes each with TTBS buffer. Then, the 
membrane was incubated for 1 hour at room temperature with horseradish peroxidase 
(HRP) conjugated secondary antibody (goat anti-rabbit IgG, Santa Cruz 
Biotechnology), diluted to 1:50,000 in TTBS buffer. After washing the membrane 
three times for 5 minutes each with TTBS buffer, the membrane was incubated in 
ECL Advanced Western Blotting Detection reagent (Amersham Biosciences) for 5 
minutes at room temperature. The membrane was wrapped after draining off excess 
detection buffer and exposed to Kodak MR film (Kodak) in an X-ray film cassette for 
4 minutes. 
The membrane was then stripped of bound antibodies and re-probed with the 
antibodies against EGFP. After washing the membrane in de-ionized water two times 
for 5 minutes each, the membrane was stripped with stripping buffer (0.2 N NaOH) 
for 5 minutes at room temperature. Following this, the membrane was washed in de-
ionized water twice and in TTBS buffer twice for 5 minutes each at room 
temperature. Then, the membrane was blocked and probed again as described above. 
The primary EGFP antibody was 1: 500,000 dilutions of mouse anti-GFP (Roche) in 
TTBS buffer. The secondary antibody was a goat anti-mouse IgG coupled with 
horseradish peroxidase (Santa Cruz Biotechnology), diluted to 1:1,000,000 in TTBS 






4.1  Improved Tools for Molecular Diagnosis of α- and β-Thalassemia in 
Southeast Asia 
 The results from different assays are shown individually below.  
 
4.1.1 Successful “reconstituted” positive controls for 7-deletion-multiplex PCR 
As shown in Figure 4-1, the reconstituted samples yield amplification results 
resembling those from actual heterozygous DNA samples, but with weaker ratios of 














Figure 4- 1 Seven-deletion multiplex-PCR analysis of the reconstituted positive control samples.  
A, Multiplex-PCR results from reconstituted (R) and actual patient (A) genomic DNA heterozygous for 
each of seven α-thalassemia deletions.  B, Multiplex-PCR results from reconstituted genomic DNA 
containing all seven plasmid constructs (R7).  L, allelic ladder comprising all 9 possible multiplex-PCR 
products; M, Generuler 1kb DNA ladder (Fermentas). 
 
4.1.2 β-Thalassemia multiplex-minisequencing assay 
A gap-PCR strategy was used to simultaneously amplify the β-globin gene 
fragment for subsequent minisequencing screen of 15 point mutations as well as to 
detect the ∆619 bp deletion mutation directly.  Under the recommended PCR 
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β-F and β-R1 (Figure 3-3).  In a ∆619 bp allele, the annealing sequence for primer β-
R1 is deleted, resulting in the amplification of a 1671 bp fragment from primers β-F 
and β-R2.  In individuals heterozygous for the ∆619 bp allele, therefore, both 
fragments are amplified and easily discriminated by simple agarose gel 
electrophoresis. 
To detect the point mutations in the β-globin gene, multiplex-minisequencing 
was performed on the amplified PCR product. Given the close proximity of a majority 
of the β-globin gene mutations, the 16-mutation assay was divided into two multiplex 
panels, and mutation-detection primers were designed to either the sense or 
complementary strand of the gene, to eliminate primer-primer overlap and primer-
dimer interactions in the reaction (Figure 3-4; Table 3-4). 
In minisequencing, a mutation-detection primer anneals such that its 3’ 
nucleotide ends just before the mutation site, and a cycle sequencing reaction is 
performed in the presence of Taq DNA polymerase and a mixture of 4 terminator 
nucleotides (ddNTPs), each labeled with a different fluorescent molecule.  As a result, 
each primer molecule is extended by one of the 4 dye-terminators, and the fluorescent 
tag(s) on the extended primer serves as a reporter of the normal and/or mutant 
genotype of the template DNA.  In normal or homozygous mutant samples, only 
normal or mutant dye-terminator is attached to the primer, so only one primer peak is 
detected on an electropherogram. 
A heterozygous sample, however, will result in attachment of either normal or 
mutant dye-terminator to the mutation-detection primer, and hence detection of two 
different fluorescent signals/peaks. The same primer tagged with two different dye-
terminators may or may not migrate identically, depending on molecular weight 
differences of the nucleotide-fluorophore combinations. Also, normal and mutant 
 93
allele peak heights may differ significantly due to differences in fluorescence 
emission of the different fluorophores (Figure 4-2).  
In each multiplex-minisequencing panel, several mutation-specific primers 
were designed for simultaneous annealing and single-base extension.  All primers, 
except for one, were designed with 5’ non-specific poly-d(A) or poly-d(GACT) tails 
of different lengths, to enable easy discrimination of terminator-incorporated primers 
based on size.  Table 3-3 summarizes the primers and their concentrations in the 
respective primer mixtures, and the expected results after incorporation of dye-
terminators.  Thus, the position of the extended primer peak in the electropherogram 
specifies the mutation locus, while the peak color(s)/fluorescence specify the 
genotype (Figures 4-2 and 4-3). 
To demonstrate that all the mutations can be detected in both homozygous and 
heterozygous state, we analyzed genomic DNA samples carrying these mutations.  
Where patient samples homozygous for particular mutations were unavailable, we 
cloned the mutant β-globin genes from heterozygous DNA samples, and performed 
the multiplex-minisequencing directly on the purified plasmid constructs.  Such tests 
were performed to confirm the absence of spurious “normal” peaks that could arise 
from promiscuous incorporation of other dye-terminators in the homozygous mutant 
state, and that would lead to misdiagnosis of homozygotes as heterozygotes.  In all 
instances, expected normal and/or mutant peaks were observed in the presence of the 
normal and/or mutant alleles, thus confirming the specificity of the assay. 
GeneScan 3.7 application software was used to automatically analyze the 
results after capillary electrophoresis.  The GeneScan electropherograms of several 
patient samples after multiplex-minisequencing with primer panels A and B are 
illustrated in Figure 4-2A and 4-2B, respectively.  To further automate the allele-
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calling process, the results were re-analyzed with Genotyper 3.7 application software.  
A “macro” file was created for both multiplex-minisequencing panels, such that each 
peak in the Genotyper-generated electropherogram could be automatically identified 
and labeled by simply launching the “macro” application (Figure 4-3).  The labels 
were designed to provide information on the mutation site, the nucleotide 
incorporated, and whether it was a normal or mutant allele.  Additionally, a template 
was created to automatically generate a tabulated report of the Genotyper 
electropherogram results (Table 4-1).  Automated allele-calling and report generation 
serves not only to simplify the diagnostic process, but more importantly minimizes 
human errors of data transcription. 
As a final validation of the multiplex-minisequencing assay, a double blind 
analysis of 81 β-thalassemia patient samples and 8 normal controls was performed.  
The genotypes of these samples were previously determined either by ARMS-PCR 
analysis or by direct DNA sequencing (Table 3-3).  Samples were coded and assayed 
by different individuals, and results were scored independently by the person 
performing the assay and by a third individual.  The genotypes scored by both 
















Figure 4-2 GeneScan™ analysis of multiplex-minisequencing products.  Electropherograms from a normal individual and patient samples with known β-thalassemia 
genotypes are shown.  A. Mutations detected by multiplex panel A.  B. Mutations detected by panel B.  For each patient sample, only the multiplex panel displaying 
mutations is shown.  The position of the extended primer peak specifies the mutation locus, while the peak color specifies the allele/nucleotide.  Each mutant allele displays a 
characteristic peak color, position and height relative to its normal allele peak.  (Red=dT, green=dA, blue=dG, black=dC). 
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Figure 4-3 Automated genotyping of multiplex-minisequencing results.  Electropherograms from a normal and two patient samples are shown for each panel.  Selection 
of the appropriate user-defined “macro” file in Genotyper™ 3.7 results in automatic tagging of each fluorescent primer peak with a label containing information on mutation 
site, nucleotide added (dA,dG,dC or dT) and normal (N) or mutant (M) status. 
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Table 4-1 Genotyper-generated report of Figure 3-4 panel A electropherogram results 
File Name Lane Category Peak 1 Peak 2 Sample Info* 
3A_C02_06.fsa 6 -29 -29 A-N  Normal 
3A_C02_06.fsa 6 Cd17 Cd17 T-N   
3A_C02_06.fsa 6 Cd71/72 Cd71/72 G-N   
3A_C02_06.fsa 6 -28 -28 T-N   
3A_C02_06.fsa 6 Cd26 Cd26 C-N   
3A_C02_06.fsa 6 Cd41/42 Cd41/42 C-N   
3A_C02_06.fsa 6 InI5 InI5 C-N   
3A_C02_06.fsa 6 InII654 InII654 C-N   
33A_A06_02.fsa 2 -29 -29 A-N  -28 / β 
33A_A06_02.fsa 2 Cd17 Cd17 T-N   
33A_A06_02.fsa 2 Cd71/72 Cd71/72 G-N   
33A_A06_02.fsa 2 -28 -28 C-M -28 T-N  
33A_A06_02.fsa 2 Cd26 Cd26 C-N   
33A_A06_02.fsa 2 Cd41/42 Cd41/42 C-N   
33A_A06_02.fsa 2 InI5 InI5 C-N   
33A_A06_02.fsa 2 InII654 InII654 C-N   
22_F11_11.fsa 11 -29 -29 A-N  Cd41-42 / InII654 
22_F11_11.fsa 11 Cd17 Cd17 T-N   
22_F11_11.fsa 11 Cd71/72 Cd71/72 G-N   
22_F11_11.fsa 11 -28 -28 T-N   
22_F11_11.fsa 11 Cd26 Cd26 C-N   
22_F11_11.fsa 11 Cd41/42 Cd41/42 G-M Cd41/42 C-N  
22_F11_11.fsa 11 InI5 InI5 C-N   
22_F11_11.fsa 11 InII654 InII654 C-N InII654 T-M  
*. With the exception of the highlighted words under the Sample Info column, the entire 
Table’s contents are generated automatically by a user-defined macro file in Genotyper. 
 
4.1.3 α-Thalassemia minisequencing assay 
As a complement or supplement to deletional α-thalassemia screening, the α2-
globin gene multiplex-minisequencing assay can be performed directly on the PCR 
product of the 7-deletion multiplex-PCR assay [36].  Alternatively, the α2-globin 
gene can be independently amplified for subsequent multiplex-minisequencing to 
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screen for specific point mutations.  The principle of liquid-phase multiplex-
minisequencing analysis has been discussed previously in describing the detection of 
common Southeast Asian and Indian β-thalassemia point mutations. 
In this present multiplex-minisequencing assay, several mutation-specific 
primers were designed for simultaneous annealing to the α2-globin gene fragment, 
followed by single-base extension.  All primers, except for one, were designed with 5’ 
non-specific poly-d(A) or poly-d(GACT) tails of differing lengths, to enable easy 
discrimination of terminator-incorporated primers based on size.  Table 3-7 
summarizes the primers and their concentrations in the primer mixture, and the 
expected results after incorporation of dye-terminators.  The position of the extended 
primer peak in the electropherogram specifies the mutation locus, while the peak 
color(s)/fluorescence specifies the genotype (Figure 4-4, 4-5). 
To demonstrate that all the mutations could be accurately detected in both 
heterozygous and homozygous/hemizygous states, genomic DNA samples carrying 
these mutations were analyzed.  Where patient samples homozygous/hemizygous for 
particular mutations were unavailable, the mutant α2-globin gene was cloned from 
carrier individuals, or from mutation-carrying amplicons generated by the PCR 
mutagenesis technique.  These plasmid clones were mixed with an equimolar amount 
of Hb Bart’s hydrops fetalis genomic DNA (−−SEA/−−SEA), and then analyzed.  
GeneScanTM 3.7 application software (Applied Biosystems) was used to analyze the 
results after capillary electrophoresis. In all instances, the GeneScan 
electropherograms displayed the expected normal and/or mutant peaks in the presence 
of the normal and/or mutant alleles, respectively, thus confirming the specificity of 
the assay (Figure 4-4).  There were no detectible spurious “normal” peaks in the 
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homozygous/hemizygous mutant samples, and thus no evidence of dye-terminator 
misincorporation by the DNA polymerase. 
Automated allele-calling of samples was also performed using GenotyperTM 
3.7 application software, in conjunction with a “macro” file which was created to 
automatically identify and label each peak in the Genotyper-generated 
electropherogram (Figure 4-5).  The labels provide information on the mutation site, 
the nucleotide incorporated, and the normal or mutant status of the allele.  
Additionally, a tabulated report was generated together with the Genotyper 
electropherogram results (Table 4-2).  Automation of the data analysis function 
minimizes operator manipulations, and can potentially reduce operator errors of data 
transcription. 
As a final validation of the multiplex-minisequencing assay, a double-blind 
analysis of 45 α-thalassemia patient samples and normal controls was performed 
(Table 3-6).  The deletions in these samples were previously determined by Southern 
blot and/or multiplex-gap-PCR analysis, while the point mutations were determined 
by MARMS PCR and/or DNA resequencing analysis.  Samples were coded and 
assayed by different individuals, and results were scored independently by the person 
performing the assay and by a third individual.  Each DNA sample was subjected to 
both the α-thalassemia 7-deletion multiplex-PCR assay [36]) and the α2-globin gene 
7-mutation multiplex-minisequencing assay.  The genotypes scored by both 
























Figure 4-4 GeneScan™ electropherogram of multiplex-minisequencing products.  Results from a 
normal individual and several DNA samples of known α-thalassemia genotype are shown.  The 
position of the extended primer peak specifies the mutation locus, while the peak color specifies the 
allele/nucleotide.  Each mutant allele displays a characteristic peak color, position and height relative to 


























Figure 4-5 Automated genotyping of multiplex-minisequencing results using Genotyper™ 3.7.  
Electropherograms from DNA samples of known α-thalassemia genotype are shown.  Upon selection 
of the appropriate user-defined “macro” file, labels containing information on mutation site, nucleotide 
added (dA,dG,dC or dT) and normal (N) or mutant (M) status are automatically generated under each 
peak.  Asterisks indicate reconstituted DNA samples containing a mixture of genomic DNA and a 
plasmid clone containing the point mutation. 
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Table 4-2 Genotyper-generated report of Figure 3 electropherogram results. 
File Name Lane Category Peak 1 Peak 2 Sample Info* 
13_E04_10.fsa 10 Cd0d1 Cd0d1 T-N    αCSα / αα  
13_E04_10.fsa 10 SD SD T-N   
13_E04_10.fsa 10 Cd30 Cd30 G-N   
13_E04_10.fsa 10 Ps Ps T-N   
13_E04_10.fsa 10 Cd59 Cd59 C-N   
13_E04_10.fsa 10 CS CS C-M CS T-N  
13_E04_10.fsa 10 QS QS T-N    
17_A05_01.fsa 1 Cd0d1 Cd0d1 T-N    αPsα ** 
17_A05_01.fsa 1 SD SD T-N   
17_A05_01.fsa 1 Cd30 Cd30 G-N   
17_A05_01.fsa 1 Ps Ps A-M   
17_A05_01.fsa 1 Cd59 Cd59 C-N   
17_A05_01.fsa 1 CS CS T-N   
17_A05_01.fsa 1 QS QS T-N    
8_H03_15.fsa 15 Cd0d1 Cd0d1 T-N    αQSα / αα 
8_H03_15.fsa 15 SD SD T-N   
8_H03_15.fsa 15 Cd30 Cd30 G-N   
8_H03_15.fsa 15 Ps Ps T-N   
8_H03_15.fsa 15 Cd59 Cd59 C-N   
8_H03_15.fsa 15 CS CS T-N   
8_H03_15.fsa 15 QS QS C-M QS T-N  
9_A02_02.fsa 2 Cd0d1 Cd0d1 G-M Cd0d1 T-N  αCd0α / αα 
9_A02_02.fsa 2 SD SD T-N   
9_A02_02.fsa 2 Cd30 Cd30 G-N   
9_A02_02.fsa 2 Ps Ps T-N   
9_A02_02.fsa 2 Cd59 Cd59 C-N   
9_A02_02.fsa 2 CS CS T-N   
9_A02_02.fsa 2 QS QS T-N    
26_B06_04.fsa 4 Cd0d1 Cd0d1 T-N    αCd30α ** 
26_B06_04.fsa 4 SD SD T-N   
26_B06_04.fsa 4 Cd30 Cd30 A-M   
26_B06_04.fsa 4 Ps Ps T-N   
26_B06_04.fsa 4 Cd59 Cd59 C-N   
26_B06_04.fsa 4 CS CS T-N   
26_B06_04.fsa 4 QS QS T-N    
37_E05_09.fsa 9 Cd0d1 Cd0d1 T-N    αSDα / αα  
37_E05_09.fsa 9 SD SD G-M SD T-N  
37_E05_09.fsa 9 Cd30 Cd30 G-N   
37_E05_09.fsa 9 Ps Ps T-N   
37_E05_09.fsa 9 Cd59 Cd59 C-N   
37_E05_09.fsa 9 CS CS T-N   
37_E05_09.fsa 9 QS QS T-N    
16_H04_16.fsa 16 Cd0d1 Cd0d1 T-N    αCd59α / αα 
16_H04_16.fsa 16 SD SD T-N   
16_H04_16.fsa 16 Cd30 Cd30 G-N   
16_H04_16.fsa 16 Ps Ps T-N   
16_H04_16.fsa 16 Cd59 Cd59 C-N Cd59 T-M  
16_H04_16.fsa 16 CS CS T-N   
16_H04_16.fsa 16 QS QS T-N    
*. Except for the highlighted words under the Sample Info column, the entire Table’s contents are generated 
automatically by a user-defined macro file in Genotyper.  ** These samples carry the --SEA allele on the other 
chromosome 16, as detected by the 7-deletion multiplex-PCR assay. 
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4.1.4 Single-tube α-globin gene triplication multiplex-PCR 
 The anti-3.7/4.2 multiplex-PCR primers were designed to only amplify either 
an anti-3.7 or an anti-4.2 junction fragment from the respective anti-3.7 or anti-4.2 
allele.  No amplification product would be generated from a normal allele (αα) or a 
deletional allele (−α or −−).  Primers AT3.7-F and AT3.7-R amplify a 1.9 kb 
fragment only from the hybrid Z1Z2 box, whereas primers AT4.2-F and AT4.2-R 
amplify a 1.7 kb fragment only from the hybrid X1X2 box.  Since the amplicon size is 
different for the anti-3.7 and anti-4.2 junction fragments, they can easily be 
distinguished by gel electrophoresis. For samples without any α-globin gene 




































































































Figure 4-6 Results of combined multiplex-PCR assays to determine α-globin genotype.  Top gel, 
7-deletion multiplex-PCR; bottom gel, Anti-3.7/4.2 multiplex-PCR.  M, 1kb DNA ladder (Fermentas, 
St Leon-Rot, Germany); AL, allelic ladder. 
 
 
To validate the anti-3.7/4.2 multiplex-PCR screening assay, a double blind 
analysis of 21 DNA samples harboring either an anti-3.7 or an anti-4.2 α-globin gene 
triplication, together with 10 negative control samples (αα/αα), was performed.  The 
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α-globin genotypes of these samples had been previously determined by Southern 
blot analysis.  The anti-3.7/4.2 multiplex-PCR was assessed in combination with the 
α-thalassemia 7-deletion multiplex-PCR assay [36] to determine their α-globin 
genotype.  Therefore, for each DNA sample to be tested, two amplification reactions 
were performed.  The 7-deletion multiplex-PCR assay screens for the 7 common α-
thalassemia deletions.  In this assay, a control α2 globin gene fragment is amplified to 
indicate heterozygosity for a non-deleted allele when a deletion is also present (Figure 
4-6); it cannot, however, distinguish between a wild-type non-deleted allele (αα) and 
a triplicated (ααα) allele.  By also performing the anti-3.7/4.2 multiplex-PCR assay, 
the presence of the triplicated allele in these samples could be detected (Figure 4-6). 
In the blinded analysis, the triplication multiplex-PCR assay detected the 
presence of the correct triplicated allele (αααanti3.7 or αααanti4.2) in all 21 triplication-
positive DNA samples (Table 4-3).  No anti-3.7 or anti-4.2 junction fragment was 
detected in any of the 10 triplication/quadruplication-negative DNA samples.  In 
combination with the 7-deletion multiplex-PCR assay, the α-globin genotype of all 31 
DNA samples was correctly determined (Table 4-3). The anti-3.7/4.2 multiplex-PCR 
assay thus serves as a useful rapid screen for the presence of the anti-3.7 and/or the 
anti-4.2 types of triplication.  For the majority of individuals negative for a triplication 
by this rapid PCR assay (~96.5-98.0% based on data extrapolation), no further 
analysis is required. Southern blot analysis will only be required in the presumptive 
2.0-3.5% of samples that are PCR-positive, to distinguish between the heterozygous 





Table 4-3 Blinded validation analysis of 31 DNA samples of known α-globin genotype. 
Anti-3.7/4.2 multiplex-PCR: 
presence/absence (+/-) of amplicon 
 Seven-deletion multiplex-PCR: 



















αα / αααanti3.7 7 + + −  + − + − − 
αα / αααanti4.2 7 + − +  + − + − − 
αααanti3.7 / −α4.2 2 + + −  + − + + − 
αααanti4.2 / −α4.2 2 + − +  + − + + − 
αααanti4.2 / −α3.7 1 + − +  + + + − − 
αααanti3.7 / −−SEA 1 + + −  + − + − + 
αααanti4.2 / −−SEA 1 + − +  + − + − + 
αα /αα 10 + − −  + − + − − 














Figure 4-7 Expected and actual southern blot results of samples with various unequal crossover 
derivative α-globin alleles or genotypes. Expected hybridizing bands of various unequal crossover 
derivative alleles (left) and genotypes (middle), and actual autoradiogram of three DNA samples 



























































































































4.2 Molecular verification of Hb H disease classification by IEF 
We first determined the α-globin gene deletions in all the patients using a 
single-tube multiplex gap-PCR assay [36].  For patients where only one double-gene 
deletion was present, we sequenced the HBA1 and HBA2 genes on the non-deleted 
chromosome 16. 
The α-globin genotypes of 67 patients diagnosed as deletional Hb H disease 
by IEF are listed in Table 4-4.  The majority of patients in this group (n=56) were 
compound heterozygous for a --SEA double-gene deletion and a -α3.7 single-gene 
deletion (-α3.7/--SEA), while two other patients had a -α4.2/--SEA genotype.  In another 
six patients, however, we observed a non-deletional Hb H genotype.  Of these, five 
carried the αCSα/--SEA genotype, and one was compound heterozygous for --SEA and 
Hb Paksé (αPsα/--SEA).  In the remaining three patients, one showed an apparent 
homozygous --SEA genotype (--SEA/--SEA), while two appeared to be heterozygous --SEA 
carriers (αα/--SEA).  Sequencing of the HBA1 and HBA2 genes on the non-deleted 
chromosome of both patients, including 493 bp of sequence upstream of the 
transcription start sites of both genes, did not reveal any mutations that could account 
for their Hb H disease classification. 
Table 4-5 summarizes the α-globin genotypes of 43 patients diagnosed as Hb 
H CS disease by IEF.  The majority of patients in this group were compound 
heterozygous for αCSα/--SEA (n=39).  Of the four remaining patients, two were 



































*Patient is either homozygous for the --SEA deletion or compound heterozygous for --SEA and another unknown deletion 
 
Table 4-5 α-Globin genotypes of 43 patients identified as Hb H CS disease by IEF. 
Genotype αCSα/−−SEA αPsα/−−SEA αCSα/−−THAI αPsα/−−THAI Total 














4.3 Characterization of the relationship between PTC and NMD 
 To determine the relationship between the position of the PTCs and NMD, 
five PTCs caused by naturally occurring β-thalassemia nonsense or frameshift 
mutations close to the 5’ end of the β-globin gene were analyzed in this study. They 
are codon 1 (−G) → PTC3/4, codon 17 (AAG→TAG) → PTC17, codon 8/9 (+G) → 
PTC21/22, codon 27/28 (+C) → PTC42/43 and codon 41/42 (−TTCT) → PTC60/61 
(Figure 4-8). The wild type and each PTC-containing human β-globin gene are driven 
by the β-globin gene promoter to prevent the possibility of any other promoter effect 
on the mRNA accumulation [96]. The EGFP gene driven by the CMV promoter was 
inserted into the same construct containing the β-globin gene to serve as a control for 
transfection efficiency. Presence of both target gene (β-globin) and reference gene 
(EGFP) in one construct ensures the precise normalization against EGFP expression, 
allowing accurate comparisons between different expressions of varying transfection 
efficiencies. Furthermore, EGFP expression allows visual determination/confirmation 
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of transfection efficiency prior to the downstream experiments. Expression levels of 
PTC-containing β-globin genes were compared with that of the wild-type β-globin 






Figure 4-8 Schematic representation of the position of PTCs involved in this study. 
 
Since NMD depends on translation, translation regulation in cytoplasm and/or 
nucleus was used to examine the subcellular localization of NMD and to differentiate 
NMD from non-NMD effects. Specific β-globin gene translation regulation was 
achieved by introducing a 35bp functional IRE fragment into the 5’-UTR of the β-
globin gene. In iron deficient cells, the cytoplasmic located iron-regulatory proteins 
(IRPs) specifically bind to IREs and thus block translation initiation; in iron sufficient 
cells, iron abolishes IRP binding and thus permits the translation [63]. IRPs are 
present only in cytoplasm; therefore this strategy allows the specific translation 
inhibition in cytoplasm without affecting nuclear translation [63]. Global translation 
inhibition was achieved by employing the general translation inhibitors anisomycin, 
puromycin and cycloheximide. 
 
4.3.1 Western blot analysis of wild type and mutant constructs 
Western blot analysis of the wild type β-globin construct confirmed the 
presence of β-globin peptide under translation-permissive condition, but absence of 
Exon 1 Exon 2 Exon 3 
5’-UTR IVSI IVSII 3’-UTR
0 30 303 104 105 146 
PTC: 3/4     17  21/22               42/43   60/61 
IRE 
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peptide in the absence of iron (Figure 4-9, lane 1 and 2), confirming the specific iron-
dependent translation regulation mediated by the IRE. However, none of the PTC-
containing constructs produced any peptides detectable by western blot, even under 
translation-permissive condition. These results are commitment with either absence of 
mutant transcripts and/or the extreme instability of the truncated peptides. In the case 
of the PTC 3/4 construct, however, even if the peptides were present, it would not be 
detectable due to its extremely small size. A theoretical minimum of 13 amino acids 
would be required for the detection by the antibody.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
Mutations Wild type Cd1 ∆1bp Cd 17 Cd 8/9 Cd 27/28 Cd41/42 
PTC − PTC 3/4 PTC 17 PTC 21/22 PTC 42/43 PTC 60/61 
Iron − + − + − + − + − + − + 






Figure 4-9 Western blot of total proteins from HeLa cells transfected with IRE-containing 
constructs. Translation regulation was achieved by supplement the culture medium with iron (iron +) 
or not (iron −). β-globin peptide can only be detected in the sample transfected with wild-type β-globin 
gene when the translation is enabled with iron. EGFP is the protein expressed from the same construct 
as β-globin and serve as a control for transfection efficiency and equal loading of the lanes. 
 
4.3.2 Nuclear and cytoplasmic levels of PTC-containing transcripts in the 
global presence of translation 
Translation initiation of β-globin transcripts was achieved by supplementing 






is enabled in the presence of translation. For PTC-containing transcripts that are 
subjected to NMD, a significant reduction in the transcript level should be observed.  
Both cytoplasmic and nuclear RNAs were extracted and the relative 
expression levels of PTC-containing β-globin genes were quantitated by real-time 
PCR. Figure 4-10 shows the results from 3 independent transfection experiments after 
normalization against EGFP expression. In the nucleus, the mutant transcripts with 
PTCs at 21/22, 42/43, and 60/61 averaged 60 to 70% of wild type transcript level, 
whereas transcripts with PTCs at 3/4 and 17 averaged around 80% of wild type 
transcript level. In the cytoplasm, mutant transcripts with PTCs at 21/22, 42/43 and 
60/61 averaged around 45 to 50% of wild type transcript level, whereas transcripts 
with PTCs at 3/4 and 17 averaged around 80% of wild type transcript level. The 
transcript levels of the PTC-containing β-globin genes are thus reduced in both 
nucleus and cytoplasm. Although all the PTCs are located upstream of the 3’ 
boundary, the levels of mutant transcripts with PTCs at the 5’ part of exon 1 such as 
PTC 3/4 and 17 are higher than the levels of mutant transcripts with PTCs at the 3’ 
part of exon 1 and in exon 2 such as PTC 21/22, 42/43 and 60/61 (80% vs. 50%), 
indicating a position effect of the PTCs on steady-state transcript levels. The reduced 
transcript levels of PTC-containing transcripts even in the nucleus are also suggestive 
















Figure 4-10 The relative expression level of PTC-containing β-globin gene in cytoplasm and 
nucleus in the global presence of translation. Average values and standard deviation of three 
independent experiments are shown. 
 
4.3.3 Nuclear and cytoplasmic levels of PTC-containing transcripts in the 
absence of cytoplasmic translation 
In order to further investigate the possibility of NMD activity in the nucleus, 
cytoplasmic translation of the β-globin gene was blocked by iron depletion, which 
causes IRP to bind to the IRE element in the 5’-UTR of the β-globin gene transcripts. 
If NMD is active in the nucleus, nuclear mutant transcript levels should still be 
reduced compared to wild type transcript even in the absence of cytoplasmic 
translation. Without cytoplasmic translation, the levels of PTC-containing transcripts 
are around 76% to 90% of wild type transcript in the nucleus (Figure 4-11). In the 
cytoplasm, the level of mutant transcripts with PTCs at 21/22, 42/43 and 60/61 are 
around 50 to 57% of wild type transcript, whereas transcripts with PTCs at 3/4 and 17 
are around 70 to 90% of wild type transcript. Compared with the RNA levels in the 
global presence of translation, these RNA levels were slightly higher. But after 
considering the unspecific (∼20%) reduction in RNA expression due to deferoxamine 






























































Nuclear RNAs in the global presence































































[127], both cytoplasmic and nuclear RNAs showed similar levels under the two 
conditions. The result of this experiment indicates that blocking cytoplasmic 
translation does not affect the mutant mRNA levels in both cytoplasm and nucleus, 











Figure 4-11 The relative expression level of PTC-containing β-globin gene in cytoplasm and 
nucleus in the absence of cytoplasmic translation. Average values and standard deviation of three 
independent experiments are shown. 
 
4.3.4 Nuclear and cytoplasmic levels of PTC-containing transcripts in the 
global absence of translation 
To further confirm that NMD was occurring in the nucleus, we performed 
expression analysis under conditions where both cytoplasmic and nuclear translation 
were inhibited. If NMD is dependent on the pioneer round of translation in the 
nucleus, NMD would be blocked in the absence of nuclear translation inhibition, and 
mutant transcript levels in the nucleus would be higher than if translation were to 
occur in the nucleus. 





























































































































Protein synthesis can be inhibited by more than 90% after 4 hours in the 
presence of cycloheximide, puromycin, or anisomycin [128, 129]. These antibiotics 
interfere with the ribosome’s ability to synthesize proteins. As shown in Figure 4-12, 
three translation inhibitors produced similar results. In the global absence of 
translation, all five PTC-containing RNAs in the nucleus present at approximately the 
same level as the wild type transcript, suggesting that global inhibition of translation 
efficiently prevented NMD where cytoplasmic translation inhibition alone did not. In 
the cytoplasm, however, PTC-containing transcript levels were lower than wild type 
transcript, suggesting an alternative degradation mechanism other than NMD at work 



































Figure 4-12 The relative expression level of PTC containing β-globin gene in cytoplasm and 
nucleus in the global absence of translation. Average values and standard deviation of three 
independent experiments are shown. 
Cytoplasmic RNA expression levels in the 
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5.1  Advantage of the improved tools for molecular diagnosis of α- and β-
thalassemia in Southeast Asia 
 The advantage of each assay is discussed individually below. 
 
5.1.1 Construction of “reconstituted” positive controls for the 7-deletion 
multiplex-PCR 
As shown in Table 3-1, molar excess of plasmid construct to haploid genome 
equivalents is required in the reconstituted positive controls, even though actual 
heterozygous patient samples contain an equal ratio of normal and deletion alleles.  
This disparity in template requirement could be due to lower amplification 
efficiencies from supercoiled DNA resulting from stearic hindrances and/or rapid 
complementary strand reannealing during the primer annealing step.  This hypothesis 
is supported by our observation of stronger signal intensities of the deletion junction 
fragments when plasmid constructs are linearized prior to mixing with genomic DNA.  
Although pre-linearization of the plasmid constructs will result in molar ratios closer 
to parity, supercoiled plasmids may be the preferred form for long-term storage in 
mixtures with genomic DNA, as they are less susceptible to trace amounts of 
nucleases than are linearized plasmids. 
Another approach to reconstituting positive control samples, which we 
initially utilized prior to cloning all the junction fragments, is to mix the isolated 
PCR-amplified deletion junction fragments directly with genomic DNA.  Although 
this method works equally well and in addition obviates the need for cloning, all the 
other optimization steps are still necessary.  Furthermore, the amount of plasmid DNA 
that can be obtained from a single bacterial culture far exceeds the amount of deletion 
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junction fragment that can be obtained by PCR.  Because one maxi-preparation yields 
sufficient, stable DNA to generate innumerable positive controls, the plasmid cloning 
strategy provides a better long-term solution. 
We also assessed the feasibility of using as positive controls the diluted 
multiplex-PCR products of patients who are positive for deletions.  Using various 
dilutions of multiplex-PCR product from a heterozygous carrier of a -α3.7 deletion, 
however, we have not been able to generate results anywhere resembling those 
obtained from actual genomic DNA samples, with only the α2 positive control 
fragment amplifying strongly (data not shown).  This observation was not surprising 
considering that the relative ratios of -α3.7, α2, and LIS1 copies in a genomic DNA 
sample are unlikely to be maintained in the amplified product. 
Furthermore, we also assessed the feasibility of generating a single-tube 
“multi-positive control” by mixing all seven plasmid constructs together with normal 
genomic DNA, in the amounts indicated in column 5 of Table 3-1.  All nine 
fragments (seven deletion junction fragments plus the α2 and LIS1 positive control 
fragments) amplified successfully from this reconstituted sample (Figure 4-1).  The 
signal intensities of the various deletion junction fragments relative to the α2 positive 
control fragment in this multi-positive control were also comparable to the 
corresponding relative intensities observed in the individually reconstituted positive 
controls.  Use of a multi-positive control sample such as this will reduce the number 
of positive control reactions necessary in the diagnostic test by seven-fold.  It remains 
to be seen whether such a reconstituted genomic sample containing multiple deletion 
alleles will find wide acceptance as a sufficiently “authentic” positive control to be 
used in a diagnostic test setting. 
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In summary, we have successfully employed a strategy to create 
“reconstituted” genomic DNA samples heterozygous for each of the seven deletions 
screened for in our multiplex-PCR assay, and these renewable reagents are now 
available upon request.  Genomic DNA samples of known mutational genotype are 
necessary reagents in the molecular diagnostic laboratory, serving a critical role as 
positive controls during testing of clinical samples.  Our reconstitution strategy 
represents a convenient, rapid and inexpensive alternative to cell immortalization 
techniques for generating renewable positive controls for α-thalassemia multiplex-
PCR testing, and should be generally applicable to other inherited disorders where 
immortalized cell lines are not readily available. 
 
5.1.2 β-Thalassemia multiplex-minisequencing assay 
β-Thalassemia mutations are relatively population-specific, each ethnic group 
having its own subset of common mutations.  Codon41/42 −TTCT and IVSII,654 
C→T are the most common mutations in Southern Chinese.  These two mutations 
together with codon17 A→T, −28 A→G, IVSI,5 G→C, IVSI,1 G→T and codon71/72 
+A account for 90% or more of all β-thalassemia alleles in this population [11, 43, 
109, 111].  In contrast, codon26 G→A/HbE is very common in a large part of 
mainland Southeast Asia, from Burma in the west to Vietnam in the east, as well as in 
the aboriginal Malay [4].  In India, codon8/9 +G, IVSI,1 G→T, IVSI,5 G→C, 
codon41/42 −TTCT, and ∆619bp together account for more than 90% of β-
thalassemia mutations [4, 22]. 
The cosmopolitan population of Singapore consists mainly of Southern 
Chinese (76.8%), Malays (13.9%) and Indians (7.9%), with Eurasians making up the 
largest proportion of the remaining ethnic groups (Singapore Population Census 
 119
2000).  With a 3-4 % β-thalassemia carrier frequency in Singapore [130] and much 
higher frequencies in many parts of Southeast Asia and India [4], prenatal diagnosis 
and screening of β-thalassemia is currently the best solution to minimizing the 
incidence of thalassemia major and alleviating its considerable healthcare burden. 
Many molecular methods have been used for screening and diagnosis of β-
thalassemia.  Among them, hybridization with allele-specific probes is the most 
widely applied method [40, 41, 109, 131, 132].  A major advantage of the 
minisequencing reaction principle over hybridization with ASO probes is that the 
distinction between the sequence variants is based on the high accuracy of the 
nucleotide incorporation reaction catalyzed by a DNA polymerase, instead of on 
differences in thermal stability between mismatched and perfectly matched hybrids 
formed with the ASO probes [133]. Current versions of thermostable enzymes used in 
minisequencing have extremely low error rates, and have significantly enhanced 
efficiency and specificity for ddNTPs [134-137].  These properties result in negligible 
primer misincorporation frequencies and provide excellent discrimination between 
homozygous and heterozygous genotypes.  Moreover, the same reaction conditions 
can be employed for detecting any variable nucleotide irrespective of the nucleotide 
sequence flanking the variable site [133]. 
Minisequencing is a direct method compared with DGGE because it 
determines the exact nucleotide at the mutation site and does not need other methods 
to verify it.  Minisequencing also accurately differentiates between heterozygosity and 
homozygosity within the same reaction, based on color and number of the peaks at 
each mutation site in the electropherogram. 
Another advantage of minisequencing is its multiplexing capability, with 
several mutations being screened in the same reaction tube.  Although several 
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mutations can be simultaneously detected using multiplex-ARMS (MARMS) [54] or 
combine-ARMS (C-ARMS) [55], only 2-5 mutations can be detected at the same 
time. This multiplex-minisequencing assay detects a total of 16 mutations in 2 parallel 
reactions.  The use of two reactions was necessitated by the fact that a few mutation 
sites in exon 1 and intron 1 of the β-globin gene are very close together, such as 
codon17, codon19, codon26, codon27/28, IVSI,1 and IVSI,5.  Placing all 16 
mutation-specific minisequencing primers in the same reaction would have resulted in 
inefficient primer annealing due to overlap of primer-binding sites and/or formation 
of primer-dimers from overlapping sense and antisense primers.  Had the mutations 
been located sufficiently far apart from each other, simultaneous detection of all 16 
mutations in the same reaction would have been theoretically possible. 
Compared with direct DNA sequencing, minisequencing assays are more rapid 
because automated fluorescent capillary electrophoresis of minisequencing products 
requires only 25 minutes compared to 2.5 h for capillary electrophoresis of standard 
sequencing products. Additionally, data analysis of minisequencing 
electropherograms is comparatively simpler and easily automatable with the aid of 
Genotyper 3.7 application software, resulting not only in significant time and 
manpower savings, but more importantly in minimization of human error during data 
analysis.  Furthermore, Genotyper can be programmed to generate a tablulated report 
of the electropherogram results, further reducing human errors of data transcription. 
The major advantage of DNA sequencing is its ability to investigate every 
nucleotide in the β-globin gene.  There is application software available for alignment 
of sample DNA sequences against a wild-type sequence template.  However, once any 
variant nucleotide has been identified, the mutation site it represents still has to be 
manually determined.  Additionally, several sequencing reactions are required to 
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achieve complete coverage of the gene, and a single standard sequencing reaction 
may not be able to detect all the common mutations.  For example, Cd41/42 and 
IVSII,654 are ~840bp apart, and thus require high quality very long-read sequencing 
to accurately genotype both mutations in the same sequencing reaction. 
Our assay contains two main modifications to the manufacturer’s 
recommended SNaPshot™ minisequencing protocol.  Firstly, we discovered that 
minisequencing primers with very long homopolymeric dA tails produced a high 
background of non-specific peaks.  Conversion of the tails to poly-d(GACT) resolved 
the non-specific peaks.  Secondly, we successfully decreased the SNaPshot™ 
reagents used in the minisequencing reaction to 50% of the recommended amount, 
without any adverse effects whatsoever on the specificity or reproducibility of the 
assay. 
We have calculated the test costs of this assay at ~S$7.5 (US $4.2) per patient 
sample.  This cost includes PCR amplification reagents and primers, purification 
enzymes, minisequencing reagents and primers, and GeneScan electrophoresis costs 
(polymer, capillary array, and other reagents), but excludes manpower.  Due to the 
automated electrophoresis and data analysis capabilities of the Genetic Analyzer 
instrument and Genotyper software, respectively, this assay is most cost-effective in 
diagnostic laboratories with moderate to high patient sample volumes.  This is 
because up to 96 DNA samples can be analyzed within 12 hours by a single 
technologist on 50% effort, with fewer samples leading to shorter turnaround times. 
A double blind validation analysis of this assay on 89 genomic DNA samples 
of known genotype produced a 100% assay specificity.  These samples were from 
normal individuals, heterozygous carriers, or β-thalassemia patients homozygous or 
compound heterozygous for the 16 mutations in the 2 panels.  It should be noted that, 
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like all other previously described assays, our assay does not detect all β-thalassemia 
mutations.  Therefore, patients who are compound heterozygous for a common point 
mutation and a rarer large deletion, such as in δβ-thalassemia, will appear as 
“homozygous” for the common point mutation.  This is because the deleted allele is 
not amplified by the β-globin gene primers, resulting in amplification and detection of 
only the allele carrying the common point mutation.  For affected patients who are 
genotyped as homozygous for a mutation, it might be prudent to genotype the parents 
to rule out the rare possibility of compound heterozygosity with a large deletional 
allele. 
 
5.1.3 α-Thalassemia multiplex-minisequencing assay 
Even though single and double α-globin gene deletions occur far more 
frequently in α-thalassemia compared with non-deletional mutations (point mutations 
and oligonucleotide insertions or deletions within either α2- or α1-globin gene), more 
than 40 α-thalassemia non-deletional mutations have been identified to date. 
However, only a few mutations account for the majority of the non-deletional alleles 
in any one ethnic group or population, akin to the situation for β-thalassemia [9, 21].  
In the Southeast Asian region, the overwhelming majority of non-deletional alleles are 
accounted for by fewer than 10 point mutations, all of which occur in the α2-globin 
gene [19]. 
This new assay complements an existing deletional multiplex-PCR assay 
which we previously developed to detect 7 common α-thalassemia deletions [36], and 
is intended to improve the overall mutation detection sensitivity for α-thalassemia, 
especially for Hb H disease genotyping.  Since deletions account for the vast majority 
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of α-thalassemia alleles, samples sent to the molecular diagnostic laboratory for α-
thalassemia genotyping should first be screened for common deletional mutations.  If 
no deletions are found or only a single or double α-globin gene deletion is identified 
in a patient suspected to carry additional mutations, the sample should then be further 
screened for the presence of non-deletional mutations.  If the 7-deletion multiplex-
PCR assay was used in the deletional analysis [36], the multiplex-minisequencing 
assay can be performed directly on the PCR product of the deletional assay to screen 
for α2-globin gene mutations. If a different deletional assay was performed or if only 
non-deletional mutations need to be screened, the α2-globin gene can be separately 
amplified for the multiplex-minisequencing analysis. 
The advantages of the MARMS PCR non-deletional α-thalassemia screen [56] 
are its simplicity, speed, cost and non-reliance on sophisticated instrumentation.  
MARMS PCR, however, cannot distinguish between heterozygosity and 
homozygosity/hemizygosity for a mutation, although it can be argued that 
homozygosity for point mutations is rarely encountered in α-thalassemia.  In order to 
rule out homozygosity for a mutation, assuming there is no deletion on the other α-
globin gene cluster, a separate PCR needs to be performed using primers specific to 
the normal allele. 
The multiplex-minisequencing method can differentiate between 
heterozygosity for a mutation and homozygosity/hemizygosity, based on color and 
number of the peaks at each mutation site in the electropherogram.  Additionally, two 
of the minisequencing primers (Cd0-F and CS-F) can detect and discriminate between 
different mutations at the same site (Table 4-3).  The assay is also fairly rapid, 
especially when used in conjunction with the deletional multiplex-PCR analysis, 
where a separate PCR is not required.  Under such a situation, results can be obtained 
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in under 3.5 h.  This assay, however, can be performed only in laboratories equipped 
with an automated sequencing instrument. 
In such laboratories, gene resequencing is yet another option to screen for 
point mutations.  Resequencing can also discriminate zygosity, and additionally 
interrogates every nucleotide and can thus screen for more potential mutations.  
However, the high GC content of the α2-globin gene creates difficulties in obtaining 
consistently good and long sequence reads, necessitating several standard or short 
sequencing reactions in both directions in order to generate high confidence 
diagnostic results. 
Another positive aspect of this multiplex-minisequencing protocol is that 
allele-calling and genotyping can be further automated with the aid of Genotyper™ 
software and user-defined “macro” files.  GenotyperTM software also can generate a 
tabulated report of the electropherogram results, which is helpful in non-deletional 
mutation identification and reduce human errors of data transcription.  This option is 
especially useful in diagnostic laboratories with moderate to high sample volumes, 
requiring only a 50% effort by one technologist to handle up to 192 DNA samples, 
with results obtained within 12 hours.  This time includes the α2-globin gene PCR (≤ 
3 h), PCR clean-up, multiplex-minisequencing and post-minisequencing clean-up (≤ 3 
h), capillary electrophoresis (25 min per 16 samples), and verification of automated 
genotyping results (1 h).  Including all consumables for PCR amplification, multiplex-
minisequencing, and capillary electrophoresis, but excluding manpower and 
equipment amortization, this assay costs approximately S$5.2 (US $2.9) per sample.  
In our double-blind validation analysis, 45 DNA samples were used to 
perform the combined 7-deletion multiplex-PCR and 7-mutation multiplex-
minisequencing assays. These samples were from normal individuals, heterozygous 
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carriers of deletions or point mutations, as well as non-deletional Hb H disease 
patients.  All samples were correctly genotyped (100% assay specificity).  Used 
together, the combined test will provide a more comprehensive mutational screen, 
improve overall mutation detection sensitivity, and enable more successful 
genotyping of a higher percentage of α-thalassemia and Hb H disease patients. 
 
5.1.4 Single-tube α-globin gene triplication multiplex-PCR 
Although triplicated alleles have no phenotypic effect in normal people, they 
will increase the phenotypic severity in individuals with β-thalassemia [2].  This 
phenomenon has been reported in various ethnic groups, and underscores the 
importance of screening for the presence of triplicated α-globin genes in β-
thalassemia carriers who are more symptomatic than expected. Current PCR methods 
can only detect the anti-3.7 allele but not the anti-4.2 allele [31, 32].  The anti-3.7/4.2 
multiplex-PCR assay serves as a useful rapid screen for the presence of the anti-3.7 
and/or the anti-4.2 types of triplication. 
It is likely that the result of our anti-3.7/4.2 multiplex-PCR assay will also be 
abnormal with the rarer ααααanti3.7 and ααααanti4.2 quadruplicated alleles, which have 
two copies of the crossover junction, one copy more than their triplicated 
counterparts. To distinguish between the triplicated and quadruplicated alleles, 
however, will require Southern blotting because both triplicated and quadruplicated 
anti-3.7 and anti-4.2 alleles should yield essentially the same ∼1.9-kb and ∼1.7-kb 
junction fragments, respectively. 
Aside from the cost and time savings of not having to perform Southern blot 
analysis on the vast majority of samples, which requires 1-2 weeks to obtain results, 
another advantage of first performing the multiplex-PCR screen is that only a single 
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Southern blot will be needed for PCR-positive samples. Without an initial anti-3.7/4.2 
multiplex-PCR screen, Southern analysis alone to detect triplications and/or 
quadruplications will require a minimum of two blots, each containing DNA digested 
by a different restriction enzyme, because no single enzyme digestion can provide full 
genotype information [116]. For example, digestion with BamHI followed by 
hybridization with an α-globin gene probe enables detection of and discrimination 
between a triplication and a quadruplication, as well as determination of zygosity, but 
cannot distinguish between the anti-3.7 and anti-4.2 types (Figure 4-7).  Conversely, a 
BglII digested DNA blot hybridized with the same probe enables the type of 
triplication or quadruplication to be determined, but does not provide information on 
zygosity.  Furthermore, a BglII Southern result by itself can be ambiguous.  For 
example, a 3.7 kb hybridizing band could indicate either a triplicated or a 
quadruplicated anti-3.7 allele (αααanti3.7 or ααααanti3.7).  Also, Southern blotting of 
BglII digested DNAs from individuals with either -α3.7/αα or αααanti4.2/αα genotype 
would yield identical results, i.e., 7.4, 12.6, and 16 kb bands. 
Performing an initial anti-3.7/4.2 multiplex-PCR screen enables determination 
of the type of triplication/quadruplication present in the patient (anti-3.7 or anti-4.2), 
thus eliminating the need for a BglII-digested Southern blot.  Therefore, only a 
BamHI-digested Southern blot hybridized with an α-globin probe has to be performed 
to detect the presence of the rare quadruplicated and homozygous genotypes. 
For the efficient laboratory diagnosis of thalassemia, an algorithm for applying 
this and other recently developed PCR-based tests is suggested (Figure 5-1).  For 
patients with MCV of <80 fL and normal HbA2 levels, and thus suspected of having 
α-thalassemia or “silent” β-thalassemia. It would be useful to perform the 7-deletion 
multiplex-PCR [36], with or without ARMS-PCR [56] or multiplex-minisequencing 
 127
[138], to determine their α-globin genotype.  For individuals determined by the 7-
deletion multiplex-PCR assay to be carriers of a double α-globin gene deletion in cis 
(such as the --SEA deletion) but whose MCV and MCH values are higher than 
expected, the anti-3.7/4.2 multiplex-PCR assay can then be performed to screen for 
co-inheritance of a triplicated/quadruplicated α-globin arrangement on the other 
chromosome 16. β-Thalassemia multiplex-minisequencing can be used to determine 
β-globin genotype. 
For patients with MCV of <80 fL and high HbA2 levels, and thus suspected of 
having β-thalassemia trait, a β-thalassemia multiplex-minisequencing screen [139] 
could be performed to determine their β-globin genotype, and the 7-deletion 
multiplex-PCR assay could be performed to detect double heterozygosity for α and β 
trait.  Individuals who have confirmed β-thalassemia trait but have lower than 
expected MCH or are clinically more severe than usual could also be screened for co-
inheritance of triplicated/quadruplicated α-globin genes.  This proposed strategy 
























Figure 5-1 Algorithm for applying the 7-deletion multiplex-PCR, anti-3.7/4.2 multiplex-PCR, and 
other PCR-based assays in the laboratory diagnosis of thalassemia. 
 
 
5.2 Molecular Verification of Hb H disease Classification by IEF 
Our study of 110 Thai patients diagnosed with Hb H disease reveals that the 
most common α-globin genotype is −α3.7/−−SEA (56 of 110 patients, 50.9%,), 
followed by αCSα/−−SEA (44 of 110 patients, 40%).  The −−SEA double-gene deletion 
was present in all but two patients, both of whom carried the −−THAI double-gene 
deletion. 
Of the 67 patients diagnosed as deletional Hb H disease by IEF, molecular 
genotyping revealed that six patients (~9%) were actually non-deletional Hb H CS (5 
patients) or Hb H Paksé (1 patient) (Table 4-4).  The reason for the IEF 
misclassification of these patients, presumably due to false negative detection of Hb 
MCV <80fL
Normal HbA2 High HbA2 
Suspect α-thalassemia or “silent”β-thalassemia Suspect β-thalassemia trait** 
Perform α-thalassemia 7-deletion multiplex-PCR* 
± α-thalassemia ARMS-PCR or multiplex- 
minisequencing to determine α-globin genotype 
and β-thalassemia multiplex-minisequencing 





 α and β trait 
If Hb low or clinically
 more severe than usual 
Negative result 
Perform anti-3.7/4.2 multiplex-PCR to detect β-
heterozygosity in association with 
triplicated/quadruplicated  α-globin genes 
* For --SEA carriers with MCV and MCH values higher than usual, may consider anti-3.7/4.2 multiplex-PCR to detect co-
inheritance of triplicated/quadruplicated α-globin allele. 
** Perform β-thalassemia multiplex-minisequencing screen of common mutations to determine β-globin genotype.
 129
Constant Spring, remains unresolved.  Equally surprising were the apparent genotypes 
of the remaining three patients in this group, one of whom was genotyped as 
homozygous --SEA while the other two patients were genotyped as heterozygous --SEA.  
Both these genotypes are inconsistent with either deletional or non-deletional Hb H 
disease.  It should be noted, however, that the genotype assignments for these three 
patients may simply reflect the limitations of the α-thalassemia genotyping assays, 
which only screen for specific mutations.  For example, we cannot exclude the 
possibility that the patient with an apparent --SEA/--SEA genotype could in fact be 
compound heterozygous for --SEA and another deletion that is not one of the seven 
deletions screened for in the multiplex gap-PCR assay.  If this other deletion 
inactivates only one α-globin gene, then the genotype would be entirely consistent 
with an Hb H disease phenotype.  Also, although we did not detect any mutation in 
the HBA1 and HBA2 genes (except poly A of HBA2 gene) in the two patients with an 
apparent αα/--SEA genotype, we cannot exclude the possibility that an undetected 
mutation exists in poly A of HBA2 or elsewhere within the α-globin gene cluster in 
these patients. 
Among the 43 patients diagnosed as Hb H CS by IEF, three patients actually 
carried the Paksé mutation (Table 4-5).  The Paksé mutation involves an A→T 
transversion in the termination codon (Codon142) of the HBA2 gene, resulting in its 
conversion to tyrosine [TAA(ter) → TAT(tyr)].  Like the Constant Spring mutation 
[Codon142, TAA(ter) → CAA(gln)], the Paksé mutation produces an aberrant α-
globin peptide that is longer by 31 amino acids.  Thus, the migration of the mutant Hb 
Paksé and Hb Constant Spring molecules in an IEF gel are most likely to be very 
similar, if not identical, resulting in the inability of the IEF assay to distinguish 
between patients with Hb H Paksé and Hb H CS. 
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As part of this study, we developed a reliable protocol to sequence the high 
GC content α-globin genes, including the entire coding region (except poly A of 
HBA2) and 5’ untranslated regions and 493 bp of promoter and upstream sequence.  
The gene sequencing approach was employed in order to detect as many non-
deletional α-thalassemia mutations as possible.  Consistent with previous studies, 
Constant Spring was the most common non-deletional mutation (45 of 49 patients, 
91.8%).  Interestingly, the Paksé mutation was observed in four patients. This 
mutation was first reported in 1994 in a single Laotian patient with Hb H disease 
[140] and initially thought to be rare.  However, new cases of the Hb Paksé mutation 
were recently reported in Thai Hb H disease patients [141-143].  Our findings confirm 
that next to Constant Spring, Paksé might be the second most common non-deletional 
α-thalassemia determinant in Thailand and neighboring regions. 
Overall, the results of this study indicate that IEF results are concordant with 
molecular genotyping results for the majority of Hb H disease patients.  However, IEF 
appeared to misclassify several non-deletional Hb H CS and Hb H Paksé patients as 
having deletional Hb H disease.  Furthermore, IEF is unable to distinguish between 
the types of double-gene deletions, and between the Constant Spring and Paksé point 
mutations.  These limitations are not anticipated to pose a major problem in 
counseling and treatment of patients, given the broad and overlapping hematological 
profiles of the deletional and non-deletional Hb H disease patients (Table 5-1).  
However, they result in the masking of the true prevalence of various deletional and 
non-deletional α-thalassemia determinants.  Molecular diagnosis is still necessary for 
accurate determination of the type of genetic mutation(s) present in patients, for 
confirmation of clinical and hematological diagnosis of α-thalassemia, and for 
prenatal diagnosis and prevention of severe α-thalassemia in at-risk pregnancies. 
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Table 5-1 Hematological profiles of deletional and non-deletional Hb H disease patients. 
Genotype Hb (g/l) ± SD / Range 
MCV (fl) ± SD / 
Range 
MCH (pg) ± SD / 
Range 
−α/−− (n=58) 8.58 ± 1.16 / 5.7 − 11.1 
62.8 ± 5.84 / 
48.2 − 79.3 
19.8 ± 1.73 / 
17.0 − 24.6 
αTα/−− (n=49) 7.23 ± 2.26 / 3.2 − 14.6 
72.0 ± 6.83 / 
55.5 − 90.3 
21.1 ± 2.44 / 
14.4 − 29.3 
 
 
5.3 Characterization of the relationship between PTC and NMD 
The phenomenon of NMD has been studied for ∼15 years [118]. In mammalian 
cells, it was first discovered during the studies of β0-thalassemias caused by PTCs 
[68]. Since then, many studies have been carried out to understand the mechanism of 
NMD. Based on our current understanding of NMD, the “3’ boundary rule” was 
established that all PTCs located more than 50-55 nucleotides upstream of last exon-
exon junction elicit NMD [64, 119]. However, human β-globin transcripts with PTCs 
located in the 5’ part of exon 1 have been shown to be resistant to NMD [98], 
suggesting that there could be another boundary at the 5’ end of a gene, upstream of 
which no NMD occurs.  
To further delineate this “5’ boundary”, five naturally occurring PTCs in exon 
1 and 2 of the human β-globin gene that result in β0-thalassemia were analyzed. The 
levels of PTC-containing transcripts were compared with wild-type transcript to study 
the effect of NMD in the gene expression. Our data showed that in the presence of 
translation (when NMD is enabled), the mutant transcripts with PTCs at or upstream 
of codon 17 were of levels similar to wild-type transcript, whereas mutant transcripts 
with PTCs at or downstream of codon 21/22 were half of wild-type transcript. These 
data confirm the existence of a boundary at the 5’end of the β-globin gene, lying 
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between codons 17 and 21/22, separating PTCs that undergo NMD and those that do 
not, and are consistent with Romao et al’s hypothesis [98].  
It was shown that NMD could be abolished by translation re-initiation 
downstream of the nonsense codons [121]. There are AUG codons located 
downstream of all the five PTCs, occuring at codons 55, 63/64, and 73/74 of the β-
globin gene. However, if translation re-initiation can abrogate NMD, all the PTCs 
located upstream of a putative initiating AUG codon should be resistant to NMD, and 
not just the PTCs at or upstream of codon 17. In addition, studies involving the 
conversion of downstream AUG codons to other amino acid codons conclude that 
resistance of 5’ end PTCs to NMD cannot be explained by downstream translation re-
initiation events [144]. In yeast, NMD does not occur if the nonsense mutation is 
located more than 100-150 nucleotides upstream of the downstream sequence element 
(DSE), a functional equivalent of the exon-exon junction complex (EJC) in human 
[145, 146]. The distance between the NMD-resistant PTC at codon 17 and the 3’ most 
exon-exon junction is 261 bp, more than 150 bp and this is consistent with the 
findings in yeast. However, it has been shown experimentally that extension of a 
NMD-susceptible PTC to almost 700 bp upstream of an EJC does not confer NMD-
resistance [147]. Recently, an “AUG aproximity effect”, that is the resistance of 5’end 
PTCs to NMD is based on the proximity of PTCs to the AUG initiation codon, was 
proposed to explain this phenomenon [144].   
Although PTC 3/4 and PTC 17 are associated with stable transcripts, they 
cause β0-thalassemia. This is different from the stable mutant transcripts with PTCs in 
exon 3 that are associated with dominantly inherited β-thalassemia. The less severe 
effect of the stable mutant transcripts with 5’ end PTCs is most likely that the short 
unstable truncated peptides synthesized pose less a burden on the proteolytic 
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processes of the red blood cell precursors than the longer terminated peptides, or 
because the short open reading frames are poorly translated [72].  
So far, it is still an enigma whether NMD leads to a reduction of the 
cytoplasmic- or nucleus-associated forms of PTC-containing mRNAs. Nucleus-
associated RNA can exist within the nucleoplasm, associated with the nuclear pore, or 
be partially exported but not yet released from the nucleus [148]. In the human β-
globin gene, there is evidence for both cytoplasmic NMD [63] and nucleus-associated 
NMD [99-102]. To unambiguously distinguish between cytoplasmic translation and 
nuclear translation, the hairpin structured IRE-element was inserted into the 5’-UTR 
of the β-globin gene constructs to specifically inhibit cytoplasmic translation only. 
Our results showed that both cytoplasmic and nuclear PTC-containing RNAs 
accumulated to similar levels less than normal under both conditions of global 
translation and absence of cytoplasmic translation. Thus, inhibition of cytoplasmic 
translation alone did not inhibit NMD, suggesting that NMD is already occurring in 
the nucleus in the presence of a pioneer round of translation.  
This deduction is further supported by the results from total cytoplasmic and 
nuclear translation inhibition. Three translation inhibitors, cycloheximide, puromycin 
and anisomycin, were used to block global translation. Although all these antibiotics 
interfere with the ribosome to inhibit translation, puromycin dissociates mRNAs from 
ribosomes, whereas cycloheximide and anisomycin maintain the association of 
mRNAs and ribosomes [149]. Concordant results from all three translation inhibitors 
were abtained (Figure 4-12). Under global translation inhibition, levels of all the PTC-
containing transcripts were equivalent to the level of wild-type β-globin transcript in 
nucleus. For PTC21/22, 42/43, and 60/61 that are subject to NMD, their mutant RNA 
levels in the nucleus in the absence of translation were much higher than their 
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corresponding levels in the presence of translation. These results strongly suggest that 
PTC-containing transcripts in the nucleus are subjected to NMD. 
Although the PTC-containing transcripts were also more stable in cytoplasm 
under translation inhibition, they were still not as stable as the wild-type transcript 
under the same conditions. A similar phenomenon has been observed in certain PTC-
containing BRCA1 transcripts, with increased stability of mutant mRNAs after 
translation inhibition but not reaching the same level as the wild-type transcript [122]. 
This difference in stability between wild type and PTC-containing transcripts in the 
cytoplasm in the global absence of translation cannot be explained by the current 
model of NMD because it obviously does not depend on translation. We hypothesized 
that there could be another mechanism in the cytoplasm acting to degrade PTC-
containing transcripts. Recent studies in mouse erythroleukemia (MEL) cells stably 
transfected with human β-globin gene suggests the presence of a specialized decay 
pathway that may be superimposed on the general NMD pathway [150]. This mRNA 
decay occurs through deadenylation-independent endonucleolytic cleavage, and 
affects nonsense-containing and, to a lesser extent, wild-type transcripts. It is possible 
that this mechanism may account for some of the difference between wild type and 









 In this study, several molecular diagnostic assays for identification of α- and 
β-thalassemia common mutations in Southeast Asia have been developed and 
validated. These new molecular diagnostic assays provide a more rapid, efficient, and 
cost-effective alternative to current thalassemia molecular testing methods based on 
single PCR, Southern blot or dot blot / reverse dot blot platforms and enable sensitive 
and accurate detection of the majority of α- and β-globin genotypes in the region. 
 In addition, the accuracy of IEF in Hb H disease classification was evaluated. 
The presence of several misclassification of deletional and nondeletional Hb H 
disease by IEF highlights the importance of molecular diagnosis in accurate 
determination of genetic mutations and confirmation of clinical and hematological 
diagnosis. 
 Furthermore, we studied the relationship between the position of premature 
termination codon (PTC) and the cell surveillance mechanism – nonsense-mediated 
mRNA decay (NMD). The results suggest the presence of a 5’-boundary located in 
between codon 17 and codon 21/22. Transcripts containing PTCs at or 5’ of codon 17 
are resistant to NMD, while transcripts containing PTCs at or 3’ of codon 21/22 are 
subject to NMD. By regulating translation specifically in the cytoplasm or globally, 
this study supports a nucleus-associated NMD mechanism for PTC-containing β-
globin gene transcripts. In addition, the results suggest that a translation-independent 
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